35272&2/6+3
7,7/( $5DQGRPL]HG'RXEOHPDVNHG3ODFHERFRQWUROOHG3KDVH
6WXG\WR$VVHVVWKH6DIHW\ 7ROHUDELOLW\3KDUPDFRNLQHWLFVDQG 
3KDUPDFRG\QDPLFVRI6LQJOH'DLO\DQG0XOWLSOH'DLO\$VFHQGLQJ'RVHVRI6+37RSLFDO2SKWKDOPLF6ROXWLRQLQ6XEMHFWVZLWK2FXODU+\SHUWHQVLRQRU3ULPDU\2SHQDQJOH*ODXFRPD32$*
'58* 6+3
,1' 
(8'5$&712
1RWDSSOLFDEOH
6321625 6KLUH+*7
6KLUH:D\/H[LQJWRQ0$86$
35,1&,3$/
&225',1$7,1*
23+7+$/02/2*,67'U
35272&2/+,6725< $PHQGPHQW9HUVLRQ 0D\
$PHQGPHQW9HUVLRQ 2FW $PHQGPHQW9HUVLRQ 0D\2ULJLQDO3URWRFRO9HUVLRQ )HE2ULJLQDO3URWRFRO9HUVLRQ  'HF
7KLVGRFXPHQWFRQWDLQVFRQILGHQWLDODQGSURSULHWDU\LQIRUPDWLRQ RI6KLUH+*7KHQFHIRUWKUHIHUUHGWRDV6KLUHDQG
LVGLVFORVHGSXUVXDQWWRFRQILGHQWLDOLW\DQGQRQGLVFORVXUHREOL JDWLRQV7KLVLQIRUPDWLRQVKRXOGEHXVHGVROHO\IRUWKH
SXUSRVHVIRUZKLFKLWZDVSURYLGHGDQGVKRXOGQRWEHFRSLHGVK DUHGZLWKRUGLVFORVHGWRDQ\WKLUGSDUW\ZLWKRXWWKH
H[SUHVVZULWWHQFRQVHQWRI6KLUH
PPD
6KLUH &21),'(17,$/ 3DJH
6+33URWRFRO$PHQGPHQW6+3 0D\
352'8&748$/,7<&203/$,176
,QYHVWLJDWRUVDUHUHTXLUHGWRUHSRUWLQYHVWLJDWLRQDOSURGXFWTX DOLW\FRPSODLQWVRUQRQPHGLFDO
FRPSODLQWVWR6KLUHZLWKLQKRXUV,IUHTXHVWHGGHIHFWLYHSUR GXFWVZLOOEHUHWXUQHGWRWKH
VSRQVRUIRULQVSHFWLRQDQGDQDO\VLVDFFRUGLQJWRSURFHGXUHV
7KLVLQFOXGHVDQ\LQVWDQFHVZKHUHLQWKHTXDOLW\RUSHUIRUPDQFH RID6KLUHSURGXFWPDUNHWHGRU
LQYHVWLJDWLRQDOGRHVQRWPHHWH[SHFWDWLRQVHJLQDGHTXDWHRU IDXOW\FORVXUHSURGXFW
FRQWDPLQDWLRQRUWKDWWKHSURGXFWGLGQRWPHHWWKHVSHFLILFDWL RQVGHILQHGLQWKHDSSOLFDWLRQIRU
WKHSURGXFWHJZURQJSURGXFWVXFKWKDWWKHODEHODQGFRQWHQWV DUHGLIIHUHQWSURGXFWVRUD
SURGXFWGHILFLHQF\WKDWUHODWHVWRLGHQWLW\TXDOLW\GXUDELOLW \UHOLDELOLW\VDIHW\DQGSHUIRUPDQFH
RIWKHSURGXFWEXWGLGQRWUHVXOWLQDQ$(ZKLFKLQFOXGHEXWD UHQRWOLPLWHGWRWKHIROORZLQJ
â€¢$IDLOXUHRIDSURGXFWWRH[KLELWLWVH[SHFWHGSKDUPDFRORJLFDO DFWLYLW\DQGRUGHVLJQ
IXQFWLRQHJUHFRQVWLWXWLRQGLIILFXOW\
â€¢0LVVLQJFRPSRQHQWV
â€¢'DPDJHWRWKHSURGXFWRUXQLWFDUWRQ
â€¢$PLVODEHOHGSURGXFWHJSRWHQWLDOFRXQWHUIHLWLQJWDPSHULQJ
â€¢$EDFWHULRORJLFDOFKHPLFDORUSK\VLFDOFKDQJHRUGHWHULRUDWLR QRIWKHSURGXFWFDXVLQJLW
WRPDOIXQFWLRQRUWRSUHVHQWDKD]DUGRUIDLOWRPHHWODEHOFOD LPV
)RULQVWUXFWLRQVRQUHSRUWLQJDGYHUVHHYHQWVUHODWHGWRSURGXFW FRPSODLQWVVHH6HFWLRQ 
3OHDVHXVHWKHLQIRUPDWLRQEHORZDVDSSOLFDEOHWRUHSRUWWKH3UR GXFW4XDOLW\&RPSODLQW
2ULJLQRI3URGXFW4XDOLW\&RPSODLQW (PDLO$GGUHVV
1RUWKDQG6RXWK$PHULFD
7HOHSKRQHQXPEHUVSURYLGHGIRUUHIHUHQFHLIQHHGHG
6KLUH/H[LQJWRQ0$86$
PPDPPD
Shire CONFIDENTIAL Page 7
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
TABLE OF CONTENTS
PROTOCOL  SIGNATURE P AGE .................................................................................................2
SUMMARY OF CHANGES F ROM PREVIOUS VERSI ON........................................................3
EMERGENCY CONTACT I NFORMATION ................................................................................4
ADDITIONAL CONTACT I NFORMATION ................................................................................5
PRODUCT QUALITY COMP LAINTS ..........................................................................................6
LIST OF TABLES .........................................................................................................................12
LIST OF FIGURES .......................................................................................................................12
ABBREVIAT IONS .......................................................................................................................13
STUD Y SYNOPSI S
......................................................................................................................15
STUDY SCHEDULES ..................................................................................................................22
1.BACKGROUND INFORMATI ON.......................................................................................34
1.1 Indication and Current Treatment Options ...............................................................34
1.2 Product Background .................................................................................................35
1.2.1
Nonclinical Information.........................................................................................35
1.2.2 Clinical I nformation ...............................................................................................36
1.3 Risk/Benefit and Ethical Assessment .......................................................................37
2.STUDY OBJECTIVES AND PURPOSE ..............................................................................39
2.1 Rationale for the Study .............................................................................................39
2.2 Study  Objectives ......................................................................................................39
2.2.1 Primary  Objectives .................................................................................................39
2.2.2 Secondary  Objectives .............................................................................................39
2.2.3 Exploratory  Objectives ..........................................................................................39
3.STUDY DESIGN ...................................................................................................................40
3.1 Study  Design and Flow Chart ..................................................................................40
3.1.1 Designated Study  Eye ................................ ................................ ............................ 40
3.1.2 Screening Period ................................ ................................ ................................ ....41
3.1.3 Study  Parts ................................ ................................ ................................ ............. 41
3.1.4 Cohorts A1- A3................................ ................................ ................................ .......41
3.1.4.1 Cohorts A1- A3: Single -dose Treatment Period ................................ .....41
3.1.4.2 Cohorts A1- A3: Multiple -dose Treatment Period ................................ ..42
3.1.5 Cohorts B1 -B3, C1- C3, and D1 -D3................................ ................................ .......42
3.2 Duration and Study  Completion Definition ................................ ............................. 43
3.3 Sites and Regions ................................ ................................ ................................ .....43
4.STUDY POPUL ATION................................ ................................ ................................ ......... 44
4.1 Inclusion Criteria................................ ................................ ................................ ......44
4.2 Exclusion Criteria ................................ ................................ ................................ .....45
Shire CONFIDENTIAL Page 8
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
4.3 Restrictions ...............................................................................................................47
4.4 Reproductive Potential .............................................................................................47
4.4.1 Female Contraception ............................................................................................47
4.4.2 Male Contraception ................................................................................................48
4.5
Discontinuation of Subjects .....................................................................................48
4.5.1
Subject Withdrawal Criteria ..................................................................................48
4.5.2 Reasons for Discontinuation ..................................................................................49
4.5.3 Subjects â€œL ost to Follow -upâ€ Prior to Last Scheduled Visit .................................49
4.5.4 Stopping Criteria for Dose Escalation ...................................................................49
5.PRIOR AND CONCOMITANT TREATMEN
T ...................................................................51
5.1 Prior Treatment ........................................................................................................51
5.2 Concomitant Treatment ............................................................................................51
5.2.1 Permitted Treatment ...............................................................................................51
5.2.2 Prohibited Treatment .............................................................................................51
6.INVESTIGAT IONAL PROD UCT ........................................................................................54
6.1 Identity  of Investigational Product ...........................................................................54
6.1.1 Masking the Treatment Assignment ......................................................................54
6.2 Administration of I nvestigational Products
..............................................................54
6.2.1 Interactive Response Technology  for Investigational Product Management ........54
6.2.2 Allocation of Subjects to Treatment ......................................................................55
6.2.3 Dosing ....................................................................................................................55
6.2.3.1 Dosing Procedures ..................................................................................55
6.2.3.2 Dose Escalation ......................................................................................56
6.2.4 Unmasking the Treatment Assignment ..................................................................58
6.3
Labeling, Packaging, Storage, and Handling ...........................................................58
6.3.1 Labeling .................................................................................................................59
6.3.2 Packaging ...............................................................................................................59
6.3.3
Storage ...................................................................................................................59
6.3.4 Special Handling ................................ ................................ ................................ ....60
6.4 Drug Accountability ................................ ................................ ................................ .60
6.5 Subject Compliance ................................ ................................ ................................ ..61
6.6 Retention of Bioavailability  and Bioequivalence Testing Samples .........................61
7.
STUDY PROCEDURES................................ ................................ ................................ ........ 62
7.1 Study  Schedule ................................ ................................ ................................ ......... 62
7.1.1 Screening Period ................................ ................................ ................................ ....62
7.1.1.1 Screening Failure ................................ ................................ .................... 63
7.1.1.2 Rescreening of Subjects ................................ ................................ ......... 63
7.1.1.3 Washout Period 1 ................................ ................................ ................... 63
Shire CONFIDENTIAL Page 9
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
7.1.2 Treatment Period ....................................................................................................63
7.1.2.1 Day -2 Through Day  2, Single -dose Treatment Period (Cohort A 
Only )
.......................................................................................................63
7.1.2.2 Day -2 Through Day  29, Multiple -dose Treatment Period (All 
Cohorts) ..................................................................................................64
7.1.3 Follow -
up...............................................................................................................65
7.1.4 Additional Care of Subjects after the Stud y ..........................................................65
7.2 Study  Evaluations and Procedures
...........................................................................65
7.2.1 Demographic and Other Baseline Characteristics .................................................65
7.2.2 Safety .....................................................................................................................65
7.2.2.1 Medical and Medication History ............................................................66
7.2.2.2 Physical Examination (Including Height and Weight) ..........................66
7.2.2.3
Ophthalmologic Examination ................................................................67
7.2.2.4
Adverse Event Collection.......................................................................71
7.2.2.5 Vital Signs ..............................................................................................72
7.2.2.6 Clinical L aboratory  Evaluations .............................................................74
7.2.2.7 Pregnancy  Test .......................................................................................75
7.2.2.8 Drug and Alcohol Screen .......................................................................75
7.2.2.9 Serology  Screen ......................................................................................76
7.2.2.10 Antidrug Antibod y Testing ....................................................................76
7.2.2.11 Electrocardiogram ..................................................................................76
7.2.3 Pharmacokinetic Procedures ..................................................................................77
7.2.3.1 Pharmacokinetic Sample Collection and Handling Procedures .............78
7.2.3.2 Shipment of P harmacokinetic Samples ..................................................78
7.2.3.3 Plasma Drug Assay  Methodology ..........................................................78
7.2.4 Pharmacod ynamic Assessments ............................................................................79
7.2.5 Volume of Blood to Be Collected from Each Subject ................................ ........... 79
8.ADVERSE AND SERIOUS ADVERSE EVENTS ASSES SMENT ....................................81
8.1
Definition of Adverse Events, Period of Obs ervation, Recording of Adverse 
Events .......................................................................................................................81
8.1.1 Severity  Categorization ................................ ................................ .......................... 81
8.1.2 Relationship Categorization ...................................................................................82
8.1.3 Outcome Categorization ................................ ................................ ........................ 82
8.1.4 Ocular and Nonocular Categorization ................................ ................................ ...83
8.1.5 Symptoms of the Disease under Study ................................ ................................ ..83
8.1.6 Clinical L aboratory  and Other Safet y Evaluations ................................ ................ 83
8.1.7 Pregnancy ................................ ................................ ................................ ............... 83
8.1.8 Abuse, Misuse, Overdose, and Medication Error ................................ .................. 84
Shire CONFIDENTIAL Page 10
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
8.2 Serious Adverse Event Procedures ..........................................................................85
8.2.1 Reference Safet y Information ................................................................................85
8.2.2 Reporting Procedures .............................................................................................85
8.2.3 Serious Adverse Event Definition .........................................................................85
8.2.4 Serious Adverse Event Collection Time Frame .....................................................86
8.2.5 Seriou
s Adverse Event Onset and Resolution Dates .............................................86
8.2.6 Fatal Outcome ........................................................................................................86
8.2.7 Regulatory  Agency , Institutional Review Board, and Site Reporting ...................86
9.DATA MANAGEMENT AND STATISTICAL METHODS
...............................................88
9.1 Data Collection .........................................................................................................88
9.2 Clinical Data Management .......................................................................................88
9.3
Data Handling Considerations..................................................................................88
9.4 Statistical Analy
sis Process ......................................................................................88
9.5 Planned Interim Anal ysis, Adaptive Design, and Dose Escalation Committee .......89
9.6
Sample Size Calculation and Power Considerations................................................89
9.7 Study  Population ......................................................................................................90
9.8 Pharmacokinetic and Pharmacod ynamic Anal yses..................................................90
9.8.1 Pharmacokinetic Analy sis......................................................................................90
9.8.1.1 Pharmacokinetic Endpoints ....................................................................90
9.8.1.2 Statistical Analy sis of Pharmacokinetic Parameters ..............................90
9.8.2 Pharmacod ynamic Anal ysis...................................................................................91
9.8.2.1 Pharmacod ynamic Endpoints .................................................................91
9.8.2.2 Statistical Analy sis of Pharmacod ynamic Parameters ...........................91
9.8.3 Pharmacokinetic and Pharmacod ynamic Anal ysis................................................92
9.9 Safety  Anal yses........................................................................................................92
9.9.1 Safety  Endpoints ....................................................................................................92
9.9.2 Statistical Analy sis of Safety  Data .........................................................................92
9.10 Other Anal yses.........................................................................................................92
10.SPONSORâ€™S AND I NVEST IGATORâ€™S RESPONSIBIL
ITIES................................ ........... 93
10.1 Sponsorâ€™s Responsibilities ................................ ................................ ....................... 93
10.1.1 Good Clinical Practice Compliance ................................ ................................ .......93
10.1.2 Public Posting of Study  Information ......................................................................93
10.1.3 Submission of Summary  of Clinical Study  Report to Competent Authorities 
of Member States Concerned and Ethics Committees ...........................................93
10.1.4 Study  Suspension, Termination, and Completion
..................................................94
10.2 Investigatorâ€™s Responsibilitie s .................................................................................94
10.2.1 Good Clinical Practice Compliance ................................ ................................ .......94
10.2.2 Protocol Adherence and Investigator Agreement ................................ .................. 94
Shire CONFIDENTIAL Page 11
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
10.2.3 Documentation and Retention of Records ................................ ............................. 95
10.2.3.1 Case Report Forms .................................................................................95
10.2.3.2 Recording, Access, and Retention of Source Data and Study  
Documents ..............................................................................................95
10.2.3.3 Audit/I nspection .....................................................................................96
10.2.3.4 Financial Disclosure ...............................................................................96
10.3 Ethical Considerations ..............................................................................................96
10.3.1 Informed Consent ...................................................................................................96
10.3.2 Institutional Review Board or Ethics Committee ..................................................97
10.4 Privacy  and Confidentiality ......................................................................................97
10.5 Study  Results/Publication Policy .............................................................................98
11.REFERENCES .....................................................................................................................100
12.APPENDI CES ......................................................................................................................102
Appendix 1
Protocol History ...................................................................................103
Appendix 2 Anterior Segment Graded Assessments
...............................................110
Shire CONFIDENTIAL Page 12
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
LIST OF TABLES
Table 1 Overall Schedule of Events ...........................................................................22
Table 2 Detailed Schedule of Events â€“Cohort A .......................................................26
Table 3 Detailed Schedule of Events â€“Cohort B .......................................................28
Table 4 Detailed Schedule of Events 
â€“Cohort C .......................................................30
Table 5 Detailed Schedule of Events â€“Cohort D .......................................................32
Table 6 Dose Margins Based on SHP639 Concentration and Dosing Regimen ........38
Table 7 Dose Margins Based on SHP639 Daily  Dose ...............................................38
Table 8
Common Excluded Medications and Associated Washout Per iod...............52
Table 9 SHP639 Drug Substance per Drop of SHP639 Ophthalmic Solution ...........54
Table 10 Anticipated Dose -
escalation Scheme ............................................................57
Table 11 Volume of Blood to Be Collected from Each Subject in Each 
Treatment Regimen: Cohort A ......................................................................79
Table 12 Volume of Blood to Be Collected from Each Subject in Each 
Treatment Regimen: Co horts B, C, and D ....................................................80
LIST OF FIGURES
Figure 1 Procedures for Screening Vital Signs (Blood Pressure â€“Pulse) ...................73
Shire CONFIDENTIAL Page 13
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
ABBREVIATIONS
ADA antidrug antibody
AE adverse event
AMD age-related macular degeneration
AUC 0-t area under the observed concentration vs time curve from time zero (predose) to the time of 
the last measurable concentration
AUC 0-Ï„ area under the observed concentration vs time curve over the dosing interval 
AUC 0-âˆž area under the observed concentration vs time curve from time zero (predose) extrapolated to 
infinity
BCVA best-corrected visual acuity
ï¢-hCG beta-human chorionic gonadotropin
BID twice daily
cGMP cyclic guanosine monophosphate
CI confidence interval
CL/F apparent clearance
Cmax maximum observed concentration
CNP C
-type natriuretic peptide
CS clinically significant
CRO contract research organization
EC 50 half maximum effective concentration
ECG electrocardiogram
eCRF electronic case report form
Emax maximum percentage intraocular pressure reduction from baseline
EMA European Medicines Agency
EU European Union
FDA Food and Drug Administration
GCP Good Clinical Practice
GLP Good Laboratory Practice
HBsAg hepatitis B surface antigen
HCV hepat itis C virus
HIPAA Health Insurance Portability and Accountability Act
HVF Humphrey visual field
IA interim analysis
IB investigator's brochure
ICF informed consent form
ICH International Council for Harmonisation
IOP intraocular pressure
IRB Institutional Review Board
IRT interactive response technology
IV intravenous
Shire CONFIDENTIAL Page 14
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
MDTP multiple -dose treatment period
MWOA midwashout ophthalmic assessment
NCS not clinically significant
NHP nonhuman primates
NOAEL no-observed -adverse -effect level
NPDR nonp roliferative diabetic retinopathy
NPR -A natriuretic peptide receptor A
NPR -B natriuretic peptide receptor B
OHT ocular hypertension
PD pharmacodynamic(s)
PK pharmacokinetic(s)
POAG primary open -angle glaucoma
QD once daily
QID 4 times daily
QTcB QT interval corrected for heart rate using the Bazett formula
QTcF QT interval corrected for heart rate using the Fridericia formula
Rac(AUC) accumulation ratio based on area under the curve
Rac(Cmax) accumulation ratio based on maximum observed concentr ation
SAE serious adverse event
SAP statistical analysis plan
SDTP single -dose treatment period
tÂ½ apparent terminal phase elimination half -life
TE max time to the maximum reduction
TID 3 times daily
tmax time to reach maximum observed concentration
US United States
Vz/F apparent volume of distribution
6KLUH &21),'(17,$/ 3DJH
6+33URWRFRO$PHQGPHQW6+3 0D\
678'<6<1236,6
3URWRFROQXPEHU 6+3 'UXJ6+3
7LWOHRIWKHVWXG\ $5DQGRPL]HG'RXEOHPDVNHG3ODFHERFRQWUROOHG3KDVH6WXG\W R$VVHVVWKH6DIHW\
7ROHUDELOLW\3KDUPDFRNLQHWLFVDQG3KDUPDFRG\QDPLFVRI6LQJOH 'DLO\DQG0XOWLSOH'DLO\$VFHQGLQJ'RVHVRI
6+37RSLFDO2SKWKDOPLF6ROXWLRQLQ6XEMHFWVZLWK2FXODU+\SH UWHQVLRQRU3ULPDU\2SHQDQJOH*ODXFRPD
32$*
1XPEHURIVXEMHFWVWRWDODQGIRUHDFKWUHDWPHQWDUP
$SSUR[LPDWHO\VXEMHFWVZLOOEHVFUHHQHGWRHQVXUHWKHHQURO OPHQWDQGFRPSOHWLRQRIVXEMHFWV7KHUHZLOOEH
DSSUR[LPDWHO\FRKRUWVHDFKFRQVLVWLQJRIVXEMHFWV
6XEMHFWVPD\EHUHSODFHGWRHQVXUHRXWRIFRPSOHWHUVSHUGR VLQJUHJLPHQFRKRUW
,QYHVWLJDWRUV 'U FRRUGLQDWLQJSULQFLSDORSKWKDOPRORJLVW
6LWHVDQG5HJLRQV
7KLVLVDPXOWLFHQWHUVWXG\FRQGXFWHGVROHO\LQWKH8QLWHG6WDW HV$SSUR[LPDWHO\ VLWHVZLOOSDUWLFLSDWHLQWKHVWXG\
6WXG\SHULRGSODQQHG
WR&OLQLFDOSKDVH 
2EMHFWLYHV
3ULPDU\
7RLQYHVWLJDWHWKHVDIHW\DQGWROHUDELOLW\RIVLQJOHDQGPXOWLS OHDVFHQGLQJGRVHVRI6+3RSKWKDOPLFVROXWLRQLQ
VXEMHFWVZLWKRFXODUK\SHUWHQVLRQ2+7RUZLWKSULPDU\RSHQDQ JOHJODXFRPD32$*
6HFRQGDU\
7RHYDOXDWHUHGXFWLRQRILQWUDRFXODUSUHVVXUH,23DVDSKDUP DFRG\QDPLF3'ELRPDUNHUIROORZLQJGLIIHUHQW
6+3GRVLQJUHJLPHQV
([SORUDWRU\
7RH[SORUHWKHSKDUPDFRNLQHWLF3.3'UHODWLRQVKLSRI6+3L QVXEMHFWVZLWK2+7RU32$*
5DWLRQDOH
6+3LVEHLQJGHYHORSHGIRUUHGXFWLRQRI,23LQJODXFRPDSDWL HQWV,WLVH[SHFWHGWRDFWWKURXJKDQRYHOPRGHRI
DFWLRQQDWULXUHWLFSHSWLGHUHFHSWRU%DJRQLVPWKDWOHDGVWRD QLQFUHDVHLQWUDEHFXODUPHVKZRUNRXWIORZWKXV
UHGXFLQJWKH,236+3LVDILUVWL QKXPDQFOLQLFDOVWXG\ IRUDWRSLFDORSKWKDOPLFIRUPXODWLRQRI6+3
8SWR GLIIHUHQWFRQFHQWUDWLRQVDQGZLOOEH H[SORUHGDQGVDIHW\DQGWROHUDELOLW\RI6+3
RSKWKDOPLFVROXWLRQZLOOEHHYDOXDWHG$VDVHFRQGDU\REMHFWLYH WKHVWXG\ZLOODOVRDLPWRFKDUDFWHUL]HWKH3'RI
6+3XVLQJ,23DVD3'ELRPDUNHU 7KH3.3'UHODWLRQVKLSZLOO EHH[SORUHGLIWKHGDWDSHUPLW
,QYHVWLJDWLRQDOSURGXFWGRVHDQGPRGHRIDGPLQLVWUDWLRQ
7RSLFDORSKWKDOPLFGURSVRI6+3FRQFHQWUDWLRQVDQGPDWFKLQ JSODFHERZLOOEHXVHGLQWKLVVWXG\
DQG(DFKFRQFHQWUDWLRQZLOOEHJLYHQLQDQDVFHQGLQJGRVH IDVKLRQRQFHGDLO\4'WZLFHGDLO\%,'
 WLPHVGDLO\7,'DQG WLPHVGDLO\4,'
0HWKRGRORJ\
7KLVLVDPXOWLFHQWHUUDQGRPL]HGGRXEOH PDVNHGSODFHERFRQWU ROOHGVLQJOHDQGPXOWLSOHGRVHHVFDODWLRQVWXG\
7KUHHGLIIHUHQW6+3FRQFHQWUDWLRQVZLOOEHVWXGLHG DQG7KHUHZLOOEHXSWRFRKRUWVLQ
WRWDOFRKRUWIRUHDFKGRVHOHYHODQGGLIIHUHQWGRVLQJUHJLPH Q(DFKFRKRUWZLOOFRQVLVWRI VXEMHFWVIRUDWRWDORI
VXEMHFWVLQWKHVWXG\(OLJLEOHVXEMHFWVZLOOEHUDQGRPL]HG LQDUDWLRWRUHFHLYHHLWKHU6+3RUSODFHER
UHVSHFWLYHO\PPD
Shire CONFIDENTIAL Page 16
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
A sufficient number of subjects will be screened and enrolled to ensure that at least 6 of 7 subjects complete each 
treatment in their assigned cohort. In the event that a sufficient number of subjects do not complete a cohort, 
replacement subjects may be enrolled. Each replacement subject w ill follow the same screening procedures and 
randomization sequence as the subject who is discontinued, regardless of when the subject discontinued. The 
anticipated doses being studied for each dosing regimen are as follows:
Treat ment Regimen Doses
Single -dose or QD A1 0.1%/Placebo
A2 0.3%/Placebo
A3 0.6%/Placebo
BID B1 0.1%/Placebo
B2 0.3%/Placebo
B3 0.6%/Placebo
TID C1 0.1%/Placebo
C2 0.3%/Placebo
C3 0.6%/Placebo
QID D1a0.1%/Placebo
D2 0.3%/Placebo
D3 0.6%/Placebo
BID=twice daily; QD=once daily; QID= 4 times daily; TID= 3 times daily.
a The dose -escalation committee decided not to enroll cohort D1, agreeing that the results would not add to the understanding 
of the safety of SHP639.
Screening Period
For all cohorts, the maximum duration of the screening period is 42 days. On the initial visit to the site, the subject 
will first give informed consent. This will be the date that he/she enters the screening period. After giving consent, 
the subject w ill be evaluated against the inclusion and exclusion criteria and undergo screening procedures. Durin g 
the screening period, subjects will return to the site approximately every 2 weeks for safety evaluations. If 
necessary, subjects w ill undergo a w ashout period from their current medications.
Follow ing the screening visit, subjects who continue to meet t he protocol -specific inclusion and exclusion criteria 
will return to the site on either Day -3 or Day -2, to reconfirm eligibility criteria for participation and undergo 
predose safety and ophthalmologic assessments.
Study Parts
The study will consist of 2 parts, Part 1 and Part 2.
ï‚·Part 1 consists of Cohorts A1, A2, and A3, each of which is a single -dose and QD multiple- dose cohort 
(1cohort for each of the 3 dose levels), followed by Cohorts B1, B2, and B3, each of w hich is a BID 
multiple -dose cohort (1 coh ort for each dose level).
ï‚·Part 2 consists of Cohorts C1, C2, and C3, each of which is a TID multiple -dose cohort (1 cohort for each dose 
level), followed by Cohorts D1, D2, and D3, each of which is a QID multiple -dose cohort (1 cohort for each 
dose level).
Cohorts A1 -A3
In Cohorts A1, A2, and A3, there w ill be a single -dose treatment period (SDTP) follow ed by a multiple -dose 
treatment period (MDTP).
In the SDTP, subjects w ill be randomized prior to administration of investigational product on Day 1 after al l entry 
criteria have been confirmed. One drop of investigational product w ill be administered topically to a designated eye. 
The first 3 of 7 subjects w ill be dosed w ith a minimum of 1 -hour intervals betw een the subjects for safety purposes. 
The subject w ill then undergo safety, ophthalmologic, and PK assessments. Subjects will be observed for the next 
24hours with appropriate medical oversight. An ophthalmologist will be on call to assess ophthalmic -related 
medical issues. If no adverse events (AEs) occur that are consistent with the predefined stopping criteria, the rest of 
Shire CONFIDENTIAL Page 17
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
the subjects in the cohort can be administered investigational product in 1 designated eye. 
After completion of the assessments scheduled for Day 2 of the SDTP, subjects w ill enter a washout period. The 
duration of the washout period w ill last between 3 and 14 days. A dose escalation meeting will occur prior to the 
advancement to the multidose part of each cohort. Following a decision to commence the MDTP for Cohorts A1, 
A2, and A3, s ubjects will attend the site on Days - 2 and -1 to undergo the scheduled safety and ophthalmic 
assessments. In Cohorts A1, A2, and A3 MDTP, all subjects will be administered investigational product in both 
eyes. The same dose concentration that was administ ered during the SDTP of Cohorts A1, A2, or A3 will be 
administered during the MDTP QD for the next 28 days. Subjects are to place 1 drop in each eye at approximately 
the same time each day.
Within each cohort (A1, A2, or A3), subjects will continue to self -administer investigational product QD for the 
duration of the MDTP. Between Day 2 and Day 26, subjects w ill return to the site for scheduled outpatient visits. On 
Day 26, subjects w ill be readmitted to the site. On Day 27, subjects will continue to self -administer investigational 
product w hile undergoing the scheduled assessments. The last dose will be administered on the morning of Day 28. 
Follow ing com pletion of the assessments scheduled for Day 29, subjects w ill then be discharged from the site.
Subject s will receive a follow -up telephone call approximately 7 days after being discharged from the site. They will 
return to the site to undergo antidrug antibody (ADA) sampling approximately 60 days after the last dose of 
investigational product.
Cohorts B1 -3, C1-3, and D1 -3
Authorization from the sponsor to proceed from 1 cohort to the next is to be received before subjects enter the 
screening period for Cohorts B, C, and D. Once authorization has been received from the sponsor, subjects are to be 
admitted to the screening period of the appropriate cohort as previously described in t his section.
Subjects will undergo the scheduled safety and ophthalmic assessments on Day -2 and Day -1. Subjects will then be 
administered investigational product per the sponsorâ€™ s authorization to proceed to that cohort. In Cohorts B, C, and 
D, subjects will be administered investigational product in both eyes.
Subjects will continue to self -administer investigational product as instructed for the duration of the cohort. Betw een 
Day 2 and Day 26, subjects will return to the site for scheduled outpatient visits. On Day 26, subjects w ill be 
readmitted to the site. On Day 27, subjects will continue to self -administer investigational product w hile undergoing 
the scheduled assessments. The last dose w ill be administered on the morning of Day 28. After completion of the 
assessments scheduled for Day 29, subjects w ill then be discharged from the site.
Subjects will receive a follow -up telephone call approximately 7 days after being discharged from the site. 
They willreturn to the site to undergo ADA sampling approximately 60 days after the last dose of investigational 
product.
Inclusion and exclusion criteria:
Inclusion criteria
1.Subjects must provide written, signed and dated informed con sent to participate in the study in accordance with 
the International Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guideline E6 and applicable 
regulations, before completing any study -related procedures.
2.Subjects must be aged from 18 through 90 at the time of consent. This inclusion criterion will only be assessed 
at the screening visit.
3.Subjects must have OHT or stable early POAG in both eyes with acceptable Humphrey visual fields (HVF). 
Early POAG for this protocol is defined as healthy ap pearing anterior chamber angles (Shaffer classification 
system grade 3 or 4) and focal and/or generalized thinning of the optic disc rim characteristic of glaucomatous 
disease. An acceptable HVF must have been performed w ithin approximately one year of scr eening, have a 
false -positive rate of 25% maximum, false -negative rate of 25% maximum, and fixation loss rate of 33% 
maximum, and mean devia tion of no worse than -6.00 dB.
4.On Day -1, subjects must have a mean IOP of â‰¥24 mmHg at 8:00 AM and a mean IOP of â‰¥22 mmHg at 
10:00 AMin at least 1 eye, with an IOP difference of <4 mmHg between eyes at both of these time points. If 
Shire CONFIDENTIAL Page 18
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
only 1 eye meets this criterion, then it will be the designated study eye for PD analysis; this eye will also be 
used for dosing in Cohor t A SDTP. 
5.Subjects must have a best -corrected visual acuity (BCVA) in both eyes of 65 letters on the Early Treatment 
Diabetic Retinopathy Study chart (Snellen equivalent âˆ¼20/60) or better at the screening and baseline 
assessments.
6.Subjects must be males o r females who are nonpregnant and nonlactating at screening (negative serum beta -
human chorionic gonadotropin [Î² -hCG]); if sexually active during the study, they must agree to comply with 
the applicable contraceptive requirements of the protocol throughout the study period and for 60 days following 
the last dose of investigational product.
7.Subjects must have a satisfactory medical assessment with no clinically significant or relevant abnormalities as 
determined by medical history, physical examination, and clinical and laboratory evaluation (hematology, 
biochemistry, urinalysis) as assessed by the investigator.
8.Subject must understand and be able, willing, and likely to fully comply with study procedures and restrictions.
9.Subjects must be nonsmokers or have had stable use of tobacco or nicotine -containing products for a 3-month 
period before signing the informed consent form (ICF).
10.Subjects who drink alcohol must have had stable use of alcohol for a 3 -month period before signing the ICF.
Exclusion criteria:
1.Subject has an anatomically narrow  angle, synechiae or evidence of prior inflammation, angle closure 
glaucoma, normal tension glaucoma, pseudoexfoliation syndrome or pigmentary dispersion syndrome with or 
without glaucoma, or secondary glaucoma.
2.Subject has corneal endothelial cell counts of less than 2000 cells/mm2(measured by noncontact specular 
microscopy) at the screening or baseline assessments. 
3.Subject has central corneal thickness less than 500 Âµm or greater than 620 Âµm at the scr eening or baseline 
assessments.
4.Subject has IOP greater than 32 mmHg in either eye before randomization.
5.Subject has used topical ocular hypotensive medications as follow s: prostaglandin ana logs, Î² -adrenoceptor 
antagonists, Î± -adrenergic agonists, or epinephrine -related medications within 4 w eeks before the first dose of 
investigational product; or pilocarpine or carbonic anhydrase inhibitors within 7 days before the first dose of 
investigati onal product.
6.Subject has a history of angle closure, ocular surgery, microinvasive glaucoma surgery device insertion, or laser 
surgery, except for the following procedures, which are allowed: uncomplicated cataract surgery, laser 
peripheral iridotomy with resultant angle of Shaffer grade 3 or 4, and postcataract neodymium -doped y ttrium -
aluminum -garnet (Nd:YAG) laser posterior capsulotomy. Cataract surgery and other procedures must have 
occurred a minimum of 3 months before randomization.
7.Subject has a histo ry of significant ocular trauma or ocular disease including but not limited to moderate to 
severe dry eye disease that requires chronic treatment or punctal plugs.
8.Subject has evidence of ocular infection, inflammation, degeneration, or dystrophy at the sc reening or baseline 
assessments, including but not limited to moderate to severe blepharitis (mild blepharitis is allow ed), 
conjunctivitis (allergic or infectious), corneal dystrophy (epithelial, stromal, or endothelial), corneal haze of 
grade 1 or greater based on the Hw ang Grading Scale of Corneal Haze, corneal opacities, keratitis, uveitis, or 
vitritis.
9.Subject has retinal disease including but not limited to: moderate or severe nonproliferative diabetic retinopathy 
(NPDR) (early NPDR is allowed), prolif erative diabetic retinopathy, intermediate or advanced dry age -related 
macular degeneration (AMD) (early dry AMD is allowed), all geographic atrophy, or all wet AMD.
Shire CONFIDENTIAL Page 19
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
10.Subject has any nonglaucomatous optic neuropathy or other significant nonglaucomatous ocul ar disease that is 
likely to affect visual function.
11.Subject has any corneal or ocular surface pathology in either eye that prevents proper IOP measurement, 
pachymetry, or other study data collection procedures.
12.Subject has had changes to their existing pr escription medication regimen for chronic disease, including those 
medicines that affect IOP, w ithin 14 days or 5 half -lives before screening, whichever is longer.
13.Subject has started any new prescription drug medication for chronic disease, including thos e medications that 
affect IOP, w ithin 14 days or 5 half -lives before screening, whichever is longer.
14.Subject has a history of corticosteroid use within 3 months before randomization, except for nonperiocular 
dermatologic use, which is allow ed. 
15.Subject has used belladonna alkaloids (scopolamine, hyoscyamine, atropine) w ithin 7 days prior to 
randomization, cannabinoids or opioids w ithin 28 days before randomization, or B -type natriuretic peptides 
within the past year before randomization; or a subject has an anticipated need for any of the aforementioned 
drugs/drug categories during the study. 
16.Subject has used amantadine within 28 days before randomization.
17.Subject is unable to discontinue contact lens use during and for 60 minutes following instillation of study 
medication, during ophthalmologic examinations, and during study visits.
18.Subject has a current or relevant history of any physical, medical, mental, or psychiatric illness, disorder, or 
condition that may require treatment during the study and/or tha t may interfere with the subject complying with 
the study rules and procedures or completing the study.
19.Subject has any condition that presents undue risk from use of the investigational product, assessment tools, or 
procedures.
20.Subject is a w oman who is p regnant (positive serum Î² -hCG pregnancy test at the time of screening), lactating, 
or less than 90 days post partum at randomization. 
21.Subject has donated blood w ithin 60 days before first dose of investigational product. 
22.Subject has donated plasma within 28 days before first dose of investigational product. 
23.Subject has used another investigational product within 30 days before the first dose of investigational product 
or is actively enrolled in a drug or vaccine clinical study.
24.Subject has a positive hum an immunodeficiency virus, hepatitis B surface antigen, or hepatitis C virus 
antibodies screen.
25.Subject has a positive drugs of abuse screen or alcohol breathalyzer test.
26.Subject has been previously enrolled in this study.
27.Subject has known hypersensitivit y or allergy to any of the ingredients of the investigational product. 
28.Subject consumes more than 21 units of alcohol per w eek or is unable to refrain from alcohol consumption 
within 48 hours before a scheduled visit. (1 alcohol unit=1 beer or 1 w ine [5 oz/150 mL] or 1 liquor 
[1.5oz/40 mL] or 0.75 oz alcohol.)
29.Subject is unable to refrain from tobacco or any products containing nicotine within 8 hours before a scheduled 
visit.
Shire CONFIDENTIAL Page 20
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
Maximum duration of subject involvem ent in the study:
The subjectsâ€™ maximum du ration of participation in the study is expected to be 146 days or approximately 5 months 
(Cohort A1, A2, and A3). The subjectsâ€™ maximum duration of participation in the study for Cohorts B, C, and D is 
expected to be 130 days or approximately 4.5 months .
ï‚·Maximum planned duration of screening and Washout 1: 42 days
ï‚·Planned duration of treatment period: 2 days for SDTP (Cohort A only) and 29 days for MDTP (all cohorts)
ï‚·Planned duration of Washout 2 (Cohort A only): 3 -14 days
Planned duration of follow -up: un til Day 88Â±4 days
Endpoints and statistical analysis:
Study Population
The safety set will consist of all subjects who have been randomized and who have received at least 1 dose of 
investigational product. 
The PK set will consist of all subjects in the safety set for whom the primary PK data are considered sufficient and 
interpretable.
The PD set will consist of all subjects in the safety set for whom the primary PD data are evaluable.
Pharmacokinetic Endpoints
Plasma concentrations of SHP639 w ill be meas ured using a fully validated bioanalytical method. If data permit, PK 
parameters for SHP639 w ill be calculated based on plasma concentration -time data using a noncompartmental 
approach ). Pharmacokinetic parameters may include, but are not limited to, the f ollowing: maximum observed 
concentration (C max); time to reach C max(tmax); area under the observed concentration vs time curve from time zero 
(predose) to the time of the last measurable concentration (AUC 0-t), over the dosing interval (AUC 0-Ï„) for each 
multiple -dose regimen, and from time zero (predose) extrapolated to infinity (AUC 0-âˆž); apparent terminal phase 
elimination half -life (tÂ½); apparent clearance (CL/F); apparent volume of distribution (Vz/F); and accumulation 
ratios based on AUC and C maxfor each multiple -dose regimen .
Pharmacodynamic Endpoints
Intraocular pressure (IOP; mmHg) will be measured using Goldmann applanation tonometry. Pharmacodynamic 
parameters will be estimated as appropriate and may include, but are not limited to, the follow ing: change from 
baseline in IOP; time to the maximum change from baseline in IOP; and proportion of subjects maintaining IOP 
reduction after specified days of treatment. 
Specific endpoints inorder tounderstand theeffect ofSHP639 onIOP willbe defined in the SAP.
Safety Endpoints
Safety and tolerability will be assessed by monitoring AEs, vital sign measurements, clinical laboratory assays, 
electrocardiogram (ECG), ADA, drop comfort assessment, and ophthalmologic examinations.
Sample Size Ju stification 
The number of subjects in this study is not based on statistical pow er considerations because the statistical analyses 
are primarily descriptive in nature. How
ever, if at least 7 subjects complete each cohort, then there will be at least 
65- 8 5% probability of observing at least 1 occurrence of any AE with a true incidence rate for a given dose group 
of at least 15 -25%, respectively.
It is estimated that dose escalation will occur for up to 3 dose levels (4 cohorts within each dose level). Eac h cohort 
will include 5 subjects randomized to active drug and 2 subjects randomized to placebo for an estimated total of at 
least 84 subjects.
For each cohort, the number of subjects w ill be increased as needed based on safety and IOP response. Any cohort
can be repeated to confirm findings with regard to safety or IOP response.
Shire CONFIDENTIAL Page 21
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
Statistical Methodology for Pharmacokinetic Endpoints
All plasma PK analyses will be performed using the PK set. Summary statistics (number of observations, mean, 
standard deviati on [SD], coefficient of variation, median, maximum [max], minimum [min], and geometric mean) 
will be determined for all plasma PK parameters and will be presented by dose, cohort, treatment period (single dose 
or multiple dose; Cohort A only), and study da y. Plasma concentrations at each nominal sampling time will also be 
summarize d using descriptive statistics.
For accumulation ratios, the 95% confidence interval (CI) for the arithmetic mean of the difference (for example, 
AUC 0-Ï„[Day  27]-AUC 0-Ï„[Day 1]) on the logarithmic scale (natural base) will be calculated. The results will be 
back -transformed to give the ratio of geometric means together with the corresponding 95% CI.
Before statistical comparisons, dose -dependent parameters (C max, AUC 0-t, AUC 0-Ï„, and AUC 0-âˆž) will be normalized 
to a common dose, assuming linearity. Additionally, the linear dose proportionality will be evaluated for C max, 
AUC 0-Ï„, AUC 0-t, and AUC 0-âˆžusing the power function model (eg, C max=Î±Â·DoseÎ²or equivalently 
log[C max]=log[Î±]+Î²Â·lo g[Dose], where C maxis considered to increase linearly proportional to dose if Î² is not 
significantly different from 1.0.
Statistical Methodology for Pharmacodynamic Endpoints
All PD analyses will be performed using the PD set.
Descriptive summary statisti cs for IOP (number of subjects, mean, SD, median, min, and max) will be provided by 
dose, cohort, treatment period (single dose or multiple dose; Cohort A only), and study day. Additionally, 95% CIs 
for each estimate and summary statistics of change from b aseline along with 95% CIs will be calculated. 
Pharm acody namic parameters w ill be calculated and summarized by dose, cohort, treatment period (single dose or 
multiple dose; Cohort A only), and study day as applicable.
All IOP data w ill be listed by dose, c ohort, subject, treatment period (single dose or multiple dose; Cohort A only), 
and study day.
Statistical methodology for PK/PD relationship
The relationship between dose of SHP639 ophthalmic solution, plasma PK parameters, and changes in IOP may be 
explo red using graphical and/or regression methods if the data permit.
Statistical Methodology for Safety Endpoints
All safety analyses will be performed using the safety set. The placebo subjects w ill be pooled toge ther as a pooled 
placebo group.
All vital sig n, clinical laboratory, ECG, ADA, drop comfort assessment, and ophthalmologic examination data (per 
schedule of events) w ill be listed by dose, cohort, subject, treatment period (single dose or multiple dose; 
Cohort Aonly), visit, day, and time point (for days with multiple assessments per day). If the ranges are available 
then abnormalities will be flagged. Summary statistics with number of subjects, mean, standard deviation, median, 
minimum, and maximum will be provided by dose, cohort, treatment period (single dose or multiple dose; Cohort A 
only), visit, day, and time point (for days with multiple assessments per day).
Adverse events will be coded using the Medical Dictionary for Regulatory Activities. The number of events, 
incidence, and percentage of treatm ent-emergent AEs will be calculated overall and by system organ class and 
preferred term by dose and cohort. Treatment -emergent AEs w ill be further summarized by severity and relationship 
to investigational product. Adverse events related to investig ational product, AEs leading to w ithdraw al, serious 
AEs, and deaths will be similarly summarized/listed. All information obtained on AEs will be displayed by dose, 
cohort, subject, treatment period (single dose or multiple dose; Cohort A only), visit, and day. A subject w ith 
multiple AEs within a body system will be counted only once.
Shire CONFIDENTIAL Page 26
SHP639 -101 Protocol Am endment 3
SHP639 11 May 201 8
Table 2 Detailed Schedule of Events â€“ Cohort A
Assessment Days Perform ed (Screening through D29)fPredose/
Morninga0 m30 
m1 h2 h3 h4 h6 h 8 h 12 h
Assessment Window  (minutes) 0 Â±5Â±15Â±15Â±15Â±15Â±15 Â±15 Â±15
Dosing SDTP: D1. MDTP: D1 through D28gX
PK blood sampling SDTP: D1. MDTP: D1, D27 X X XXX X
Drop comfort assessmentbSDTP: D1. MDTP: D1, D7, D14, D21, D27, D28 X
Physical examination SCR. SDTP: D -2, D2. MDTP: D- 2, D14, D26, D29 X
Vital signs All visi ts except Day 88/FU X X X X
ECG All visits except MWOA, Day 28, and Day 88/FUhX X X X
BCVA All visits except Day 26 and Day 88/FU X X X
Manifest refraction SCR. SDTP: D -2 MDTP: D -2, D29. X
Slit lamp examination of 
anterio r segmentcSCR, D- 14, SDTP: D -2, D-1, D1, D2. MDTP: D -2 and D -1, D1, 
D2, D7, D14, D21, D27, D28, D29X X X
Conjunctival rednessSCR, D- 14, SDTP: D -2,D-1, D1, D2. MDTP: D -2 and D -1, D1, D2, 
D7, D14, D21, D27, D28, D29.X X X X X
Corneal hazeSCR, D -14. SDTP:D -2,D-1, D1, D2. MDTP: D -2 and D -1), D1, 
D2, D7, D14, D21, D27, D28, D29X X X X X
Corneal epithelial integrity 
using fluorescein stainSCR, D- 14, SDTP: D -2, D-1, D1, D2. MDTP: D -2,D-1, D1, D2, 
D7, D14, D21, D27, D28, D29X X X X X
Anterior chamber cell and flareSCR, D- 14, SDTP: D -2, D-1, D1, D2. MDTP: D -2, D-1), D1, D2, 
D7, D14, D21, D27, D28, D29X X X
Lens opacification SCR, D29 X
IOP, abbreviated schedule SCRe, D-14d, MDTP: D7, D14, D21, D29dX X X X X
IOP, full schedule SDTP: D -2, D-1, D1, D2. MDTP: D -2 and D -1, D1, D2, D27, D28. X X XXXXX X X
Posterior segment examinationSCR (dilated). SDTP: D -2; nondilated. MDTP: D -2; nondilated, 
D29 (dilated)X
GonioscopyeSCR,D29 X
Specul ar microscopy, 
noncontactSCR. SDTP: D -1, D2. MDTP: D- 1, D14, D29 X
Corneal pachymetry SCR. SDTP: D -1D1, D2. MDTP: D- 1, D1, D2, D7, D14, D29 X XX X X
Antidrug Ab blood sampling D-2, D14, D29, D88/FU. X
Drugs of abuse SCR, D- 14, SDTP: D -2, MDTP: D -2 and D -1, D1, D14, D21, D26. X
Shire CONFIDENTIAL Page 27
SHP639 -101 Protocol Am endment 3
SHP639 11 May 201 8
Table 2 Detailed Schedule of Events â€“ Cohort A
Assessment Days Perform ed (Screening through D29)fPredose/
Morninga0 m30 
m1 h2 h3 h4 h6 h 8 h 12 h
Assessment Window  (minutes) 0 Â±5Â±15Â±15Â±15Â±15Â±15 Â±15 Â±15
Alcohol breath test SCR, D- 14, SDTP: D -2, MDTP: D -2 and D -1, D1, D14, D21, D26. X
Serum pregnancy test (female 
subjects)SCR, SDTP: D -2, MDTP: D -2, D1, D26, D29 X
Biochemist ry, hematology, and 
urinalysisSCR, SDTP: D -2, D2. MDTP: D- 2, D1, D7, D14, D21, D26, D27, 
D29.X
Ab=antibody; BCVA=best -corrected visual acuity; D=day; ECG=electrocardiogram; FU=follow up; h=hours; IOP=intraocular pressure; m=minutes; MDTP=multi ple-dose 
treatment period; PK=pharmacokinetic; SCR=screening; SDTP=single -dose treatment period.
aAssessments will take place 60-30 minutes before dosing or in the morning on nondosing days.
bDrop comfort assessments will be obtained immediately, 1, 2, an d 3 minutes after instillation of the investigational product; to be assessed at morning doses only. If the score is 
not â‰¤3 at minute 3, the drop comfort assessment should be repeated at minutes 5, 10, and 15 until the score is â‰¤3. If the sco re is >3 at mi nute 15, it should be recorded as an 
adverse event.
cSlit lamp examination of anterior segment will be performed only during the morning assessment on the following days: Screeni ng, Day -14, SDTP Day -2, SDTP Day -1, 
MDTP Day -2,MDTP Day -1, and Day 29.
dAt screening IOP may be done at any time during the day. At MWOA (D -14), IOP should be done at 10:00am + 3 hours. IOP only needs to be done at one time during 
screening, MWOA, and Day 29.
eGonioscopy at screening can be done at any time of day. Goniosco py on Day 29 will be performed at the morning time point.
fOphthalmologic assessments on screening, MWOA (D -14), and Day 29 need to be done one time during the day only. 
These assessments include: BCVA, Manifest Refraction (Screening), Slit Lamp examina tion of anterior segment, Conjunctival Redness, Corneal Haze, Corneal Epithelial 
integrity using fluorescein stain, Anterior Chamber cell and flare, Lens Opacification, IOP, Posterior Segment Examination, d ilated (Screening and Day 29), Specular 
Microscopy , Noncontact (Screening and Day 29), Corneal Pachymetry (Screening and Day 29)
gSubjects will be administered the last dose of study drug on the morning of Day 28.
hECG is to be performed at one time point only on Day 26 and Day 29
Timings relate to dos e administration or the equivalent morning assessment. Refer to Section 7.1for guidance on the priority order of assessments. Assessments on nondosing days 
(screening, baseline, and Day 29) will take place once in the morning only unless otherwise specifi ed.
Shire CONFIDENTIAL Page 28
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
Table 3 Detailed Schedule of Events â€“ Cohort B
Assessment Days Perform ed (Screening through D29)fPredose/
Morninga0 m 30 m 1 h2 h3 h 4 h 6 h 8 h 12 h
Assessment Window  (minutes) 0 Â±5 Â±15Â±15Â±15 Â±15 Â±15 Â±15 Â±15
Dosing D1 through D28gX X
PK blood sampling D1, D27 X X XXX X
Drop comfort assessmentbD1, D7, D14, D21, D27, D28 X
Physical examination SCR, D- 2, D14, D26, D29 X
Vital signs All visits except Day 88/FU X X X X
ECG All visits except MWOA, Day 28, and Day 88/FUhX X X X
BCVA All visits except Day 26 and Day 88/FU X X X
Manifest refraction SCR, D- 2, D29 X
Slit lamp examination of anterior 
segmentc SCR, D- 14, D -2,D-1, D1, D2, D7, D14, D21, D27, D 28, D29 X X X
Conjunctival redness SCR, D- 14,D -2,D-1, D1, D2, D7, D14, D21, D27, D28, D29 X X X X X
Corneal haze SCR, D- 14, D -2,D-1, D1, D2, D7, D14, D21, D27, D28, D29 X X X X X
Corneal epithelial integrity using 
fluorescein stainSCR, D-14, D -2,D-1, D1, D2, D7, D14, D21, D27, D28, D29 X X X X X
Anterior chamber cell and flare SCR, D- 14. D -2,D-1, D1, D2, D7, D14, D21, D27, D28, D29 X X X
Lens opacification SCR, D29 X
IOP, abbreviated schedule SCRe, D-14d, D7, D1 4, D21, D29dX X X X X
IOP, full schedule D-2, D-1, D1, D2, D27, D28. X X XXX X X X X
Posterior segment examination SCR (dilated), D -2; nondilated, D29 (dilated) X
GonioscopyeSCR, D29 X
Specular microscopy, noncontact SCR, D- 1, D14, D29 X
Corneal pachymetry SCR, D- 1, D1, D2, D7, D14, D29 X XX X X
Antidrug Ab blood sampling D-2, D14, D29, D88/FU X
Drugs of abuse SCR, D- 14), D -2 and D -1, D1, D14, D21, D26 X
Shire CONFIDENTIAL Page 29
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
Table 3 Detailed Schedule of Events â€“ Cohort B
Assessment Days Perform ed (Screening through D29)fPredose/
Morninga0 m 30 m 1 h2 h3 h 4 h 6 h 8 h 12 h
Assessment Window  (minutes) 0 Â±5 Â±15Â±15Â±15 Â±15 Â±15 Â±15 Â±15
Alcohol breath test SCR, D- 14, D -2, D-1, D1, D14, D21, D26 X
Serum pregnancy test (female 
subjects)SCR, D- 2 D1, D26, D29. X
Biochemistry, hematology, and 
urinalysisSCR, D- 2, D1, D7, D14, D21, D26, D27, D29. X
Ab=antibody; BCVA=best -corrected visual acuity; D =day; ECG=electrocardiogram; FU=follow up; h=hours; IOP=intraocular pressure; m=minutes; MDTP=multiple -dose 
treatment period; PK=pharmacokinetic; SCR=screening.
aAssessments will take place 60-30minutes before the first dose of the day or in the morning on nondosing days.
bDrop comfort assessments will be obtained immediately, 1, 2, and 3 minutes after instillation of the investigational product; to be assessed at morning doses only. If the score is 
not â‰¤3 at minute 3, the drop comfort assessment should be repeated at minutes 5, 10, and 15 until the score is â‰¤3. If the score is >3 at minute 15, it should be recorded as an 
adverse event.
cSlit lamp examination of anterior segment will be performed only during the morning assessment on the following days: Screening, Day -14, Day -2,Day -1 and Day 29.
dAt screening IOP may be done at any time during the day. At MWOA (D -14), IOP should be done at 10:00am + 3 hours. IOP only needs to be done at one time dur ing screening, 
MWOA, and Day 29.
eGonioscopy at screening can be done at any time of day. Gonioscopy on Day 29 will be performed at the morning time point.
fOphthalmologic assessments on screening, MWOA (D -14), and Day 29 need to be done one time during the day only. 
These assessments include: BCVA, Manifest Refraction (Screening), Slit Lamp examination of anterior segment, Conjunctival Red ness, Corneal Haze, Corneal Epithelial 
integrity using fluorescein stain, Anterior Chamber cell and flare, Lens Opa cification, IOP, Posterior Segment Examination, dilated (Screening and Day 29), Specular 
Microscopy, Noncontact (Screening and Day 29), Corneal Pachymetry (Screening and Day 29).
gSubjects will be administered the last dose of study drug on the morning of Day 28.
hECG is to be performed at one time point only on Day 26 and Day 29.
Timings relate to the first dose of the day or the equivalent morning assessment. Refer to Section 7.1for guidance on the priority order of assessments. Assessments on nondosin g 
days (screening, baseline, and Day 29) will take place once in the morning only unless otherwise specified.
Shire CONFIDENTIAL Page 30
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
Table 4 Detailed Schedule of Events â€“Cohort C
Assessment Days Perform ed (Screening through D29)fPredose/
Morninga0 m30 
m1 h 2 h3 h4 h6 h8 h 12 h
Assessment Window  (minutes) 0 Â±5Â±15 Â±15Â±15Â±15Â±15Â±15 Â±15
Dosing D1 through D28gX X X
PK blood sampling D1, D27 X X XX X X
Drop comfort assessmentbD1, D7, D14, D21, D27, D28 X
Physical exa mination SCR, D- 2, D14, D26, D29 X
Vital signs All visits except Day 88/FU X X X X
ECG All visits except MWOA, Day 28, and Day 88/FUhX X X X
BCVA All visits except Day 26 and Day 88/FU X X X
Manifest refraction SCR, D- 2, D29 X
Slit lamp examination of 
anterior segmentc SCR, D- 14, D -2, D-1, D1, D2, D7, D14, D21, D27, D28, D29 X X X
Conjunctival redness SCR, D- 14, D -2,D-1, D1, D2, D7, D14, D21, D27, D28, D29 X X X X X
Corneal haze SCR, D- 14,D -2,D-1, D1, D2, D7, D14, D21, D27, D28, D29 X X X X X
Corneal epithelial integrity 
using fluorescein stainSCR, D- 14, D -2,D-1, D1, D2, D7, D14, D21, D27, D28, D29 X X X X X
Anterior chamber cell and flare SCR, D- 14, D -2, D-1, D1, D2, D7, D14, D21, D27, D28, D29. X X X
Lens opacification SCR, D29 X
IOP, abbreviated schedule SCRe, D-14d, D7, D14, D21, D29dX X X X X
IOP, full schedule D-2, D-1, D1, D2, D27, D28. X X XX XXXX X
Posterior segment examination SCR (dilated), D -2; nondilated, D29 (dilated) X
GonioscopyeSCR, D29 X
Specular microscopy, 
noncontactSCR, D- 1 D14, D29 X
Corneal pachymetry SCR, D- 1 D1, D2, D7, D14, D29 X XX X X
Antidrug Ab blood sampling D-2, D14, D29, D88/FU X
Shire CONFIDENTIAL Page 31
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
Table 4 Detailed Schedule of Events â€“Cohort C
Assessment Days Perform ed (Screening through D29)fPredose/
Morninga0 m30 
m1 h 2 h3 h4 h6 h8 h 12 h
Assessment Window  (minutes) 0 Â±5Â±15 Â±15Â±15Â±15Â±15Â±15 Â±15
Drugs of abuse SCR, D- 14, D -2, D-1, D1, D14, D21, D26. X
Alcohol breath test SCR, D- 14), D -2, D-1, D1, D14, D21, D26. X
Serum pregnancy test (female 
subjects)SCR, D- 2, D1, D26, D29. X
Biochemistry, hematology, and 
urinal ysisSCR, D- 2, D1, D7, D14, D21, D26, D27, D29. X
Timings relate to the first dose of the day or the equivalent morning assessment. Refer to Section 7.1for guidance on the priority order of assessments. Assessments on nondosing 
days (screening, baseline, and Day 29) will take place once in the morning only unless otherwise specified.
Ab=antibody; BCVA=best-corrected visual acuity; D=day; ECG=electrocardiogram; FU=follow up; h=hours; IOP=intraocular pressure; m=minutes; MDTP=multi ple-dose 
treatmen t period; PK=pharmacokinetic; SCR=screening
aAssessments will take place 60-30 minutes before the first dose of the day or in the morning on nondosing days.
bDrop comfort assessments will be obtained immediately, 1, 2, and 3 minutes after instillation of the investigational product; to be assessed at morning doses only. If the score is 
not â‰¤3 at minute 3, the drop comfort assessment should be repeated at minutes 5, 10, and 15 until the score is â‰¤3. If the sco re is >3 at minute 15, it should be recorded as an 
adverse event.
cSlit lamp examination of anterior segment will be performed only during the morning assessments on the following days: Screen ing, Day -14, Day -2, â€“Day 1, and Day 29.
dAt screening IOP may be done at any time during the day. At MWOA ( D-14), IOP should be done at 10:00am + 3 hours. IOP only needs to be done at one time during screening, 
MWOA, and Day 29.
eGonioscopy at screening can be done at any time of day. Gonioscopy on Day 29 will be performed at the morning time point. 
f Ophthal mologic assessments on screening, MWOA (D -14), and Day 29 need to be done one time during the day only. 
These assessments include: BCVA, Manifest Refraction (Screening), Slit Lamp examination of anterior segment, Conjunctival Red ness, Corneal Haze, Corne al Epithelial 
integrity using fluorescein stain, Anterior Chamber cell and flare, Lens Opacification, IOP, Posterior Segment Examination, d ilated (Screening and Day 29), Specular 
Microscopy, Noncontact (Screening and Day 29), Corneal Pachymetry (Screening and Day 29).
gSubjects will be administered the last dose of study drug on the morning of Day 28.
h ECG is to be performed at one time point only on Day 26 and Day 29.
Timings relate to the first dose of the day or the equivalent morning assessment. Refe r to Section 7.1for guidance on the priority order of assessments. Assessments on nondosing 
days (screening, baseline, and Day 29) will take place once in the morning only unless otherwise specified.
Shire CONFIDENTIAL Page 32
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
Table 5 Detailed Schedule of Events â€“Cohort D
Assessment Days Perform ed (Screening through D29)fPredose/
Morninga0 m 30 m 1 h 2 h 3 h 4 h 6 h 8 h 12 h
Assessment Window  (minutes) 0 Â±5 Â±15 Â±15 Â±15 Â±15 Â±15 Â±15 Â±15
Dosing D1 through D28gX X X X
PK blood sampling D1, D27 X X X X X X
Drop comfort assessmentbD1, D7, D14, D21, D27, D28 X
Physical examination SCR, D- 2, D14, D26, D29 X
Vital signs All visits except Day 88/FU X X X X
ECG All visits except MWOA, Day 28, and Day 88/FUhX X X X
BCVA All visits except Day 26 and Day 88/FU X X X
Manifest refraction SCRD -2, D29 X
Slit lamp examination of 
anterior segmentcSCR, D- 14, D -2,D-1, D1, D2, D7, D14, D21, D27, 
D28, D29X X X
Conjunctival rednessSCR, D- 14, D -2,D-1, D1, D2, D7, D14, D21, D27, 
D28, D29X X X X X
Corneal hazeSCR, D- 14D-2,D-1, D-1, D1, D2, D7, D14, D21, 
D27, D28, D29X X X X X
Corneal epithelial integrity 
using fluorescein stainSCR, D- 14, D -2,D-1, D1, D2, D7, D14, D21, D27, 
D28, D29X X X X X
Anterior chamber cell and flare SCR, D- 14, D -2 and D -1, D1, D2, D7, D14, D21, 
D27, D28, D29.X X X
Lens opacification SCR, D29 X
IOP, abbreviated schedule SCRe, D-14d, D7, D14, D21, D29dX X X X X
IOP, full schedule D-2, D-1, D1, D2, D27, D28. X X X X X X X X X
Posterior segment examination SCR (dilated), D -2; nondilated, D29 (dilated) X
GonioscopyeSCR D29 X
Specular microscopy, 
noncontactSCR, D- 1, D14, D29 X
Shire CONFIDENTIAL Page 33
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
Table 5 Detailed Schedule of Events â€“Cohort D
Assessment Days Perform ed (Screening through D29)fPredose/
Morninga0 m 30 m 1 h 2 h 3 h 4 h 6 h 8 h 12 h
Assessment Window  (minutes) 0 Â±5 Â±15 Â±15 Â±15 Â±15 Â±15 Â±15 Â±15
Corneal pachymetry SCR, D- 1, D1, D2, D7, D14, D29 X X X X X
Antidrug Ab blood sampling D-2, D14, D29, D88/FU X
Drugs of abuse SCR, D- 14, D -2, D-1, D1, D14, D21, D26. X
Alcohol breath test SCR, D- 14, D -2,D-1, D1, D14, D21, D26. X
Serum pregnan cy test (female 
subjects)SCR, D- 2, D1, D26, D29. X
Biochemistry, hematology, and 
urinalysisSCR, D- 2D1, D7, D14, D21, D26, D27, D29. X
Ab=antibody; BCVA=best-corrected visual acuity; D=day; ECG=electrocardiogram; FU=follow up; h=hours; IOP=intraocular pressure; m=minutes; MDTP=multiple-dose 
treatment period; PK=pharmacokinetic; SCR=screening
aAssessments will take place 60-30 minutes before the first dose of the day or in the morning on nondosing days.
bDrop comfort assessments will be obtained immediately, 1, 2, and 3 minutes after instillation of the investigational product; to be assessed at morning dose s only. If the score 
is not â‰¤3 at minute 3, the drop comfort assessment should be repeated at minutes 5, 10, and 15 until the score is â‰¤3. If the score is >3 at minute 15, it should be recorded as an 
adverse event.
cSlit lamp examination of anterior segment will be performed only during the morning assessment on the following days: Screeni ng, Day -14, Day -2, Day 1, and Day 29.
dAt screening IOP may be done at any time during the day. At MWOA (D -14), IOP should be done at 10:00am + 3 hours. IOP only needs to be done at one time during 
screening, MWOA, and Day 29.
eGonioscopy at screening can be done at any time of day. Gonioscopy on D ay29 will be performed at the morning time point.
fOphthalmologic assessments on screening, MWOA (D -14), and Day 29 need to be done one time during the day only. 
These assessments include: BCVA, Manifest Refraction (Screening), Slit Lamp examination of anterior segment, Conjunctival Redness, Corneal Haze, Corneal Epithelial 
integrity using fluorescein stain, Anterior Chamber cell and flare, Lens Opacification, IOP, Posterior Segment Examination, d ilated (Screening and Day 29), Specular 
Microscopy, Nonco ntact (Screening and Day 29), Corneal Pachymetry (Screening and Day 29)
gSubjects will be administered the last dose of study drug on the morning of Day 28.
hECG is to be performed at one time point only on Day 26 and Day 29.
Timings relate to the first dose of the day or the equivalent morning assessment. Refer to Section 7.1for guidance on the priority order of assessments. Assessments on nondosing 
days (screening, baseline, and Day 29) will take place once in the morning only unless otherwise specifi ed.
Shire CONFIDENTIAL Page 34
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
1. BACKGROUND INFORMATI ON
SHP639 is a 9 -amino acid, sy nthetic, C -type natriuretic peptide (CNP) analog that is a potent and 
selective agonist of natriuretic peptide receptor B (NPR -B). It is being developed by  Shire for the 
treatment of glaucoma and ocu lar hypotension (OHT). Interaction of SHP639 with NPR -B 
would potentially  have an intraocular pressure (IOP) -lowering effect with a novel mode of action 
that targets the primary outflow mechanism tha t is altered in these diseases.
Natriuretic peptides are potent activators of the cell membrane -bound guany lyl cyclases, thereby  
increasing the intracellular concentration of cy clic guanosine monophosphate (cGMP). C- type 
natriuretic peptide or CNP analog activation of NPR -B can consequentl y increase cGMP leading
to various phy siological effects (eg, smooth muscle relaxation, vasorelaxation, and vascular 
remodeling) including trabecular meshwork relaxation. I t has been reported in several 
publications that compounds that increase cellular concentrations of cGMP wi ll lower IOP by  
potentially  increasing aqueous humor outflow through relaxation of the trabecular meshwork 
(Becker, 1990; Nathanson, 1988; Nathanson, 1992; Stein and Clack, 1994 ). Targeting the 
trabecular meshwork pathway , which is the dominant ocular outflow mechanism responsible for 
the majority  of aqueous humor drainage , can potentially  translate into an attractive target for 
treating OHT and glaucoma.
In vitro, SHP639 has shown to be highl y selective towards activating NPR- B receptors (50% of 
maximal effective concentration [EC 50]=61.4Â±11.0nM) when compared with natriuretic peptide 
receptor A ( NPR -A)receptors (EC 50=2179Â±335nM), ie, SHP639 is 35 times more potent for the 
NPR -B receptor compared with NPR- A receptor .
In vivo ,a robust lowering of IOP was noted in rabbits and dogs following topical ocular 
instillation of SHP639. I n rabbit models, a dose -depe ndent IOP -lowering efficacy  (â‰¥40% IOP 
reduction at 0.6%) was observed and the IOP- lowering effect persisted for at least 8 hours for the 
highest dose tested (0.6%/180 Âµg per ey e). Single -dose administration also significantl y 
increased outflow facility (tr abecular outflow) b y 2.6-fold in the same species.
Topical ocular administration of SHP639, at a concentration up to 0.6%, was well tolerated in 
rabbits and monkey s. The no -
observed-adverse- effect level (NOAEL) following 28 day s of 
topical administration w as 0.6%, administered as 1 drop, into both ey es, 4 times daily  (QID) 
(total daily  dose of 1.51 mg/day  of SHP639).
1.1 Indication and Current Treatment Options 
Glaucoma is an optic neuropathy  characterized by  retinal ganglion cell degeneration and death, 
evide nt at the optic nerve head, and which results in visual field loss. Glaucoma can be classified 
by anatomy  (open -
angle or angle- closure glaucoma) or b y etiology  (primary , secondary , or 
congenital). Primary  open -angle glaucoma (POAG) can progress asy mptomati cally  for months 
or years, causing a delay  in diagnosis and treatment. I n contrast, OHT is a condition of elevated 
IOP without signs of early  glaucoma but which increases the risk of developing the disease.
Shire CONFIDENTIAL Page 35
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
Glaucoma is a leading cause of irreversible visio n loss worldwide ( Weinreb et al., 2014; Quigley  
and Broman, 2006 ). Primary  open -angle glaucoma affe cted approximately  58 million people in 
2015; this number is projected to increase to approximately  66 million in 2020 ( Kapetanakis et 
al., 201 6). Additionally , approximately  2.71 million Americans had open -angle glaucoma in 
2011, a prevalence expected to almost triple to 7.32 million by  2050 ( Vajaranant et al., 2012 ). 
Intraocular pressure is the major modifiable risk factor of glaucoma ( Leske et al., 2003 ), 
including in patients w ith IOP in the statistically  â€œnormalâ€ range ( Collaborative Normal- Tension 
Glaucoma Study  Group, 1998 ).Reduction of IOP has been demonstrated in landmark studies to 
protect against further damage to the optic nerve in patients with earl y (Heijl et al., 2002) and 
advanced ( AGIS Investigators, 2000 ) glaucoma and to decrease the risk of progression to 
glaucoma in patients with OHT ( Kass et al., 2002 ).
Based on data from the Early  Manifest Glaucoma Trial ( Heijl et al., 2002 ) and Collaborative 
Initial Glaucoma Treatment Study  (Lichter et al., 2001 ), ophthalmologists consider a patientâ€™s 
clinical status, age, and lifesty le in order to decide on an initial target IOP, along with the 
therapeutic measures to achieve that IOP. While closely  following the patientâ€™s visual fields and 
optic disc status, the target IOP will b e reassessed periodicall y or if the patient demonstrates 
evidence of glaucoma progression. 
Intraocular pressure elevation can occur because of a decrease in aqueous humor outflow 
through the trabecular meshwork (conventional pathway ) or uveoscleral outflo
w (unconventional 
pathway ) or a relative increase in aqueous humor production compared to outflow ( Goel et al., 
2010). Pharma cotherap y options can target an y or all of these mechanisms. The main classes of 
topical ocul ar hypertensive either decrease aqueous humor production (prostaglandin analogs, 
Î±
-adrenergic agonists, and cholinergic agonists) or increase aqueous humor outflow (carbonic 
anhy drase inhibitors, Î² -blockers, and Î± -adrenergic agonists). Orall y administered carbonic 
anhy drase inhibitors are more effective at lowering IOP compared with topically  applied 
medication; however, the high incidence of s ystemic side effects associated with an oral regimen 
(Weinreb and Khaw, 2004 ) makes it an unacceptable option for routine clinical use.
1.2 Product Background
1.2.1 Nonclinical Information
In vitro and in vivo primary  pharmacology  studies, in vitro secondary  pharmacology  studies to 
assess â€œoff -target â€ potential, and in vivo pharmacokinetics and distribution studies were 
performed. Good Laboratory  Practice (GL P)-compliant safet y pharmacology studies using 
SHP639 were conducted in vitro in a human ether -Ã 
-go-go-related gene assay  and in vivo by  the 
intravenous (IV) route in rats and nonhuman primates (NHPs). Pivotal GL P-compliant 4 -week 
toxicology  studies with topical SHP639 were conducted in rabbits and NHPs, with 
accompan ying toxicokinetics. A 4- week toxicology  and toxicokinetics study  with intravenously  
administered SHP639 was performed to assess potential sy stemic toxicity . Rabbits and NHPs are 
both pharmacologically relevant species and both are commonl y used species to assess topical 
and sy stemic toxicity  in ocular drug development. The topical safe ty studies in both species 
included a full assessment of potential sy stemic toxicity  (toxicokinetics, clinical pathology , and 
anatomic pathology  for a full list of organs), such that a single species (NHP) to assess the IV 
Shire CONFIDENTIAL Page 36
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
toxicity  of SHP639 was considered appropriate. The SHP639 formulation used in the pivotal 
topical studies is identical to the proposed clinical formulation. This formulation contains 
standard components t ypically  used in topical ocular formulations. In vitro and in vivo 
genotoxicity  studies were also GL P compliant.
The nonclinical studies demonstrated that topically  administered SHP639 has robust and 
dose-dependent IOP -lowering efficacy  in rabbits and dogs, is distributed to relevant ocular 
tissues with minimal sy stemic absorption, and is well tolerated in rabbits and NHPs when 
administered up to QID for 1 month of treatment at concentrations of up to 0.6% SHP639 (30 ÂµL 
drop). Clinical signs of ocular discomfort were minimal, transient, and not associated with an y 
ocular pathology or toxici ty. Following topical administration, sy stemic exposure to SHP639 is 
very low to nondetectable, suggesting a low risk of producing s ystemic toxicities. Central 
nervous s ystem, cardiovascular, respiratory , and renal safet y pharmacology and systemic toxicity
were characterized following IV SHP639 administration, and SHP639 was well tolerated. The 
nonclinical findings following IV administration were generally  transient and monitorable and/or 
occurred at s ystemic exposures markedl y higher than those expected c linically . SHP639 was 
nongenotoxic in in vitro and in vivo assay s.
The nonclinical data therefore adequatel y support the initiation of this clinical study. Refer to the 
latest version of the SHP639 investigatorâ€™s brochure (IB) for additional nonclinical in formation.
1.2.2 Clinical Information
There have been no prior clinical studies administering the topical ophthalmic solution of 
SHP639 that will be used for this study . Alcon, the previous sponsor of intravitreally  
administered SHP639 (formerl y known as AL -5941 2C), initiated a study in adult subjects with 
no light perception vision in their study  eye to assess the safet y and efficacy of intravitreall y 
administered SHP639. Subjects were randomized to receive either 30 Âµg SHP639 in a phosphate 
vehicle as a 50 ÂµL intravitreal (IVT) injection or 80 ng travoprost via a 50 ÂµL IVT injection. The 
SHP639 I VT formulation was a different formulation from the SHP639 topical ophthalmic 
solution t hat will be used in this study .
Four subjects were recruited for the first cohort and 3 of the 4 subjects received their IVT 
injection: 2 subjects randomized to SHP639 and 1 subject to travoprost. One of the 
2SHP639 -treated subjects developed moderate corneal edema 10 minutes after SHP639 
administration, which resolved within 8 hours (no treatment was required for the event). The 
other experienced a marked rise in IOP, in addition to corneal edema, immediatel y after SHP639 
administration. The subject was treated for the events; however, the elevated IOP persisted for 
2 weeks. The subject who received 80 ng travoprost did not develop any  significant adverse 
findings; travoprost was administered by  the IVT route with a different formulation to that of 
SHP639.
Based on the unexpected occurrence of these corneal findings in the 2 subjects w ho received the 
50 ÂµL  IVT injection containing 30 Âµg SHP639, further enrollment in the study  was suspended. 
Alcon initiated some exploratory  IVT toxicity  studies in rabbits to bette r understand the effects 
noted.
Shire CONFIDENTIAL Page 37
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
Alway s refer to the latest version of the S HP639 investigatorâ€™s brochure (IB) for the overall 
risk/benefit assessment and the most accurate and current information regarding the drug 
metabolism, pharmacokinetics, efficacy , and safety  of SHP639.
1.3 Risk/Benefit and Ethical Assessment
There are no expec ted benefits to the subjects enrolled in this study . The safety  profile of 
topically  administered SHP639 in rabbits and NHPs shows that the compound is well tolerated 
with no adverse effects up to 0.6% when administered QID as 1 drop (30 ÂµL) in both ey es. 
Although, following IVT administration, corneal opacity  was seen clinically , the topical ocular 
toxicity  studies in rabbits and NHPs using an exaggerated dosing regimen of QID for 4 weeks 
did not demonstrate corneal adverse effects up to 0.6% (in a 30 ÂµL drop; total daily  dose of 
1.51 mg). 
The topical formulation used for this study  is the same as that evaluated nonclinically  in rabbits 
and NHPs, and utilizes a well- characterized and widely  used vehicle, similar to the marketed 
MAXIDEXÂ®vehicle. Refer to Section 3.3 of the current SHP639 IB for further details.
Considering topical administration, the safet y margin for SHP639 ocular drops is calculated 
based on approximate conjunctival surface area. As the corneal and conjunctival surface areas in 
rabbits a nd humans are similar, the human- equivalent dose to the rabbit NOAEL  is equivalent to 
a drop of 0.6% topical solution when administered QID in both ey es, equivalent to a dose of 
1.51 mg SHP639 per ey e per day .
As the anticipated toxicities for SHP639 are l ocal ocular discomfort, as noted in the animal 
studies, the proposed topical concentrations to be administered clinically  to both ey es (with the 
exception of Cohort A single -dose treatment period [SDTP], which will occur in 1 designated 
study  eye only ) will initiate as a once dail y (QD) administration, and will be escalated to 
multiple times daily  based on clinical tolerability . Frequent, serial ophthalmologic examinations, 
including thorough slit lamp and retinal examinations, will ensure that an y corneal or other 
effects will be detected early , although it is considered highl y unlikely that any such effects may 
occur. The tables below show the margins for each of the dose and dose schedule escalations 
proposed, based on 1) SHP639 concentrations/drop number s, and 2) based on SHP639 Âµg/day , 
using a nonclinical NOAEL  (both ey es) of 0.6% QID or 1.51 mg/eye/day . 
Margins to proposed clinical concentrations, based on concentration of SHP639 and the number 
of drops/day , are shown in Table 6.
Shire CONFIDENTIAL Page 38
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
Table 6 Dose Margins Based on SHP639 Concentration and Dosing Regimen
Topical 
ConcentrationDose Margina
QD/Both Eyes BID/Both Eyes TID/Both Eyes QID/Both Eyes
0.1% (50 Âµg/drop) 24-fold 12-fold 9-fold 6-fold
0.3% (150 Âµg/drop) 8-fold 4-fold 3-fold 2-fold
0.6% (300 Âµg/drop) 4-fold 2-fold 1.5-fold 1-fold
BID=twice daily; NOAEL=no
-observed -adverse -effect level; QD=once daily; QID=4 times daily; TID=3 times daily
aDose margin is based on concentration and number of drops per day; nonclinical single ey e NOAEL/clinical dose.
Rabbit NOAEL for both eyes is 0.6%, 8 drops per day (4 drops per eye).
Margins to proposed clinical doses, based on SHP639 Âµg/day , are shown in Table 7.
Table 7 Dose Margins Based on SHP639 Daily Dose
Topic al 
ConcentrationDose Margina
QD/Both Eyes BID/Both Eyes TID/Both Eyes QID/Both Eyes
0.1% per 50 ÂµL 
(50 Âµg/drop)15-fold 7.5-fold 5-fold 3.75- fold
0.3% per 50 ÂµL 
(150 Âµg/drop)7.5-fold 3.75- fold 2.5-fold ~2-fold
0.6% per 50 ÂµL 
(300 Âµg/drop)2.5-fold 1.3-fold ~1-fold 0.6-fold
BID=twice daily; NOAEL=no-observed -adverse -effect level; QD=once daily; QID=4 times daily; TID=3 times daily
aDose margin is based on Âµg/day dose; nonclinical single eye NOAEL/clinical dose.
The NOAEL is 0.6% = 0.6 mg/100 ÂµL = 0.18 mg/30 ÂµL drop; the actual drop size in the animal studies was 31.5 ÂµL drop 
(equivalent to 189 Âµg/drop).
189 Âµg/drop Ã— both eyes Ã— QID = 1.51 mg (free-base equivalent); the clinical studies propose a maximal volume of 50 ÂµL drop.
Alway s refer to the l atest version of the SHP639 investigatorâ€™s brochure (IB) for the overall 
benefit/risk assessment and the most accurate and current information regarding drug 
metabolism, pharmacokinetics, efficacy , and safety  of SHP639
Shire CONFIDENTIAL Page 39
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
2. STUDY OBJECTIVES AND PURPOSE
2.1 Rational e for the Study
SHP639 is being developed for reduction of IOP in glaucoma patients. It is expected to act 
through a novel mode of action (NPR -B agonism) that leads to an increase in trabecular 
meshwork outflow, thus reducing the IOP. SHP639- 101 is a first -in-human clinical study  for a 
topical ophthalmic formulation of SHP639. Up to 3 different concentrations (0.1%, 0.3%, and 
0.6%) will be explored and safet y and tolerability of SHP639 ophthalmic solution will be 
evaluated. As a secondary objective, the stu dy will also aim to characterize the 
pharmacod ynamics (PD) of SHP639, using IOP as a PD biomarker. The pharmacokinetic 
(PK) -PD relationship will be explored if the data permit.
2.2 Study Objectives
2.2.1 Primary Objectives
The primary  objective of this study  is to i nvestigate the safety  and tolerability  of single and 
multiple ascending doses of SHP639 ophthalmic solution in subjects with OHT or with POAG.
2.2.2 Secondary Objectives
The secondary  objective of this study  is to evaluate reduction of IOP, as a PD biomarker, 
following different SHP639 dosing regimens.
2.2.3 Exploratory Objectives
The exploratory  objective for this study  is to explore the PK -PD relationship of SHP639 in 
subjects with OHT or POAG. 
Shire CONFIDENTIAL Page 40
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
3. STUDY DESIGN
3.1 Study Design and Flow Chart
This is a multicenter, randomiz ed, double -masked, placebo-controlled, single- and multiple -dose 
escalation stud y. Three different SHP639 concentrations will be studied: 0.1%, 0.3%, and 0.6%. 
There will be up to 12 cohorts in total, 1 cohort for each dose level and different dosing regim en. 
Each cohort will consist of 7 subjects for a total of 84 subjects in the study . Eligible subjects will 
be randomized in a 5:2 ratio to receive either SHP639 or placebo, respectively . The anticipated 
doses being studied for each dosing regimen are prese nted in the dose- escalation scheme in 
Table 10.
A sufficient number of subjects will be screened and enrolled t
o ensure that at least 6 of 
7subjects complete each treatment in their assigned cohort. In the event that a sufficient number 
of subjects do not complete a cohort, replacement subjects may  be enrolled. Each replacement 
subject will follow the same screening procedures and randomization sequence as the subject 
who is discontinued, regardless of when the subject discontinued.
3.1.1 Designated Study Eye
For the purpose of overall analy sis, 1 ey e will be designated as the primary  eye for the duration 
of the subjectâ€™s participation in the trial. I n Cohort A SDTP, the investigational product will be 
dosed in the designated study  eye only . For all subjects part icipating in the MDTP, a designated 
study  eye will be also identified and the investigational product will be dosed in both ey es. The 
following procedure will be used to determine the designated study  eye:
ï‚·For each subject, the mean baseline IOP at a time point will be the mean of the IOPs on 
days -2 and - 1 at that time point.
ï‚·The designated stud y eye will be the ey e with the highest mean baseline IOP at the 
predose time point.
ï‚·If both ey es have equal mean baseline IOPs, the eye with the highest mean IOP at the 
+2-hour time point will be the designated study  eye.
ï‚·If both ey es have equal mean IOPs at the +2 -hour time point, the ey e with the highest 
mean IOP at the +4 -hour time point will be the designated study  eye.
ï‚·If both ey es have equal mean IOPs at the +4 -hour time point, the ey e with the highest 
mean IOP at the +8 -hour time point will be the designated study  eye.
ï‚·If both ey es have equal mean IOPs at the +8 -hour time point, the right ey e will be the 
designated study  eye.
Shire CONFIDENTIAL Page 41
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
3.1.2 Screening Period
For all cohorts, the maximum duration of the screening period is 42 day s. On the initial visit to 
the site, the subject will first give informed consent. This will be the date that he/she enters the 
screening period. After giving consent, the subject will be evaluated agai nst the inclusion and 
exclusion criteria and undergo the procedures as outlined in Table 1.
During the screening period, subjects will return to the site a
pproximately  every  2weeks for 
safet y evaluations. Subjects requiring a washout from current medicati ons will begin their 
washout period as required in Section 5.2.2 and Table 8.
Following the screening visit, subjects who continue to meet the protocol -
specific inclusion and 
exclusion criteria will return to the site on either Day - 3 or Day -2, to reconfi rm eligibility  
criteria for participation and undergo the predose safet y and ophthalmologic assessments as 
outlined in Table 1.
3.1.3 Study Parts
The study  will consist of 2 parts, Part 1 and Part 2.
ï‚·Part 1 consists of Cohorts A1, A2, and A3, each of which is a single -dose and QD 
multiple -dose cohort (1 cohort for each of the 3 dose levels), followed b y Cohorts B1, B2, 
and B3, each of which is a twice dail y (BID) multiple -dose cohort (1 cohort for each dose 
level). 
ï‚·Part 2 consists of Cohorts C1, C2, and C3, each of which is a 3 times daily (TID) 
multiple -dose cohort (1 cohort for each dose level), followed b y Cohorts D1, D2, and D3, 
each of which is a QID multiple -
dose cohort (1 cohort for each dose level). 
3.1.4 Cohorts A1 -A3
In Cohorts A1, A2, and A3, there will be an SDTP followed by  a multiple -dose treatment period 
(MDTP).
3.1.4.1 Cohorts A1 -A3: Single -dose Treatment Period
Subjects will be randomized prior to administration of investigational product on Day 1 after all 
entry  criteria have been confirmed.
One drop of inves tigational product will be administered topicall y to a designated eye. The first 
3of 7subjects will be dosed with a minimum of 1- hour intervals between the subjects for safet y 
purposes. The subject will then undergo assessments at the time points outline d in Table 1and 
Table 2.
Subjects will be observed for the next 24 hours with appropriate medical oversight. An 
ophthalmologist will be on call to assess ophthalmic -
related medical issues. If no adverse events 
(AEs) occur that are consistent with the predefined stopping criteria, the rest of the subjects in 
the cohort can be administered investigation al product in 1 designated ey e.
Shire CONFIDENTIAL Page 42
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
3.1.4.2 Cohorts A1 -A3: Multiple -dose Treatment Period
After completion of the assessments scheduled for Day  2 of the SDTP, subjects will enter a 
washout period. The duration of the washout period will last between 3 and 14 day s. A dose 
escalation meeting will occur prior to the advancement to each cohort (refer to Section 6.2.3.2
for additional details). For each cohort, following a decision to commence the MDTP, subjects 
will attend the site on Day s -2 and -1 to undergo the scheduled safet y and ophthalmic 
assessments. In Cohorts A1, A2, and A3 MDTP, all subjects will be administered investigational 
product in both ey es. The same dose con centration that was administered during the SDTP of the 
relevant cohort (A1, A2, or A3) will be administered during the MDTP QD for the next 28 day s. 
Subjects are to place 1 drop in each ey e at approximately  the same time each day . Refer to 
Table 1and Sec tion 6.2.3 for additional details.
Subjects will be admitted to the site on Day 1 and will be discharged after completion of all 
Day 2 assessments. On Day s 7, 14, and 21, subjects will return to the site as described in Table 1. 
On Day  26, subjects will be
readmitted to the site. On Day  27, subjects will continue to 
self-administer investigational product while undergoing the scheduled assessments. The last 
dose will be administered on the morning of Day  28. After completion of the assessments 
scheduled for Day 29, subjects will then be discharged from the site. 
Subjects will receive a follow -up telephone call approximately  7days after being discharged 
from the site. They  will return to the site to undergo antidrug antibody  (ADA) sampling 
approximately  60 day s after the last dose of investigational product (Day  88).
3.1.5 Cohorts B1
-B3, C1- C3, and D1- D3
Authorization from the sponsor to proceed from 1 cohort to the next is to be received before 
subjects enter the screening period for Cohorts B, C, and D. Once aut horization has been 
received from the sponsor, subjects are to be admitted to the screening period of the appropriate 
cohort as previousl y described in this section.
Subjects will undergo the scheduled safet y and ophthalmic assessments on Day - 2 and Day -1
(refer to Table 1). Subjects will then be administered investigational product per the sponsorâ€™s 
authorization to proceed to that cohort. In Cohorts B, C, and D, subjects will be administered 
investigational product in both ey es. Refer to Section 6.2.3 for additional details.
Subjects will continue to self -administer investigational product as instructed for the duration of 
the MDTP. Subjects will be admitted to the site on Day 1 and will be discharged after 
completion of all Day 2 assessments. On Day s 7, 14, and 21 ( Â±2 day s, each) , subjects will return 
to the site as described in Table 1. On Day  26, subjects will be readmitted to the site. On Day  27, 
subjects will continue to self
-administer investigational product while undergoing the scheduled 
assessment s. The last dose will be administered on the morning of Day  28. After completion of 
the assessments scheduled for Day 29, subjects will then be discharged from the site.
Subjects will receive a follow -up telephone call approximately  7 day s after being disc harged 
from the site. They  will return to the site to undergo ADA sampling approximately  60 day s after 
the last dose of investigational product (Day  88).
Shire CONFIDENTIAL Page 43
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
3.2 Duration and Study Completion Definition
The subjectsâ€™ maximum duration of participation in the study  is expected to be 146 day s or 
approximately  5
months (Cohort A1, A2, and A3). The subjectsâ€™ maximum duration of 
participation in the study  for Cohorts B, C, and D is expected to be 130 days or approximately  
4.5 months.
ï‚· Maximum planned duration of screening and Washout 1: 42 day s
ï‚· Planned duration of treatment period: 2 day s for SDTP (Cohort A only ) and 29 days 
for MDTP (all cohorts)
ï‚· Planned duration of Washout 2 (Cohort A only ): 3-14 day s 
ï‚· Planned duration of follow -up: until Day  88Â±4 day s (final assessment visit and 
anticipated Study  Completion Date for each subject)
The study  will be completed in approximately  56 weeks.
The Study  Completion Date is defined as the date the final subject, across all sites, completes 
their final protocol -defined assessment. Please note that this includes the follow -up visit or 
contact, whichever is later. The Study  Completion Date is used to ascertain timing for study  
results posting and reporting.
3.3 Sites and Regions
SHP639 -101 will be a multicenter study  conducted in the United States. Approximately  7sites 
will participate in the study .
Shire CONFIDENTIAL Page 44
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
4. STUDY POPULATION
Each subject must participate in the informed consent process and provide written informed 
consent/assent before any procedures specified in the protocol are performed.
4.1 Inclu sion Criteria
The subject will not be considered eligible for the study  without meeting all of the criteria below.
Subjects cannot be enrolled or randomized before all inclusion criteria (including test results) are 
confirmed.
1.Subjects must provide written , signed and dated informed consent to participate in the study  
in accordance with the International Council for Harmonisation (I CH) Good Clinical Practice 
(GCP) Guideline E6 and applicable regulations, before completing an y study -related 
procedures.
2.Subje cts must be aged from 18 through 90 at the time of consent. This inclusion criterion will 
only be assessed at the screening visit.
3.Subjects must have OHT or stable early  POAG in both ey es with acceptable Humphrey  
visual fields (HVF). Early POAG for this pr otocol is defined as healthy  appearing anterior 
chamber angles (Shaffer classification s ystem grade 3 or 4) and focal and/or generalized 
thinning of the optic disc rim characteristic of glaucomatous disease. An acceptable HVF 
must have been performed withi n approximately  one y ear of screening, have a false -positive 
rate of 25% maximum, false -negative rate of 25% maximum, and fixation loss rate of 33% 
maximum, and mean deviation of no worse than - 6.00 dB.
4.On Day  -1, subjects must have a mean IOP of â‰¥24 mmHg at 8:00 AMand a mean IOP of 
â‰¥22mmHg at 10:00 AMin at least 1 ey e, with an IOP difference of <4 mmHg between ey es 
at both of these time points. I f onl y 1 ey e meets this criterion, then it will be the d
esignated 
study  eye for pharmacody namic anal ysis; this ey e will also be used for dosing in Cohort A 
SDTP (designated study  eye criteria are detailed in Section 3.1.1).
5.Subjects must have a best
-corrected visual acuity  (BCVA) in both ey es of 65 letters on t he 
Early Treatment Diabetic Retinopathy Study chart (Snellen equivalent âˆ¼20/60) or better at 
the screening and baseline assessments.
6.Subjects must be males or females who are nonpregnant and nonlactating at screening 
(negative serum beta -human chorionic gonadotropin [Î² -hCG]); if sexually  active during the 
study , they  must agre e to comply  with the applicable contraceptive requirements (refer to 
Section 4.4) throughout the study  period and for 60 day s following the last dose of 
investigational product. 
7.Subjects must have a satisfactory  medical assessment with no clinically  signi ficant or 
relevant abnormalities as determined b y medical history, ph ysical examination, and clinical 
and laboratory  evaluation (hematology , biochemistry , urinal ysis) as assessed by  the 
investigator.
Shire CONFIDENTIAL Page 45
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
8.Subject must understand and be able, willing, and likely to fully  comply  with study  
procedures and restrictions.
9.Subjects must be nonsmokers or have had stable use of tobacco or nicotine -containing 
products for a 3 -month period before signing the informed consent form (ICF).
10.Subjects who drink alcohol must have had stable use of alcohol for a 3 -month period before 
signing the ICF.
4.2 Exclusion Criteria
The subject will be excluded from the stud y if an y of the following exclusion criteria are met:
1.Subject has an anatomically  narrow angle, s ynechiae or evidence of pr ior inflammation, 
angle closure glaucoma, normal tension glaucoma, pseudoexfoliation sy ndrome or 
pigmentary  dispersion syndrome with or without glaucoma, or secondary  glaucoma.
2.Subject has corneal endothelial cell counts of less than 2000 cells/mm2(measured b y 
noncontact specular microscopy ) at the scr eening or baseline assessments.
3.Subject has central corneal thickness less than 500 Âµm or greater than 620 Âµm at the 
screening or baseline assessments.
4.Subject has IOP greater than 32 mmHg in either ey e befor e randomization.
5.Subject has used topical ocular hypotensive medications as follows: prostaglandin analogs, 
Î²-adrenoceptor antagonists, Î±- adrenergic agonists, or epinephrine -related medications within 
4 weeks before the first dose of investigational produc t; or pilocarpine or carbonic anh ydrase 
inhibitors within 7 day s before the first dose of investigational product.
6.Subject has a history  of angle closure, ocular surgery , microinvasive glaucoma surgery  
device insertion, or laser surgery , except for the fol lowing procedures, which are allowed: 
uncomplicated cataract surgery , laser peripheral iridotomy  with resultant angle of Shaffer 
grade 3 or 4, and postcataract neod ymium-doped yttrium -aluminum -garnet (Nd:YAG) laser 
posterior capsulotom y. Cataract surgery a nd other procedures must have occurred a 
minimum of 3 months before randomization.
7.Subject has a history  of significant ocular trauma or ocular disease including but not limited 
to moderate to severe dry ey e disease that requires chronic treatment or punct al plugs .
8.Subject has evidence of ocular infection, inflammation, degeneration, or d ystrophy  at the 
screening or baseline assessments, including but not limited to moderate to severe blepharitis 
(mild blepharitis is allowed), conjunctivitis (allergic or in fectious), corneal dy strophy  
(epithelial, stromal, or endothelial), corneal haze of grade 1 or greater based on the Hwang 
Grading Scale of Corneal Haze, corneal opacities, keratitis, uveitis, or vitritis.
9.Subject has retinal disease including but not limited to: moderate or severe nonproliferative 
diabetic retinopath y (NPDR) (early NPDR is allowed), proliferative diabetic retinopath y, 
intermediate or advanced dry  age-related macular degeneration (AMD) (early  dry AMD is 
allowed), all geographic atrophy , or a ll wet AMD.
10.Subject has an y nonglaucomatous optic neuropathy or other significant nonglaucomatous 
ocular disease that is likely  to affect visual function.
Shire CONFIDENTIAL Page 46
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
11.Subject has an y corneal or ocular surface pathology in either eye that prevents proper IOP 
measurement, pachy metry , or other study  data collection procedures.
12.Subject has had changes to their existing prescription medication regimen for chronic 
disease, including those medicines that affect IOP, within 14 day s or 5 half -lives before 
screening, whichever i s longer.
13.Subject has started an y new prescription drug medication for chronic disease, including those 
medicines that affect IOP, within 14 day s or 5 half -lives before screening, whichever is 
longer.
14.Subject has a history  of corticosteroid use within 3 months before randomization, except for 
nonperiocular dermatologic use, which is allowed.
15.Subject has used belladonna alkaloids (scopolamine, hy oscyamine, atropine) within 7 day s 
prior to randomization, cannabinoids or opioids within 28 day s before randomiza tion, or 
B-type natriuretic peptides within the past y ear before randomization; or a subject has an 
anticipated need for an y of the aforementioned drugs/drug categories during the stud y.
16.Subject has used amantadine within 28 day s before randomization.
17.Subject is unable to discontinue contact lens use during and for 60 minutes following 
instillation of study  medication, during ophthalmologic examinations, and during study  
visits.
18.Subject has a current or relevant history  of an y physical, medical, mental, or psychiatric 
illness, disorder, or condition that may  require treatment during the study  and/or that may  
interfere with the subject comply ing with the study rules and proc edures or completing the 
study .
19.Subject has an y condition that presents undue risk fro m use of the investigational product, 
assessment tools, or procedures.
20.Subject is a woman who is pregnant (positive serum Î²- hCG pregnancy  test at the time of 
screening), lactating, or less than 90 day s post partum at randomization. 
21.Subject has donated blood within 60 day s before first dose of investigational product. 
22.Subjec t has donated plasma within 28 day s before first dose of investigational product. 
23.Subject has used another investigational product within 30 day s before the first dose of 
investigational product or is actively enrolled in a drug or vaccine clinical study.
24.Subject has a positive human immunodeficiency  virus (HIV), hepatitis B surface antigen 
(HBsAg), or hepatitis C virus (HCV) antibodies screen.
25.Subject has a positive drugs of abuse screen or alcohol breathal yzer test.
26.Subject has been previously  enrolled i n this study .
27.Subject has known h ypersensitivity  or allergy  to any  of the ingredients of the investigational 
product.
Shire CONFIDENTIAL Page 47
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
28.Subject consumes more than 21 units of alcohol per week or is unable to refrain from alcohol 
consumption within 48 hours before a scheduled visit. (1 alcohol unit=1 beer or 1 wine 
[5oz/150 mL ] or 1 liquor [1.5 oz/40 mL ] or 0.75 oz alcohol.)
29.Subject is unable to refrain from tobacco or an y products containing nicotine within 8 hours 
before a scheduled visit.
4.3 Restrictions
1.Subjects should refr ain from strenuous phy sical exercise from 48 hours before admission to 
the site and during the visit.
2.Subjects must refrain from alcohol from 48 hours before admission to the site and during the 
visit.
3.Subjects should refrain from foods or beverages contai ning caffeine/xanthine from 48 hours 
before admission to the site and during the visit.
4.During washout periods, subjects should attempt to limit the use of alcohol and tobacco or 
nicotine -containing products.
5.Subjects must avoid using tobacco and other nic otine -containing products (smoking, 
chewing, patch, etc.) from 8 hours before admission to the site and during the visit.
6.Subjects must adhere to the restrictions on use of artificial tears as detailed in Section 5.2.2.
4.4 Reproductive Potential
4.4.1 Female Contra ception
Sexually  active females of childbearing potential must use an acceptable form of contraception 
throughout the stud
y period and for 60 days following the last dose of investigational product. If 
hormonal contraceptives are used, they  should be administered according to the package insert. 
Females of childbearing potential who are not currently  sexually  active must agree to use 
acceptable contraception, as defined below, if they become sexually  active during the period of 
the study  and 60 day s followi ng the last dose of investigational product.
Female subjects should be one of the following:
ï‚·Postmenopausal (12 consecutive months of spontaneous amenorrhea and age ï‚³51years)
ï‚·Surgicall y sterile (having undergone one of the following surgical acts: h ysterectom y, 
bilateral tubal ligation, bilateral oophorectom y, or bilateral salpingectom y)and at least 
6 weeks after sterilization, or
ï‚·A female of childbearing potential with a negative serum ï¢-hCG pregnancy test at the 
screening visit and before randomization. Females of childbearing potential must agree to 
abstain from sexual activity  that could result in pregnancy  or agree to use acceptable methods 
of contraception.
Acceptable methods of contraception are:
Shire CONFIDENTIAL Page 48
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
ï‚·Intrauterine devices plus condoms
ï‚·Double- barrier meth ods (eg, condoms and diaphragms with spermicidal gel or foam)
ï‚·Hormonal contraceptives (oral, depot, patch, injectable, or vaginal ring), stabilized for at 
least 30 day s before the first dose of investigational product, plus condoms. Note: If subject 
become s sexually  active during the study , they  should use one of the other acceptable 
methods noted above in addition to the hormonal contraceptive until it has been stabilized for 
30days.
4.4.2 Male Contraception
Male subjects will be required to use a condom in con junction with spermicidal gel, foam, 
cream, film, or suppository from the time of first dosing until 60 day s after the last dose of 
investigational product.
Childbearing female partners of male stud y participants will be required to follow the acceptable 
methods of contraception for this study  (described in Section 4.4.1) from the time of first dosing 
until 60 day s after the last dose of investigational product.
Male subjects must not donate sperm for 3 months after the last dose of investigational product.
4.5 Discontinuation of Subjects
A subject may  withdraw from the study  at any  time for an y reason without prejudice to their 
future medical care b y the physician or at the institution. The investigator or sponsor may  
withdraw the subject at any  time (eg, in th e interest of subject safet y). The investigator is 
encouraged to discuss withdrawal of a subject from investigational product with the medical 
monitor when possible.
If investigational product is discontinued, regardless of the reason, the early withdrawal
evaluations listed in Table 1are to be performed as completely  as possible. Whenever possible, 
all discontinued subjects should also undergo the protocol
-specified follow -up. Comments 
(spontaneous or elicited) or complaints made b y the subject must be re corded in the source 
documents. The reason for termination and date of stopping investigational product must be 
recorded in the electronic case report form (eCRF) and source documents.
Randomized subjects who discontinue from the study  may  be replaced at t he sponsorâ€™s discretion 
to ensure that at least 6 out 7 subjects complete a dosing regimen cohort. Replacement subjects 
will be assigned to the same treatment group as the subject they  are replacing.
4.5.1 Subject Withdrawal Criteria
At any  time in the study , subjects will be discontinued from the stud y if the IOP measurement in 
either ey e reaches a reading greater than 36 mmHg or a reading less than 8 mmHg. If the subject 
falls outside the above measurements, rescue treatment will be started b y the investigator as per 
the current standard of care.
If subjects experience corneal hazing of grade 3 or greater on the Hwang Grading Scale of 
Corneal Haze, they  will be discontinued from the study  and standard of care will be initiated. 
Shire CONFIDENTIAL Page 49
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
The early  termination evaluations listed in Table 1are to be performed as completely  as possible. 
Whenever possible, all discontinued subjects should also undergo the protocol -specified 
follow -up.
4.5.2 Reasons for Discontinuation
The reason for withdrawal must be determined b y the investigator and recorded in the subjectâ€™s 
medical record and on the eCRF. If a subject is withdrawn for more than 1 reason, each reason 
should be documented in the source document and the most clinically  relevant reason should be 
entered on the eCRF.
Reasons for disc ontinuation include but are not limited to:
ï‚·Completed
ï‚·Adverse event
ï‚·Withdrawal by  subject
ï‚·Noncompliance with investigational product
ï‚·Physician decision
ï‚·Study  terminated by  sponsor
ï‚·Lost to follow -up
ï‚·Pregnancy
ï‚·Protocol deviation
ï‚·Screen failure
ï‚·Other 
4.5.3 Subjec ts â€œLost to Follow-upâ€ Prior to Last Scheduled Visit
A minimum of 3 documented attempts must be made to contact an y subject lost to follow -up at 
any time point before the last scheduled contact (office visit or telephone contact). At least 
oneof these doc umented attempts must include a written communication sent to the subjectâ€™s 
last known address via courier or mail (with an acknowledgement of receipt request) asking that 
they return to the site for final safet y evaluations and return an y unused investiga tional product.
4.5.4 Stopping Criteria for Dose Escalation
1.Progressing from a dosing regimen cohort to the next or from a study  part to the next will not 
occur in the presence of moderate or severe drug- related ocular AEs in 2 or more 
SHP639 -treated subjects in a given cohort.
2.If 1 or more subjects experience corneal hazing of grade 3 or greater on the Hwang Grading 
Scale of Corneal Haze, they  will be discontinued from the study . At that time, the study  will 
stop for further evaluation by  the Shireâ€™s Dose Escala tion Committee.
Shire CONFIDENTIAL Page 50
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
3.If 2 or more subjects in a given cohort receiving active drug have a severe AE in the same 
organ or bod y system, no further subjects will be enrolled or dosed until further evaluation of 
the available data is made by  the medical monitor and investigator to determine whether to 
stop or proceed with the study . Following a safety review of the event, study enrollment or 
dosing of currentl y enrolled subjects may be restarted if the medical monitor and the 
investigator determine that it is safe t o proceed with the study .
4.If any other drug -related event occurs in subjects receiving active drug and is deemed to pose 
an unacceptable risk to subjects by  the investigator or medical monitor after further 
evaluation, no further subjects will be enrolled or dosed until further evaluation of the 
available data is made by the medical monitor and investigator to determine whether to stop 
or proceed with the study. Following a safety  review of the event, study  enrollment or dosing 
of currently  enrolled subject s may  be restarted if the medical monitor and the investigator 
determine that it is safe to proceed with the study .
Shire CONFIDENTIAL Page 51
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
5. PRIOR AND CONCOMITAN T TREATMENT
5.1 Prior Treatment
Prior treatment includes all treatments (including but not limited to prescription treatment s, 
investigational products, vitamins, herbal treatments, and nondrug therapies) received within 
30days or 5 half -lives (whichever is longer) before the date of the first dose of investigational 
product and an y procedures performed within the 5 years before the date of the first dose of 
investigational product. Prior treatment information must be recorde d on the appropriate eCRF 
page.
5.2 Concomitant Treatment 
Concomitant treatment refers to all treatment and ocular procedure received between the dates of 
thefirst dose of investigational product and the end of the follow- up period, inclusive. 
Concomitant treatment information must be recorde d on the appropriate eCRF page.
5.2.1 Permitted Treatment
Subjects should refrain from taking an y medications (excluding those medications listed below) 
during the course of the study , until after discharge from the site on Day  29 of the MDTP; refer 
to Section 5.2.2 for details. Any  medication that is considered necessary  for the subjectâ€™s safety  
and well -being may  be given at th e discretion of the investigator. The administration of all 
medications (including investigational products) must be listed on the appropriate eCRF page.
The following medications are permitted during the study :
ï‚·A stable dose (defined as at least 4 weeks) of prescription medication for chronic use (with 
the exception of those medications listed in Section 5.2.2, Table 8), including but not limited 
to:
â€“Hormonal contraceptives for females of childbearing potential administered according to 
the package insert (see Section 4.4.1)
â€“Hormone replacement therap y
â€“Antihy pertensive medication if the subject is on a stable dose for at least 4 weeks
â€“A stable dose (defined as at least 4 weeks) of medication that can substantially  alter IOP 
(with the exception of those medi
cations listed in Table 8)
ï‚·Occasional use of acetaminophen (paracetamol) and ibuprofen
Refer to Section 5.2.2 for information on use of artificial tears.
5.2.2 Prohibited Treatment
Table 8details the washout period (relative to randomization) for common prior medications that 
are excluded for this study . Refer to Section 7.1.1.3 for details of the washout period for 
prohibited medications. Subjects must not take these medications until after discharge from the 
site on Day  29 of the MDTP, at which time they  may  resume taking their usual medication.
Shire CONFIDENTIAL Page 52
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
Table 8 Common Excluded Medications and Associated Washout Period
MedicationMinim um Tim e Before Randomization
7 days 14 days 28 days 3months 1year
Steroids (except for 
nonperiocular 
derma tologic use)X
Belladonna alkaloids 
(scopolamine, 
hyoscyamine, 
atropine)X
B-type natriuretic 
peptides (eg, 
nesiritide)X
Prostaglandins X
Î²-adrenoceptor 
antagonists (eye 
drops)X
Î±-adrenergic agonists 
(eye drops)X
Epinephrine -related 
medications (eye 
drops)X
Carbonic anhydrase 
inhibitors (eye drops)X
Pilocarpine (all 
drops)X
Carbachol (eye 
drops)X
Echothiop hate (eye 
drops)X
Glycerol X
Mannitol X
Theophylline X
Amantadine X
Shire CONFIDENTIAL Page 53
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
The use of all preserved artificial tears and an y ocular gels and other lubricants is prohibited at 
all times during the stud y.
The use of 
nonpreserved artificial tears is prohibited during the following intervals, which 
include study  visits:
ï‚·Cohort A, SDTP: Day  -2 to Day  2, after final assessment
ï‚·Cohort A, MDTP: Day  
-2 to Day  29, after final assessment
ï‚·Cohorts B, C, and D: Day -2 to Day  29, after final assessment
The use of nonpreserved artificial tears is allowed only during washout periods , according to 
the schedule below. 
ï‚·Cohort A, SDTP, Washout 1: Start of screening until the evening of Day  -2, SDTP
ï‚·Cohort A, Washout 2: Day  2 after last assessment until the e vening of Day  
-2, MDTP
ï‚·Cohorts B, C, and D, Washout 1: Start of screening until the evening of Day  -2
Refer to Section 4.3for restrictions on the use of alcohol, tobacco, caffeine, and xanthine.
Other medications not listed in Table 8may be considered a llowable; see Section 5.2.1 for 
further details.
Shire CONFIDENTIAL Page 54
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
6. INVESTIGATIONAL PROD UCT
6.1 Identity of Investigational Product
The test product is SHP639 ophthalmic solution, which will be provided as an ophthalmic 
solution packaged in 7.5 mL (filled to 5 mL) multiuse ey e drop bottles. SHP639 ophthalmic 
solution is a sterile, colorless topical solution containing 0.1%, 0.3%, or 0.6% SRD006086 (as 
free-base equivalent). The SHP639 ophthalmic solution is preserved with benzalkonium chloride 
and will be supplied in a multiuse low- density  poly ethylene ey e drop bottle. Additional 
information is provided in the current SHP639 IB. 
The quantities of SHP639 drug substance per drop of SHP639 ophthalmic solution are shown in 
Table 9.
Table 9 SHP639 Drug 
Substanc eper Drop of SHP639 Ophthalmic Solution
Topical Concentration (% weight/volume) Quantity of SH639 Drug Substance per Drop (Âµg)
0.1 35
0.3 104
0.6 208
Quantities of drug substance per drop were calculated using a drop volume of 34.7 ÂµL, which was the mean volume obtained at 
various temperatures, bottle orientations, and concentrations. Values have been rounded to the nearest microgram.
The reference product is placebo, which will be provided as an ophthalmic solution packaged in 
7.5mL (filled to 5 mL) multiuse ey e drop bottles identical to those used for the SHP639 
ophthalmic solution. The placebo solution will contain the same excipients as the SHP639 
ophthalmic solution but will not contain SHP639.
6.1.1 Masking the Treatment Assignment
This is a double -masked, placebo -controlled study. The packaging, appearance, and labeling of 
the investigational products will match. 
6.2 Administration of Investigational Products
6.2.1 Interactive Response Technology for Investigational Product Management
The actual treatment given to individual subjects is determined b y a randomization schedule. The 
associated treatment assignments giving details of individual subject treatment are in the form of 
a randomization schedule created b y the interactive response technology (IRT) vendo r.
Each bottle/carton of SHP639 ophthalmic solution or matching placebo will be assigned a unique 
packaging identification number corresponding to the investigational product allocated to the 
subject, once eligibility  has been determined. When a bottle/car ton of SHP639 ophthalmic 
solution or matching placebo is assigned to a subject, the packaging identification number will 
be recorded in the eCRF and in the drug accountability  records. Once assigned, it is important 
that the bottle/carton remains with the same subject throughout the stud y.
Shire CONFIDENTIAL Page 55
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
6.2.2 Allocation of Subjects to Treatment
This is a double -masked, placebo -controlled study.
Subject numbers are assigned to all subjects as they consent to take part in the study . Within each 
site (numbered uniquel y within a p rotocol), the subject number is assigned to subjects according 
to the sequence of presentation for study  participation. This will be a 4-digit number starting at 
0001.
For screen failures, the screening number will be the identifying number used throughout the 
eCRF.
The actual treatment given to individual subjects is determined b y a randomization schedule.
The randomization number represents a unique number corresponding to investigational product 
allocated to the subject and will be allocated before dosin g after eligibility  has been determined.
A randomization number is allocated before dosing once eligibility  has been determined. Once a 
randomization number has been assigned, that number must not be used again, if for example, a 
subject is withdrawn from the study . If a randomization number is allocated incorrectly , the 
study  monitor must be notified as soon as the error is discovered.
Replacement subjects are to be assigned the same treatment as subjects they are replacing.
Individual subject treatment is automatically  assigned by  the IRT.
Investigational product packaging identification numbers, separate from randomization 
numbers/unique identifiers, may  also be assigned to subjects for specific treatment assignment as 
dictated b y the study. In these case s, the same investigational product packing identification 
number may  not be assigned to more than 1 subject.
6.2.3 Dosing
6.2.3.1 Dosing Procedures
After satisfy ing all screening and entry  criteria for the study  before dosing on Day  1 of each 
cohort, subjects will be r andomized to receive either SHP639 ophthalmic solution or placebo, 
respectivel y. Investigational product (SHP639 ophthalmic solution or placebo) will be 
administered topically  in 1 designated ey e (Cohort A, SDTP only ) or in both ey es (Cohort A, 
MDTP only , and Cohorts B, C, and D) at the time points specified in Table 1.
Subjects will receive their assigned dose as dispensed by  the pharmacist or designee at each site. 
Investigational product will be administered by
 the principal ophthalmologist or trained de signee 
at each site while subjects are on site, and will then be self-administered by each subject for the 
remainder of the treatment period.
Subjects should receive the single dose or first dose if multiple daily  dosing (depending on 
cohort assignment) ea ch day  between 7:00am and 9:00am. This is particularly  important for 
cohorts C and D as these subjects will receive 3 and 4 doses daily . 
Shire CONFIDENTIAL Page 56
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
In Cohort A onl y, there will be a SDTP and an MDTP. The 2 treatment periods will be separated 
by a washout period of 3 -14days. In Cohort A, single -dose administration of the corresponding 
dose level (concentration) will occur first, followed by  the multiple -dose administration of the 
same dose level (concentration) QD. The dosing regimens for Cohorts B, C, and D will con sist 
of multiple -dose administration of the appropriate dose level concentration BID, TID, or QID, 
respectivel y. For all cohorts, the final dose during the MDTP will be administered on the 
morning of Day 28.
In Cohort A onl y, as a safety measure, the first 3 subjects in the SDTP will be dosed with a 
minimum of 1 -hour intervals between subjects. Subjects will then be observed overnight and 
until the next day  (24 hours after dosing) with an ophthalmologist on call. If no AEs occur that 
are consistent with the predefined stopping criteria, dosing the rest of the cohort (Cohort A, 
single dose) will proceed as previousl y outlined. Designated stud y eye criteria are detailed in 
Section 3.1.1.
6.2.3.2 Dose Escalation
Throughout the stud y, dose escalation meetings will comme nce at regular time points to review 
safet y data and authorize progression into the next cohort. The anticipated dose escalation 
scheme is presented in Table 10.
ï‚·Single -dose cohorts: a dose escalation meeting may  convene after a minimum of 6 subjects 
have completed the 24 -
hour assessments for the SDTP. At the dose escalation meeting, a 
preselected Dose Escalation Committee will determine whether it is safe to continue to the 
anticipated cohort at either the next dose le vel or the next dosing regimen.
ï‚·Multip le-dose cohorts: a dose escalation meeting may convene after a minimum of 6 subjects 
have completed the Day 14 assessments for the MDTP. At the dose escalation meeting, a 
preselected Dose Escalation Committee will determine whether it is safe to continue t o the 
anticipated cohort at either the next dose level or the next dosing regimen. If the dose 
escalation meeting was held prior to the completion of the cohort, the remainder of the 
treatment period will be completed following the dose escalation meeting.
Shire CONFIDENTIAL Page 57
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
Table 10 Anticipated Dose -escalation Scheme
Dose Authorized by CommitteeEnabling Required Dose -escalation Activity
Before Switch from  Single to Multiple Dose -BID, TID, or QID Before Increasing Dose Level
Cohort Dose Regim en Cohort Dose Regim en Cohort Dose Regim en
A1 0.1% /Placebo SD NA â€“ â€“ NA â€“ â€“
A1 0.1%/ Placebo QD A1 0.1%/ Placebo SD NA â€“ â€“
A2 0.3% /Placebo SD NA â€“ â€“ A1 0.1% /Placebo SD
A2 0.3%/ Placebo QD A2 0.3% /Placebo SD A1 0.1% /Placebo QD
A3 0.6% /Placebo SD NA â€“ â€“ A2 0.3%/Placebo SD
A3 0.6% /Placebo QD A3 0.6% /Placebo SD A2 0.3% /Placebo QD
B1 0.1% /Placebo BID A1 0.1% /Placebo QD NA /â€“ â€“
B2 0.3% /Placebo BID A2 0.3% /Placebo QD B1 0.1% /Placebo BID
B3 0.6% /Placebo BID A3 0.6% /Placebo QD B2 0.3% /Placebo BID
C1 0.1% /Placeb o TID B1 0.1% /Placebo BID NA /â€“ â€“
C2 0.3% /Placebo TID B2 0.3% /Placebo BID C1 0.1%/ Placebo TID
C3 0.6% /Placebo TID B3 0.6% /Placebo BID C2 0.3% /Placebo TID
D1a0.1% /Placebo QID C1 0.1% /Placebo TID NA â€“/ â€“
D2 0.3% /Placebo QID C2 0.3% /Placebo TID D1 0.1% /Placebo QID
D3 0.6% /Placebo QID C3 0.6% /Placebo TID D2 0.3% /Placebo QID
BID=twice daily; NA= not applicable; QD=once daily; QID=4 times daily; SD=single dose; TID=3 times daily.
aCohort D1 is not to be enrolled as it was decided that the resulting data w ould not contribute to the understanding of the safety of SHP639.
Shire CONFIDENTIAL Page 58
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
Shireâ€™s Dose Escalation Committee will consist of, at a minimum, the coordinating principal 
ophthalmologist, the Shire medical monitor, and the Shire ophthalmic study  physician. 
Additional team members may  be included as needed. 
At any  time during the course of the study , subjects will be discontinued from the study  if their 
IOP measurement reaches a reading of greater than 36 mmHg or a reading of less than 8 mmHg. 
Additionally , if subject s experience corneal hazing of grade 3 or greater on the Hwang Grading 
Scale of Corneal Haze, then they  will be discontinued from the stud y. Should an event occur that 
requires a subjectâ€™s discontinuation from the study, the study  will be halted for furthe r evaluation 
by Shireâ€™s Dose Escalation Committee.
The Dose Escalation Committee may  authorize progression from 1 cohort to the next after the 
completion of the previous treatment regimen cohort and completion of the previous dose level 
cohort, as appropri ate. Additionally , more than 1 cohort of safet y data may be reviewed at a dose 
escalation meeting depending on scheduling and study  progress. A minimum of 6 subjects 
should have completed the previous cohort(s) without clinically significant adverse change s; this 
includes findings on the ophthalmologic examination. Additionally , progression will not occur in 
the presence of moderate or severe drug-related ocular AEs in 2 or more subjects.
If, in the judgment of the coordinating principal ophthalmologist, th e Shire medical monitor, and 
the Shire ophthalmic study  physician, it is unclear whether there is a potential safet y concern or 
whether dose escalation should occur, a dose level may  be reduced, modified, or repeated 
depending on the outcome of the safet y data review between doses or treatments. Further, based 
on the findings from the dose escalation review meetings, a cohort (or cohorts) may  be 
determined to not be necessary  to determine the safet y of SHP639. Finall y, upon completion of 
all dose cohorts, a dditional doses may  be studied based on emergent safet y, PD, and PK data 
following the necessary  protocol amendment and Institutional Review Board (IRB) reviews.
6.2.4 Unmasking the Treatment Assignment
The treatment assignment code must not be broken during the study  except in emergency  
situations where the identification of the investigational product is required for further treatment 
of the subject. The investigator should contact the medical monitor as soon as possible after the 
investigator has been unmasked .
In the event that the treatment assignment code is broken and the date and signature of the person 
who broke the code are recorded in the IRT and the source documents. The reason for breaking 
the code will be captured in the clinical database. Upon break ing the code, the subject is 
withdrawn from the study but should be followed up for safety  purposes. Any  code breaks that 
occur must be reported to the contract research organization (CRO) and sponsor. Code -break 
information is held by  the pharmacist/desig nated person at the site.
6.3 Labeling, Packaging, Storage, and Handling
SHP639 ophthalmic solution will be supplied in a multiuse low -density  poly ethylene ey e drop 
bottle containing 5 mL of ophthalmic solution. Each labeled bottle will be placed into a single
labeled carton. Bottles must be stored at refrigerated temperatures (2- 8Â°C) at all times.
Shire CONFIDENTIAL Page 59
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
6.3.1 Labeling
Labels containing study  information and pack identification are applied to the investigational 
product(s) container.
All investigational product is labeled with a minimum of the following: protocol number, 
medication identification number, dose form, directions for use, storage conditions, expiry  date 
(if applicable), batch number and/or packaging reference number, the statements, â€œFor clinical 
trial use only â€ and/or â€œCAUTION: New Drug â€“Limited by  Federal (or US) Law to 
Investigational Use,â€ and the sponsorâ€™s name and address. Any additional labeling requirements 
for participating countries and/or controlled substances will also be included on the label, if 
necessary . 
Additional labels (eg, those used when dispensing marketed product) may , on a case
-by-case 
basis, be applied to the investigational product in order to satisfy  local or institutional 
requirements, but must not:
ï‚·Contradict the clinical study  labe l
ï‚·Obscure the clinical study label
ï‚·Identify  the study  subject by  name
Additional labels may  not be added without the sponsorâ€™s prior full agreement.
6.3.2 Packaging
Investigational product is packaged in the following labeled containers:
The investigational prod uctbottles will be labeled and then each bottle will be placed into an 
individual labeled carton. This carton will then be secured with a tamper -evident seal. 
Changes to sponsor -supplied packaging before dosing may  not occur without full agreement in 
advance b y the sponsor.
6.3.3 Storage
The investigator has overall responsibility  for ensuring that investigational product is stored in a 
secure, limited -access location. L imited responsibility  may  be delegated to the pharmacy  or
member of the study team, but this delegation must be documented. Investigational products are 
distributed by  the pharmacy  or nominated member of the study  team (eg, site pharmacist or 
principal ophthalmologist). 
Investigational product must be stored in accordance with labeled storage co nditions. 
Temperature monitoring is required at the storage location to ensure that the investigational 
product is maintained within an established temperature range. The investigator is responsible 
for ensuring that the temperature is monitored throughout the duration of the study  and that 
records are maintained; the temperature should be monitored continuously  by using either an 
in-house sy stem, a mechanical recording device such as a calibrated chart recorder, or by  manual 
means, such that both minimum a nd maximum thermometric values over a specific time period 
can be recorded and retrieved as required. 
Shire CONFIDENTIAL Page 60
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
Such a device (ie,certified minimum/maximum thermometer) would require manual resetting 
upon each recording. The sponsor must be notified immediately  upon discovery  of an y excursion 
from the established range. Temperature excursions will require site investigation as to cause and 
remediation. The sponsor will determine the ultimate impact of excursions on the investigational 
product and will provide suppor tive documentation as necessary . Under no circumstances should 
the product be dispensed to subjects until the impact has been determined and the product is 
deemed appropriate for use by  the sponsor.
The sponsor should be notified immediately  if there are a ny changes to the storage area of the 
investigational product that could affect the integrity  of the product(s), eg, fumigation of a 
storage room.
6.3.4 Special Handling
Not applicable. 
6.4
Drug Accountability
Investigators will be provided with sufficient amounts of the investigational product to carry  out 
this protocol for the agreed- upon number of subjects. The investigator or designee will 
acknowledge receipt of the investigational product, documenting shipment content, and 
condition. Accurate records of all inv estigational product dispensed, used, returned, and/or 
destroy ed must be maintained as detailed further in this section.
The investigator has overall responsibility  for administering/dispensing investigational product. 
Where permissible, tasks may  be deleg ated to a qualified designee (eg, a pharmacist) who is 
adequatel y trained in the protocol and who works under the direct supervision of the investigator. 
This delegation must be documented in the applicable study  delegation of authority  form.
The investiga tor or his/her designee (as documented by  the investigator in the applicable study  
delegation of authorit y form) will administer and dispense the investigational product only to 
subjects included in this study  following the procedures set out in the study  protocol. Each 
subject will be given only the investigational product carrying his/her treatment assignment with 
instructions as how to administer and store the product. All administered and dispensed 
medication will be documented in the eCRFs and/or other investigational product record. The 
investigator is responsible for assuring the retrieval of all study  supplies from subjects. Due to 
the health/safet y concerns with returning the investigational product container, the investigator 
must request that subjects keep the empt y investigational product packaging after use and return 
it to the site for drug accountability  purposes.
No investigational product stock or returned inventory  from a Shire -sponsored study  may  be 
removed from the site where originall y shipped without prior knowledge and consent by  the 
sponsor. If such transfer is authorized by  the sponsor, all applicable local, state, and national 
laws must be adhered to for the transfer.
The sponsor or its representatives must be permitted access to revi ew the supplies storage and 
distribution procedures and records provided the masking of the stud y is not compromised. 
Shire CONFIDENTIAL Page 61
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
With the written agreement of the sponsor, at the end of the study , all used and unused stock are 
to be sent to a nominated contractor on behalf of the sponsor. In this case, destruction records 
identify ing what was destroy ed, when and how, must be obtained with copies provided to the 
sponsor. Destruction of investigational products must be in accordance with local, state, and 
national laws. Based on entries in the site drug accountability  forms, it must be possible to 
reconcile investigational products delivered with those used and returned. All investigational 
products must be accounted for and all discrepancies investigated and documented to the 
sponsorâ€™s satisfaction.
6.5 Subject Compliance
Compliance must be assessed by  observation of dosing by  the investigator or designee during 
site visits. I n addition, the site personnel should witness the ophthalmic drop administration by  
the subject dur ing these visits to ensure proper technique of drop administration. The 
investigator/nominated person will record details on the drug accountability  log(s) and/or source 
documents. In addition, in-clinic dosing details (time, date, dose level, dosing regim en) will be 
captured on the appropriate eCRF page.
Subjects must be instructed to bring their unused investigational product and empty /used 
investigational product packaging to every  visit. Drug accountability  must be assessed at the 
container/packaging le vel for unused investigational product that is contained within the original 
tamper -evident sealed container (eg, bottles, tray s, vials) or at the individual count level for 
opened containers/packaging. The pharmacist/nominated person will record details o n the drug 
accountability  form.
6.6 Retention of Bioavailability and Bioequivalence Testing Samples
Not applicable.
Shire CONFIDENTIAL Page 62
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
7. STUDY PROCEDURES
7.1 Study Schedule
See Table 1for the visits at which each assessment and procedure will be performed. See 
Table 2, Table 3, Table 4, and Table 5for the time points at which assessments and procedures 
will be performed for Cohorts A, B, C, and D, respectivel y.
Visit windows for the MDTP are as follows: 
ï‚·Start of screening: For all subjects, the maximum duration of the screening peri od is 42 day s. 
ï‚·Days 7, 14, and 21: Â±2 days
ï‚·Follow -up telephone call: 7Â±2 day s after the final dose administration
ï‚·Day 88 follow -up visit: Â±4 days
The following is a suggested â€œpriority  orderâ€ when more than 1 procedure or assessment is 
required at a part icular time point. The actual order of procedures will be dictated by  the clinical 
setting. Departure from the priority  order below will not be considered a protocol deviation.
ï‚·Spontaneous or solicited AE reporting
ï‚·Vital signs
ï‚·Electrocardiogram (ECG)
ï‚·Physical examination
ï‚·Clinical laboratory  tests
ï‚·Dosing
ï‚·Drop comfort assessment (must not be performed within 30 minutes after instillation of 
topical anesthetic)
ï‚·Ophthalmologic examination
ï‚·Intraocular pressure measurement 
ï‚·Pharmacokinetic blood sampling
NOTE: Bl ood sampling for PK evaluation must be performed at the precise protocol -scheduled 
time. Actual sampling time(s) must be accurately recorded in the source document and on the 
appropriate eCRF page.
7.1.1 Screening Period 
For all subjects, the maximum duration o f the screening period is 42 day s. All screening 
assessments and procedures are to be performed by the principal ophthalmologist or a qualified 
designee. See Table 1for details of the screening procedures to be performed.
Shire CONFIDENTIAL Page 63
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
Written, signed, and dated inform ed consent before the performance of an y study -related 
procedures must be obtained by  the principal ophthalmologist or a designee. A copy  of the 
signed ICF must be given to the subject for their records.
7.1.1.1 Screening Failure
A screen failure is a subject who has given informed consent and failed to meet the inclusion 
and/or met at least one of the exclusion criteria and has not been enrolled/randomized or 
admini stered investigational product.
For the purposes of data collection, subjects who give consent to th e study  but are not enrolled 
and/or randomized will be reported with a study  discontinuation reason of â€œsponsor decisionâ€ in 
the eCRF if they  were otherwise full y eligible for the study (for example, alternates/reserve 
subjects).
7.1.1.2 Rescreening of Subjects
Subjects who fail to meet all inclusion/exclusion criteria will not be permitted to be rescreened 
for the stud y at an y point. Any  subject who is qualified but not dosed (ie, an alternate subject) 
may be rescreened at a later date for the study . 
Eligible sub jects who meet all inclusion/exclusion criteria but are unable to participate in the 
study  due to scheduling conflicts/timing may  be rescreened based on investigator discretion and 
sponsor approval should their availability to participate fall outside the screening window. In 
these cases, a new screening number must be assigned for each subject who is rescreened and a 
new ICF must be signed.
7.1.1.3 Washout Period 1
A washout period (Washout 1) of up to 28 day s is required for certain predefined prescription 
medica tion as detailed in Section 5.2.2, Table 8. The washout will take place during the 
screening period and may start from Day -28 onwards depending on the length of washout 
required. Subjects will continue not to take prohibited medications until discharge fr om the site 
on Day  29 of the MDTP.
A midwashout ophthalmic assessment (MWOA) will be performed on both ey es 14 Â±2 day s after 
a subject either starts the washout period or undergoes a previous MWOA. Ophthalmic and 
safet y assessments will be performed during the MWOA at the visits specified in Table 1; the 
time points during each visit are specified in Table 2, Table 3, Table 4, and Table 5for Cohorts 
A, B, C, and D, respectively .
7.1.2 Treatment Period 
Investigational product will be administered by  study  staff w hen subjects are present at the site 
during stud y visits.
7.1.2.1 Day -2 Through Day 2, Single -dose Treatment Period (Cohort A Only)
Following screening and Washout 1, eligible subjects in Cohort A will be admitted to the site for 
the SDTP, either on Day -
3 (optio nal earl y check -in to unit if more convenient for the subject) or 
Shire CONFIDENTIAL Page 64
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
on the morning of Day -2. Subjects will undergo baseline assessments on Day -2 and Day -1 as 
specified in Table 1.
On Day  1 of the SDTP, before dosing, subjects who continue to be eligible w ill be randomized to 
SHP639 ophthalmic solution or placebo, as described in Section 6.2.2. I n each treatment period, 
subjects will receive a single dose of investigational product in 1 ey e, according to the treatment 
to which they  are assigned.
On Day  1 of the SDTP, subjects will undergo assessments and procedures as specified by  visit in 
Table 1and b y time point during each visit in Table 2.
Subjects will be discharged from the site on Day  2 after completion of the evening assessments. 
After subject check out on Day  2 of the SDTP, subjects will have a washout period (Washout 2) 
of 3-14 day s and then return for the MDTP. 
7.1.2.2 Day -2 Through Day 29, Multiple -
dose Treatment Period (All Cohorts)
Subjects will attend the site daily  on Day -2 and Day -1 for MDTP base line procedures, as 
specified in Table 1.
Time points of ophthalmic assessments performed on Day  -2 and Day  -1 should be carried 
forward to assessments on Day  1. This ensures that the baseline IOP time points established 
before dosing begins are time -match
ed to the IOP assessments performed during dosing day s for 
the duration of the stud y.
On the morning of Day  1 of the MDTP, subjects will be admitted to the site. Before dosing, 
subjects in Cohorts B, C, and D who continue to be eligible will be randomized to SHP639 
ophthalmic solution or placebo, as described in Section 6.2.2. Subjects will receive doses of 
investigational product according to the treatment to which they  are assigned. (Subjects in 
Cohort A will continue to receive SHP639 ophthalmic solution or placebo according to the 
treatment assigned on Day  1 of the SDTP.) All subjects in the MDTP cohorts will receive 
investigational product in both ey es.
On Day  1 of the MDTP, subjects will receive dose(s) during the day  depending on their cohort 
assignme nt (Cohort A, B, C, or D). They  will undergo assessments and procedures as specified 
by visit in Table 1and b y time point during each visit in Table 2, Table 3, Table 4, and Table 5
for Cohorts A, B, C, and D, respectively .
Subjects will be discharged on Day 2 following study  procedures and the dispensing of SHP639 
ophthalmic solution for subject use on an outpatient basis. Subjects will be trained on SHP639 
ophthalmic solution administration and will be provided with diaries to record dosing times.
On Day s 3
-26, subjects will be responsible for their outpatient dosing and for rec ording dosing in 
their diaries.
On each of Day s 7, 14, and 21, subjects will attend the site for assessments and procedures as 
specified b y visit in Table 1and b y time point durin g each visit in Table 2, Table 3, Table 4 , and 
Table 5for Cohorts A, B, C, and D, respectively .
Shire CONFIDENTIAL Page 65
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
Subjects will be readmitted to the site on the evening of Day  26. Subjects will continue to receive 
their assigned doses, with the final dose being administere d on the morning of Day 28. Subjects 
will undergo assessments and procedures as specified by  visit in Table 1and by  time point 
during each visit in Table 2, Table 3, Table 4, and Table 5, for Cohorts A, B, C, and D, 
respectivel y. They  will be discharged f rom the site after completion of the morning assessments 
on Day 29.
Subjects who are prematurely  discontinued from the study  will complete the Day 29 assessments 
as fully  as possible.
7.1.3 Follow -up
A follow -up telephone call will take place 7Â±2 days after the final dose (Day 28 of the MDTP). 
Site staff will query  subjects for serious AEs (SAEs), AEs, and concomitant treatments. In the 
event that a subject is prematurely  discontinued from the study , every  attempt should be made to 
complete the follow -up assessme nts.
On Day  88Â±4 day s, subjects will attend the site for ADA blood sample collection. Site staff will 
query  subjects for serious AEs (SAEs), and AEs. Adverse events that occur from Day  33 to Day  
88 should be captured on the AE eCRF page. Concomitant medica tions during this period will 
also be captured. All AEs and SAEs that are not resolved at the time of this contact will be 
followed for an additional 30 day s (see Section 8.1).
7.1.4
Additional Care of Subjects after the Study
No aftercare is planned for this study .
7.2 Study Evaluations and Procedures
7.2.1 Demographic and Other Baseline Characteristics
7.2.2 Safety
The name and address of each third -party vendor (eg, clinical laboratory ) used in this study  will 
be maintained in the investigatorâ€™s and sponsorâ€™s files.
Actual sa fety assessment times will be monitored and recorded. The sponsorâ€™s expectation is that 
the investigator will ensure that every  effort is made to perform all assessments at the precise 
protocol -scheduled time. Any  safet y assessment that deviates from the s cheduled assessment 
time set forth in the protocol by  more than ï‚±15 minutes will be considered a protocol deviation.
Ophthalmic assessments are considered safet y assessments. If an ophthalmic assessment deviates 
from the scheduled assessment time set forth in the protocol b y more than ï‚±15 minutes (or 5
minutes for the 15- minute and 30 -minute time points), it will be c onsidered a protocol deviation.
All AEs, prior medication use, and concomitant medication use will be assessed and monitored 
from the time the subject signs the ICF to comp letion of the study  (including to time of screen 
failure or drop out/discontinuation); see Sections 7.2.2.4 and 8.1for further details. The AEs will 
include nontreatment -emergent AEs (ie, those occurring from the time of informed consent 
Shire CONFIDENTIAL Page 66
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
signature to the first dose of investigational product) and treatment -emergent AEs (ie, AEs 
occurring after the first dose). While housed at the site, subject safet y will also be closely 
monitored through stud y procedures and ph ysician oversight. 
7.2.2.1 Medical and Medication Hi story
A complete medical and medication history , as well as demographic information, will be 
collected at the screening visit by  a qualified licensed phy sician, phy sicianâ€™s assistant, or a nurse 
practitioner. The medical history  will be reviewed and record ed, including:
ï‚·Date of birth
ï‚·Sex
ï‚·Race and ethnicity
ï‚·Recent ingestion of medication (Section 5.1)
ï‚·History  of respiratory , cardiovascular, renal, gastrointestinal, hepatic, endocrine, 
hematological, neurological, psy chiatric, and other diseases
7.2.2.2 Physical Exa mination (Including Height and Weight)
A complete ph ysical examination will be performed at the visits specified in Table 1by a 
qualified licensed ph ysician, phy sicianâ€™s assistant, or nurse practitioner.
The phy sical examination will include a review of t
he following bod y systems:
ï‚·General appearance
ï‚·Skin
ï‚·Head, ey es, ears, nose, and throat
ï‚·Spine/neck/thy roid
ï‚·Musculoskeletal
ï‚·Respiratory
ï‚·Cardiovascular
ï‚·Neurological
ï‚·Abdomen (including liver and kidney s)
Abnormalities identified at the screening visit will be documented in the subjectâ€™s source 
documents and on the medical history  eCRF page. Clinically  significant changes after the 
screening visit will be captured as AEs on the AE eCRF page, as deemed by the investigator.
Height and weight will be recorded at sc reening only .
Shire CONFIDENTIAL Page 67
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
7.2.2.3 Ophthalmologic Examination 
Ophthalmologic examinations of both ey es will be performed at the visits specified in Table 1; 
the time points during each visit are specified in Table 2, Table 3, Table 4, and Table 5for 
Cohorts A, B, C, and D, r espectivel y. Both ey es will be assessed at each examination unless 
otherwise specified.
Manifest Refraction
Manifest refraction will be determined at the following visits in order to assess BCVA:
ï‚·Screening
ï‚·SDTP (Cohort A only ): Day -
2
ï‚·MDTP (all cohorts): D ay-2 and Day  29
The manifest refraction will be repeated if the BCVA has decreased by  10 or more letters. Full 
instructions for performing the manifest refraction are included in the ophthalmology  procedures 
manual.
Best- Corrected Visual Acuity
Using the manifest refraction, the BCVA will be assessed at distance before slit lamp 
examination at the following visits:
ï‚·Screening
ï‚·Midwashout assessment
ï‚·SDTP (Cohort A only ): Days -2 and -1and Day s 1 and 2
ï‚·MDTP (all cohorts): Days -2 and -1 and Day s 1, 2, 7, 14, 21, 27, 28, and 29
SeeTable 2, Table 3, Table 4, and Table 5for detailed timings by  cohort .
Full instructions for measuring BCVA are provided in the ophthalmology  procedures manual.
A decrease in BCVA b y 6 or more letters may  be considered clinically  significant (CS) or not 
clinically  significant (NCS) and requires a dilated posterior segment examination. A 10 -letter 
loss in BCVA is considered CS and requires a repeat manifest refraction and dilated posterior 
segment examination. Clinically  significant c hanges should be recorded as AEs in the source 
document and eCRF.
Slit Lamp Biomicroscopy
Slit lamp biomicroscopy will be performed at the following visits:
ï‚·Screening
ï‚·Midwashout assessment
Shire CONFIDENTIAL Page 68
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
ï‚·SDTP (Cohort A only ): Day s -2 and -1 and Day s 1 and 2
ï‚·MDTP (all coh orts): Days - 2 and - 1 and Day s 1, 2, 7, 14, 21, 27, 28, and 29
SeeTable 2, Table 3, Table 4, and Table 5for detailed timings by  cohort .
The anterior segment will be examined through the slit lamp before performing IOP 
measurements, pach ymetry, or graded assessments. The following structures will be evaluated as 
normal or abnormal. If abnormal, the findings should be described and recorded as either CS or 
NCS. Any  CS findings should be recorded as AEs; the investigator may  use his/her discretion to 
determi ne whether a finding considered NCS is reported as an AE. Findings and assessment of 
clinical significance should be recorded in the source documents and eCRF.
The following will be examined at each visit: 
ï‚·Lids/lashes/lacrimal
ï‚·Conjunctiva
ï‚·Cornea
ï‚·Anterior chamber
ï‚·Iris
ï‚·Lens
Anterior Segment Graded Assessments
Anterior segment graded assessments will be performed at the following visits:
ï‚·Screening
ï‚·Midwashout assessment
ï‚·SDTP (Cohort A only ): Day s -2 and -1 and Day s 1 and 2
ï‚·MDTP (all cohorts): Days - 2 and - 1 and Day s 1, 2, 7, 14, 21, 27, 28, and 29
See Table 2, Table 3, Table 4, and Table 5for detailed timings by  cohort.
Anterior segment graded assessments should be performed during the slit lamp examination but 
before IOP measurement. The following assessments will be performed:
ï‚·Conjunctival redness score assessment
ï‚·Corneal haze assessment
ï‚·Corneal epithelial integrity  assessment b y fluorescein staining
ï‚·Anterior chamber cell and flare
ï‚·Lens opacification (performed during dilated examination only )
Shire CONFIDENTIAL Page 69
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
The procedures are outlined in Appendix 2 ; full instructions are provided in the ophthalmology  
procedures manual.
Any abnormal findings should be described and recorded as either CS or NCS. Any  CS findings 
should be recorded as AEs; the investigator may  use his/her discr etion to determine whether a 
finding considered NCS is reported as an AE. Findings and assessment of clinical significance 
should be recorded in the source document and eCRF.
Intraocular Pressure
Intraocular pressure will be measured at the following visit s:
ï‚·Screening
ï‚·Midwashout assessment
ï‚·SDTP (Cohort A only ): Day s -2 and -1, Day s 1 and 2
ï‚·MDTP (all cohorts): Days - 2 and - 1 and Day s 1, 2, 7, 14, 21, 27, 28, and 29
See Table 2, Table 3, Table 4, and Table 5for detailed timings by  cohort.
Predose morning IOP assessments must be completed at least 30 minutes before dosing to allow 
the anesthetic to wear off.
Intraocular pressure will be measured at the slit lamp using Goldmann applanation tonometry. 
The procedure for measuring IOP is outlined in the ophthalmol ogy procedures manual. Special 
care must be taken to avoid placing pressure on the globe with the fingers when moving the 
eyelids to fully  expose the cornea.
Intraocular pressure must be measured after assessing the corneal epithelium for fluorescein 
staining and before pachymetry , gonioscop y, or dilation for posterior segment examination (if 
being performed).
Two consecutive IOP measurements, to the nearest mmHg, will be made in the designated stud y 
eye (designated study  eye criteria are detailed in Section 3.1.1); if the 2 measurements differ b y 
more than 2 mmHg, then a third measurement will be performed. All (2 or 3) readings will be 
used to determine the mean IOP at the given time point. The procedure will be repeated in the 
nonstudy  eye. All measuremen ts will be recorded in the source document and eCRF.
Every  effort should be made to obtain an accurate IOP measurement. If the mires are irregular 
and/or an IOP reading is not obtainable, this should be noted in the source document and eCRF.
Posterior Segm ent Examination
The posterior segment will be visualized by  a fundus examination at the following visits:
ï‚·Screening 
â€“dilated
ï‚·SDTP â€“nondilated Day -2
Shire CONFIDENTIAL Page 70
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
ï‚·MDTP â€“nondilated Day -2
ï‚·Day 29 â€“ dilated
A dilated posterior segment examination of both eyes should also be performed if the BCVA in 
either ey e decreases by  6 or more letters.
The following structures will be assessed (suggested technique):
ï‚·Vitreous (binocular indirect examination)
ï‚·Optic nerve head (slit lamp biomicroscopy )
ï‚·Cup-to-disc ratio (slit lamp biomic roscopy )
ï‚·Macula (slit lamp biomicroscop y)
ï‚·Retina vasculature
ï‚·Retina, outside of arcades, including periphery
ï‚·Choroid
Observations will be described and/or will be graded as normal or abnormal. Abnormal findings 
will be described. Clinically  significant abn ormalities will be recorded as AEs; NCS findings 
will be recorded as AEs at the investigatorâ€™s discretion. Further details will be specified in the 
ophthalmology  procedures manual.
Gonioscopy 
Gonioscopy  to assess the iridocorneal angles will be performed 
at screening and on Day 29. 
Gonioscopy  should be performed after the corneal epithelium has been evaluated for defects with 
fluorescein and after IOP has been measured but before dilated posterior segment examination 
(Day 29). The angle of each eye should be graded in all 4 quadrants using the Shaffer grading 
system.
Noncontact Specular Microscopy 
Noncontact specular microscop y will be performed to assess endothelial cell count at the 
following visits:
ï‚·Screening
ï‚·SDTP (Cohort A only ): Day -1 and Day  2
ï‚·MDTP (all cohorts): Day -1 and Day s 14 and 29
Details of the procedure will be found in the ophthalmology  procedures manual.
Shire CONFIDENTIAL Page 71
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
Corneal Pachymetry 
Corneal pach ymetry to assess central corneal thickness will be performed after the predose 
examination and at 1, 2, 4, and 12 hours after dosing. With the pachy meter set to perform a 
single measurement, take and record 3 consecutive measurements at each applicable time point 
at the following visits:
ï‚·Screening
ï‚·SDTP (Cohort A only ): Day -1 and Day s 1 and 2
ï‚·MDTP (all cohor ts): Day -1 and Day s 1, 2, 7, 14, and 29
If the range of the measurements is 15 microns or less, the set of readings is acceptable; if not, 
discard all measurements and repeat until an acceptable set of 3 measurements is obtained. 
Record all 3 measures in the source document and the eCRF.
See Table 2, Table 3, Table 4, and Table 5for detailed timings by  cohort.
Full details of the procedure are provided in the ophthalmology  procedures manual.
Drop Comfort Assessment
Drop comfort assessment should be perfo rmed immediately  after instillation of investigational 
product and before IOP assessment (which requires topical anesthetic).
Drop comfort assessments will be performed for the first dose of the day  as follows:
ï‚·SDTP (Cohort A only ): Day  1 
ï‚·MDTP (all cohort s): Days 1, 7, 14, 21, 27, and 28
Drop comfort assessment will not be captured in the subject's dail y journal.
The drop comfort assessment will be performed for each eye except for Cohort A during the 
SDTP, when only  the study  eye will be assessed. The ass essment will be performed immediately  
and 1, 2, and 3 minutes after instillation of the investigational product. The subject will be asked 
to rate drop comfort on a scale of 0 -10, where 0=very  comfortable and 10=very  uncomfortable.
If the score is not â‰¤3 at minute 3, the drop comfort assessment should be repeated at 5, 10, and 
15 minutes after dosing until the score is â‰¤3. If the score is >3 at 15 minutes after dosing, it 
should be recorded as an AE.
7.2.2.4 Adverse Event Collection
At each stud y visit, subjects wi ll be questioned in a general way  to ascertain if AEs have 
occurred since the previous visit (eg, â€œHave you had an y health problems since your last visit?â€). 
Adverse events are collected from the time informed consent is signed until Day 88/FU (refer to 
Section 8). Adverse events that occur after Day  33 to Day  88/FU should be captured on the AE 
eCRF page.
Shire CONFIDENTIAL Page 72
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
7.2.2.5 Vital Signs
Blood Pressure and Pulse Rate
Blood pressure and pulse rate will be measured at the visits specified in Table 1; the time points 
during each v
isit are specified in Table 2, Table 3, Table 4, and Table 5for Cohorts A, B, C, and 
D, respectively . Additional blood pressure and pulse rate measurements may  be performed, as 
determined b y the investigator, in order to ensure appropriate monitoring of s ubject safety  and 
accurate recording of vital sign measurements. Any  changes from baseline that are deemed 
clinically  significant b y the investigator areto be recorded as an AE.
The same method for obtaining blood pressure measurement (auscultatory  or osc illometric) 
should be used throughout the study  for all subjects (and documented). 
In addition, the 
conditions of vital sign measurements should be controlled and as consistent as possible during 
the study , in order to minimize external variability of the readings. It is advised that 
measurements be collected at a comfortable room temperature with little to no background noise, 
using the same (appropriately sized) cuff placed at the same location of the same arm during the 
study . The bladder deflation rate should be deflated (calibrated for oscillometric method or 
manually  by auscultatory method) at a rate of 2-3 mmHg/s (and the first and last audible sounds 
recorded as s ystolic and diastolic pressure) after at least 5 minutes of rest in the assumed 
position .
The cuff should have a bladder length that is 80% and a width that is at least 40% of arm 
circumference (a length -to-width ratio of 2:1). 
The subject should be asked to remove all clothing that covers the location of cuff placement. 
The subject should b e instructed to relax as much as possible for at least 5 minutes before 
collection. The subject should remain quiet during this time and through the measurement.
The subject should be comfortably  seated, with the legs uncrossed, with feet flat on the floor , and 
the back and arm supported, such that the middle of the cuff on the upper arm is at the level of 
the right atrium (the midpoint of the sternum).
At the screening visit, blood pressure should be compared between both arms. When there is a 
consistent i nterarm difference confirmed over 3 consecutive measurements (>10 mmHg), the 
arm with the higher blood pressure should be used for inclusion at screening and the last 
measurement recorded in the eCRF. The same (right or left) arm with the higher blood pres sure 
will be used throughout the study .
For details on blood pressure and pulse procedures, see Figure 1.
Shire CONFIDENTIAL Page 73
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
Figure 1Procedures for Screening Vital Signs (Blood Pressure â€“Pulse)
If there is a â‰¤ 10mmHg difference between arms 
for both SBP and DBP :
Site may select to use either arm for subsequent vital 
sign assessments . If there is a >10mmHg difference between arms on either the SBP or DBP reading :
1. Perform triplicate readings of SBP /DBP-pulse on both arms at intervals of at least 1 minute
2. For each arm , calculate the mean of these 3 readings (SBP/DBP-pulse )
3. Calculate the difference of the means between right and left arms .
If  difference >10mmHg on either arm for either SBP or DBP readings :
Identify whether the SBP or DBP has the larger mean difference . If the DBP 
has the larger mean difference (as in the example below ), then use the DBP 
values to select the arm with the higher blood pressure for subsequent 
vital sign assessments .If difference â‰¤ 10mmHg for both SBP and DBP
(or the difference between the right and left
means for both systolic and diastolic 
readings is zero ):
Site may select to use either arm for subsequent 
vital sign assessments.
SBP/DBP and pulse for selected arm should 
be entered into eCRF .The blood pressure and heart rate entered 
into the eCRF should be the last (3rd) 
triplicate on the arm with the higher mean .
Example :            Systolic       Diastolic    
Right mean  135    /   65 
Left mean   138   /   76
Mean difference            3       11
Use left armExample :              Systolic     Diastolic    
Right mean 126  /   70 
Left mean    120  /   75
Mean difference            6         5
Site preference on armPerform screening blood pressure and pulse on 
both arms after a 5-10 minute rest in sitting or 
supine position .
A single measurement is performed .
DBP=diastolic blood pressure ; eCRF =electronic case report form ; SBP=systolic blood pressure
Shire CONFIDENTIAL Page 74
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
One reading (seated s ystolic blood pressure/diastol ic blood pressure and pulse rate) should be 
taken. 
The use of automated devices for measuring pulse rate is acceptable, although, when done 
manually , pulse rate will be measured in the brachial/radial artery  for at least 30 seconds. When 
the timing of the se measurements coincides with a blood collection, blood pressure and pulse 
rate should be obtained before the nominal time of the blood collection.
Body Temperature
Body temperature will be measured at the visits specified in Table 1; the time points duri ng each 
visit are specified in Table 2, Table 3, Table 4, and Table 5for Cohorts A, B, C, and D, 
respectivel y.
Oral temperature should be taken b y placing a digital thermometer under the tongue for at least 
30 seconds. Ty mpanic temperature may  also be use d. 
7.2.2.6 Clinical Laboratory Evaluations
All clinical laboratory  assay s will be performed according to the laboratory â€™s normal procedures. 
Reference ranges are to be supplied by  the laboratory  and will be used to assess the clinical 
laboratory  data for clinical significance and out -
of-range pathological changes. The investigator 
should assess out -of-range clinical laboratory  values for clinical significance, indicating if the 
value(s) is/are not clinically  significant or clinically  significant. Abnormal clinical laboratory  
values, which are unexpected or not explained by  the subjectâ€™s clinical condition, may , at the 
discretion of the investigator or sponsor, be repeated as soon as possible until confirmed, 
explained, or resolved. Any  laboratory  results that are d etermined to be clinically  significant or 
indicative of an AE, as determined b y the investigator, will be captured in the clinical database.
The following clinical laboratory  assessments will be performed: 
Biochemistry
Blood samples (8.5 mL) for serum bio chemistry  will be collected into a gel separator tube at the 
visits specified in Table 1. The following parameters will be assessed: 
Sodium Total CO 2(Bicarbonate)
Potassium Albumin
Glucose Aspartate aminotransferase
Blood urea nitrogen Alanine ami notransferase
Creatinine Gamma -glutam yltransferase 
Calcium Alkaline phosphatase 
Chloride Total bilirubin 
Shire CONFIDENTIAL Page 75
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
Phosphorus Uric acid
Total protein ï¢-hCGa
aFemales only. Only females of child- bearing potential ie, not postmenopausal or surgically sterile, as defined in Section 
4.4.1 ,will be required to have Î² -hCG evaluated. Reported values of Î² -hCG that are >1.0 and <6.0 mIU/mL are less than the 
upper range for non -pregnant, post-menopausal female (7.0-8.3 mIU/mL) and are considered negative.
Hematology
Blood samples (4 mL) for hemat ology  will be collected into an ethy lenediaminetetraacetic acid 
tube at the visits specified in Table 1. The following parameters will be assessed:
Hemoglobin Total neutrophils (absolute)
Hematocrit Eosinophils (absolute)
Red blood cells Monocy tes (absol ute)
Platelet count Basophils (absolute)
White blood cell count (total and differential) Lym phocy tes (absolute)
Urinalysis
A urine sample for urinaly sis will be collected at the visits specified in Table 1. The following 
parameters will be assessed:
pH Blood Nitrites
Glucose Ketones Leukocy te esterase
Protein Bilirubin Specific gravit y
Microscopic examination will be conducted if protein and/or blood is/are detected during 
urinaly sis. At a minimum, the microscopic examination will consist of red bloo d cells, white 
blood cells, casts, and bacteria.
7.2.2.7 Pregnancy Test
For all female subjects (regardless of reproductive potential status), a serum pregnancy  test will 
be performed at the visits specified in Table 1; or if pregnancy  is suspected; or on withdraw al of 
the subject from the study . Pregnancy  test results must be confirmed as negative before 
proceeding in the stud y.
7.2.2.8 Drug and Alcohol Screen
A urine screen for drugs of abuse and a urine screen or breathal yzer test for alcohol will be 
performed at the vi sits specified in Table 1. Additional drug and alcohol screens may  be 
performed at the investigatorâ€™s discretion.
Shire CONFIDENTIAL Page 76
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
Urine samples are to be tested for amphetamines, barbiturates, benzodiazepines, cannabinoids, 
cocaine, methadone, opiate metabolite, and phenc yclidine. Additional drugs of abuse, eg, 
methamphetamines and tricy clic anti -depressants, which are included in currently  marketed 
products for drugs of abuse screening, will also be tested in these samples. 
Results of drug and alcohol screens will be rev iewed and verified b y the study  monitor but will 
not be collected in the eCRF database.
Any positive result for drugs of abuse or alcohol at screening or on Day  -1 will exclude the 
subject from further participation in the study .
7.2.2.9 Serology Screen
At the scr eening visit, a blood sample of approximately  8mL will be collected into a serum 
separator tube to test for the presence of HIV, HBsAg, and HCV antibod y.
The test results must be confirmed negative before randomization. I f a test result is positive, the 
subject will be excluded from entering the stud y. Results of the virology screen will be reviewed 
and verified b y the study  monitor but will not be collected in the eCRF database.
7.2.2.10 Antidrug Antibody Testing
A blood sample of approximately  6mL will be collec ted to test for antidrug antibodies in serum 
at the visits specified in Table 1. On dosing day s, samples will be collected before the first dose 
of the day . A full description of the ADA sample collection, handling, storage, and shipping is 
provided in the
laboratory  manual.
Any subject with newl y developed antidrug antibodies at the Day 60 (Day  88/FU) assessment, 
which is 60 day s after dosing, may  require follow- up. This will be discussed as necessary  by the 
principal ophthalmologist and medical monitor on a case -by-case basis.
7.2.2.11 Electrocardiogram
Twelve -lead ECGs will be performed at the visits specified in Table 1; the time points during 
each visit are specified in Table 2, Table 3, Table 4, and Table 5for Cohorts A, B, C, and D, 
respectivel y.
The followin g parameters will be recorded on the appropriate eCRF page: heart rate, PR, RR, 
QRS, and QT intervals. The QT interval corrected for heart rate using the Bazett formula (QTcB) 
and QT interval corrected for heart rate using the Fridericia formula (QTcF) wil l be derived from 
the data in the database. The investigatorâ€™s assessment of the ECG tracing as normal or abnormal 
must be documented, and if abnormal, his/her determination of whether the abnormality  is 
clinically  significant or not will be documented on the tracing and recorded in the eCRF.
The subject should be asked to remove all clothing that covers the location of lead placement. 
The subject must be resting in the supine position for at least 5 minutes before collecting the 
ECG.
Shire CONFIDENTIAL Page 77
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
In some cases, it may  be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality. It is important that leads are placed in the 
same positions each time in order to achieve precise ECG recordings. 
One complete recording, in cluding a 10
-second rhy thm strip, should be taken at each time point. 
It should be immediatel y assessed as a valid recording and, if not valid, it should be repeated. 
Invalid recordings will not be entered in the eCRF.
The ECG collected before dosing on Da y 1 will serve as the subjectâ€™s baseline ECG.
To ensure the safet y of the subjects, a qualified individual at the investigator site will make 
comparisons to baseline measurements.
If the QTcF interval (calculated online on site) is increased b y >45 msec fr om the baseline or an 
absolute QTcF value is >500 msec for an y scheduled ECG, then 2 additional ECGs will be 
collected, approximately  2-4 minutes apart, to confirm the original measurement. If either of the 
QTcF values from these repeated ECGs remains abov e the threshold value (>45 msec from the 
baseline; or is >500 msec), then a single ECG must be repeated at least hourly until QTcF values 
from 2 successive ECGs fall below the threshold value that triggered the repeat measurement. 
When triplicate ECGs are collected, the mean of the triplicate measurements should be used to 
trigger the decision to collect follow- up ECGs.
If QTcF values remain above 500 msec (or >45 msec from the baseline) for >4 hours (or sooner 
at the discretion of the investigator) or QTcF intervals get progressivel y longer, the subject 
should undergo continuous ECG monitoring. A cardiologist should be consulted if QTcF 
intervals do not return to <500 msec (or to <45 msec above the baseline) after 8 hours of 
monitoring (or sooner at the dis cretion of the investigator). The parameters from the continuous 
ECG monitoring will be recorded in the source documents.
If a machine -read QTcF/QTcB value is prolonged, as defined above, repeat measurements may  
not be necessary  if a qualified phy sicianâ€™s interpretation determines that the QTcF/QTcB values 
are in the acceptable range.
7.2.3 Pharmacokinetic Procedures
The name and address of the bioanal ytical laboratory (ies) for this study  will be maintained in the 
investigatorâ€™s files at each site and in the Tria l Master File at the CRO. A laboratory  manual full y 
describing the schedule and method of sample handling will be provided.
Actual PK blood (for plasma) sample collection times versus time of dosing will be monitored. 
The sponsorâ€™s expectation is that the investigator will ensure that every  effort is made to collect 
all PK samples at the precise protocol scheduled time. Pharmacokinetic sample collection must 
not deviate from the nominal collection time set forth in the protocol by  more than ï‚±5 minutes 
from samples collected within 4 hours after dosing or by more than ï‚±15minutes for samples 
collected bey ond 4 hours after dosing. Samples collected outside these parameters will be 
considered protocol deviations. 
Shire CONFIDENTIAL Page 78
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
7.2.3.1 Pharmacokinetic Sample Collection and Handling Procedures
Blood samples will be collected for determination of plasma concentrations of SHP639 at the 
visits specified in Table 1; the time points during each visit are specified in Table 2, Table 3, 
Table 4, and Table 5for Cohorts A, B, C, and D, respec tivel y. Potential metabolites may  also be 
determined as appropriate.
A full description of the PK blood sample collection, handling, storage, and shipping is provided 
in the laboratory  manual.
Polypropy lene plasma sample tubes for bioanal ysis must be freez er-safe and identified with 
freezer -safe labels provided by  the central laboratory . The labels will contain the following 
information:
ï‚·Study  number (SHP639 -101)
ï‚·Subject identifier 
ï‚·Cohort (eg, A1, A2, A3)
ï‚·Treatment period (single dose or multiple dose; Coh ort A only )
ï‚·Nominal day
ï‚·Nominal time
ï‚·Matrix identifier (plasma)
ï‚·Split (primary  or back- up)
7.2.3.2 Shipment of Pharmacokinetic Samples
All PK samples should be double -bagged to contain leaks and packed with a sufficient quantit y 
of dry  ice to ensure that they  rema in frozen for at least 72 hours to allow for delay s in shipment. 
Primary  and back -up samples must be shipped separatel y. A courier that will track shipments 
and replenish dry  ice if necessary  should be used. All applicable shipping regulations must be 
followed. Shipments should be scheduled so that no samples arrive on the weekend and should 
be shipped Monday -Wednesday  only. Samples should be transported to ensure that they arrive at 
the bioanal ytical laboratory  between the hours of 9:00 AMand 4:00 PM. The recipient and 
primary  Shire contact must be notified by  telephone or email when the samples are shipped and 
they must be provided with the shipment tracking number.
All PK samples, along with the corresponding documentation, should be shipped according to
the instructions provided in the laboratory  manual.
Pharmacokinetic samples will be stored nominally at -70oC before and after anal ysis at the 
laboratory  until their disposal is authorized by  Shire.
7.2.3.3 Plasma Drug Assay Methodology
Plasma sample anal ysis wil l be performed according to the laboratory  standard operating 
procedures.
Shire CONFIDENTIAL Page 79
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
Plasma concentrations will be measured using a validated bioanal ytical method based on liquid 
chromatograph y with mass spectrometry . In addition, selected plasma samples may  be used to 
investigate incurred sample reproducibility  (full details will be described in the bioanal ytical 
study  plan). The presence of other metabolites or artifacts may  be monitored or quantified as 
appropriate. Raw data will be stored in the archive of the des ignated bioanaly tical contract 
laboratory . 
7.2.4 Pharmacodynamic Assessments
Intraocular pressure (in mmHg) will be measured using Goldmann applanation tonometry  at the 
visits specified in Table 1; the time points during each visit are specified in Table 2, Tab le3, 
Table 4, and Table 5for Cohorts A, B, C, and D, respectivel y. Refer to Section 7.2.2.3 for 
details.
7.2.5 Volume of Blood to Be Collected from Each Subject
For Cohort A, it is expected that approximately  241.5 mL of blood will be collected from all 
subjec ts, regardless of sex ( Table 11).
For Cohorts B, C, and D, it is expected that approximately  192.5 mL of blood will be collected 
from all subjects, regardless of sex ( Table 12).
Table 11 Volume of Blood to Be Collected from Each Sub ject in Each Treatment 
Regimen: Cohort A
Assessment Sample Volume (mL)Number of 
Samples Total Volum
e (mL)
Pharm acokinetic samples 4 18 72
HBsAg, HIV, HCV 8 1 8
Safety Biochemistry and 
ï¢-hCGa8.5 11 93.5
Hem atology 4 11 44
Antidrug antibody 6 4 24
Total 241.5
ï¢-hCG=beta -human chorionic gonadotropin; HBsAg=hepatitis B surface antigen; HCV=hepatitis C virus; HIV=human 
immunodeficiency virus
aï¢-hCG testing for females only. ï¢ -hCG will be assessed in 6 of the 11 samples collected for biochemistry as sessments 
(screening, SDTP [Day -2], MDTP [Day -2, Day 1, Day 26, and Day 29]) 
Cohort A: Single -dose treatment followed by multiple-dose treatment once daily.
Shire CONFIDENTIAL Page 80
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
Table 12 Volume of Blood to Be Collected from Each Subject in Each Tre atment 
Regimen: Cohorts B, C, and D
Assessment Sample Volume (mL)Number of 
Samples Total Volume (mL)
Pharm acokinetic samples 4 12 48
HBsAg, HIV, HCV 8 1 8
Safety Biochemistry and 
ï¢-hCGa8.5 9 76.5
Hem atology 4 9 36
Antidrug antibody 6 4 24
Total 192.5
ï¢-hCG=beta -human chorionic gonadotropin; HBsAg=hepatitis B surface antigen; HCV=hepatitis C virus; HIV=human 
immunodeficiency virus
aï¢-hCG testing for females only. ï¢ -hCG will be assessed in 5 of the 9 samples collected for biochemistry assessmen ts 
(screening and MDTP [Day -2, Day 1, Day 26, and Day 29])
Cohort B: Multiple -dose treatment twice daily; Cohort C: Multiple -dose treatment 3 times daily; Cohort D: Multiple -dose 
treatment 4 times daily.
Note: The amount of blood to be collected for eac h assessment is an estimate. The amount of 
blood to be collected may vary  according to the instructions provided by  the manufacturer or 
laboratory  for an individual assessment. When more than 1 blood assessment is to be done at the 
time point/period, if they require the same t ype of tube, the assessments may be combined.
Shire CONFIDENTIAL Page 81
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
8. ADVERSE AND SERIOUS ADVERSE EVENTS ASSES SMENT
8.1 Definition of Adverse Events, Period of Observation, Recording of Adverse Events
An AEis any  untoward medical occurrence in a clinical investi gation subject administered a 
pharmaceutical product and that does not necessarily  have a causal relationship with this 
treatment. An AE can therefore be an y unfavorable and unintended sign (including an abnormal 
laboratory  finding), s ymptom, or disease te mporally  associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigational) product (ICH 
Guideline E2A 1995).
All AEs are collected from the time the informed consent is signed until the defined foll ow-up 
period stated in Section 7.1.3 . This includes events occurring during the screening phase of the 
study , regardless of whether or not investigational product is administered. Where possible, a 
diagnosis rather than a list of sy mptoms should be recorde d. If a diagnosis has not been made, 
then each s ymptom should be listed individually . All AEs should be captured on the appropriate 
AE pages in the eCRF and in source documents. Adverse events that occur from Day  33 to Day  
88/FU should be captured on the A E eCRF page. In addition to untoward AEs, unexpected 
benefits outside the investigational product indication should also be captured on the AE eCRF 
page.
All AEs must be followed to closure (the subjectâ€™s health has returned to his/her baseline status 
or all variables have returned to normal), regardless of whether the subject is still participating in 
the study . Closure indicates that an outcome is reached, stabilization achieved (the investigator 
does not expect any  further improvement or worsening of th e event), or the event is otherwise 
explained. When appropriate, medical tests and examinations are performed so that resolution of 
event(s) can be documented.
8.1.1 Severity Categorization
The severit y of AEs must be recorded during the course of the event incl uding the start and stop 
dates for each change in severit y. An event that worsens in severit y should be captured as a new 
event. Worsening of pretreatment events, after initiation of investigational product, or a pre -
existing medical history with worsening severit y, must be recorded as new AEs (for example, if 
a subject experiences mild intermittent dy spepsia before dosing of investigational product, but 
the dy spepsia becomes severe and more frequent after first dose of investigational product has 
been admi nistered, a new AE of severe d yspepsia [with the appropriate date of onset] is recorded 
on the appropriate eCRF page). If an AE is a recurrence, even if at a lower severit y, it should be 
captured as a new AE.
The medical assessment of severit y is determine d by using the following definitions:
Shire CONFIDENTIAL Page 82
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
Mild: A type of AE that is usually  transient and may  require only  minimal treatment or 
therapeutic intervention. The event does not generally  interfere with usual 
activities of daily  living.
Moderate: A type of AE that is usually  alleviated with specific therapeutic intervention. The 
event interferes with usual activities of daily  living, causing discomfort but poses 
no significant or permanent risk of harm to the research subject.
Severe: A type of AE that interrupts usual activities of daily living, or significantl y affects 
clinical status, or may  require intensive therapeutic intervention.
8.1.2 Relationship Categorization
A phy sician/investigator must make the assessment of relationship to investigational product for 
each AE. The investigator should decide whether, in his/her medical judgment, there is a 
reasonable possibility  that the event may  have been caused b y the investigational product. If 
there is no valid reason for suggesting a relationship, then the AE should be classified as â€œnot 
related.â€ Otherwise, if there is an y valid reason, even if undetermined or untested, for suspecting 
a possible cause -and-effect relationship between the investigational product and the occurrence 
of the AE, then the AE should be consider ed â€œrelated.â€ The causality  assessment must be 
documented in the source document and the eCRF.
The following additional guidance may  be helpful:
Term Relationship Definition
Related The temporal relationship between the event and the administration of the
investigational product is compelling and/or follows a known or suspected response 
pattern to that product, and the event cannot be explained by the subjectâ€™s medical 
condition, other therapies, or accident.
Not Related The event can be readily explained by other factors such as the subjectâ€™s underlying 
medical condition, concomitant therapy, or accident and no plausible temporal or 
biologic relationship exists between the investigational product and the event.
8.1.3 Outcome Categorization
The outcome of AEs must be recorded during the course of the study  on the eCRF. Outcomes are 
as follows:
ï‚·Fatal
ï‚·Not recovered/not resolved
ï‚·Recovered/resolved
ï‚·Recovered/resolved with sequelae
ï‚·Recovering/resolving
ï‚·Unknown.
Shire CONFIDENTIAL Page 83
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
8.1.4 Ocular and Nonocular Categorization
The investigator wi ll categorize AEs as ocular (specified as left ey e, right eye, or both ey es) or 
nonocular.
8.1.5 Symptoms of the Disease under Study
Symptoms of the disease under study  should not be classed as AEs as long as they  are within the 
normal day -to-day fluctuation or expected progression of the disease and are part of the efficacy  
data to be collected in the study; however, significant worsening of the s ymptoms should be 
recorded as an AE.
8.1.6 Clinical Laboratory and Other Safety Evaluations
A change in the value of a clin ical laboratory , vital sign, or ECG assessment can represent an AE 
if the change is clinically relevant or if, during treatment with the investigational product, a shift 
of a parameter is observed from a normal value to an abnormal value, or a further wors ening of 
an alread y abnormal value. When evaluating such changes, the extent of deviation from the 
reference range, the duration until return to the reference range, either while continuing treatment 
or after the end of treatment with the investigational product, and the range of variation of the 
respective parameter within its reference range, must be taken into consideration.
If, at the end of the treatment phase, there are abnormal clinical laboratory , vital sign, or ECG 
values that were not present at the pretreatment value observed closest to the start of stud y 
treatment, further investigations should be performed until the values return to within the 
reference range or until a plausible explanation (eg, concomitant disease) is found for the 
abnormal va lues.
The investigator should decide, based on the above criteria and the clinical condition of a 
subject, whether a change in a clinical laboratory , vital sign, or ECG parameter is clinicall y 
significant and therefore represents an AE.
8.1.7 Pregnancy
All pregn ancies are to be reported from the time informed consent is signed until the defined 
follow -up period stated in Section 7.1.3.
Any report of pregnancy  for any  female study  participant or the partner of a male study  
participant must be reported within 24 ho urs to the Shire Global Drug Safety  Department using 
the Shire Investigational and Marketed Products Pregnancy  Report Form. A copy  of the Shire 
Investigational and Marketed Products Pregnancy  Report Form (and any  applicable follow -
up 
reports) must also be sent to the CRO/Shire medical monitor using the details specified in the 
emergency  contact information section of the protocol. The pregnant female study  participant 
must be withdrawn from the study .
Every  effort should be made to gather information regard ing the pregnancy  outcome and 
condition of the infant. It is the responsibility  of the investigator to obtain this information within 
30 calendar day s after the initial notification and approximately  30 calendar day s post partum.
Shire CONFIDENTIAL Page 84
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
Pregnancy  complications su ch as spontaneous abortion/miscarriage or congenital abnormality  
are considered SAEs and must be reported using the Shire Clinical Study  Serious Adverse Event 
and Nonserious AEs Required by  the Protocol Form. Note: An elective abortion is not 
considered an SAE.
In addition to the above, if the investigator determines that the pregnancy  meets serious criteria, 
it must be reported as an SAE using the Shire Clinical Study  Serious Adverse Event and 
Nonserious AEs Required by  the Protocol Form as well as the Shi re Investigational and 
Marketed Products Pregnancy  Report Form. The test date of the first positive serum/urine ï¢-hCG 
test or ultrasound result will determine the pregnancy  onset date.
8.1.8 Abuse, Misuse, Overdose, and Medication Error
Abuse, misuse, overdose, or medication error (as defined below) must be reported to the sponsor 
according to the SAE reporting procedure whether or not it results in an AE/SAE as described in 
Section 8.2. Note: The 24 -hour reporting requirement for SAEs does not apply  to reports o f 
abuse, misuse, overdose, or medication errors unless these result in an SAE. 
The categories below are not mutually  exclusive; the event can meet more than 1 category .
ï‚·Abuse â€“ Persistent or sporadic intentional intake of investigational product when used for a 
nonmedical purpose (eg, to alter oneâ€™s state of consciousness or get high) in a manner that 
may be detrimental to the individual and/or society
ï‚·Misuse â€“ Intentional use of investigational product other than as directed or indicated at any  
dose (Note : this includes a situation where the investigational product is not used as directed 
at the dose prescribed b y the protocol)
ï‚·Overdose 
â€“ Intentional or unintentional intake of a dose of investigational product higher 
than the protocol -prescribed dose
ï‚·Medic ation Error â€“ An error made in prescribing, dispensing, administration, and/or use of 
an investigational product. For studies, m edication errors are reportable to the sponsor only  
as defined below.
Cases of subjects missing doses of the investigational pro duct are not considered reportable as 
medication errors.
Medication errors should be collected/reported for all products under investigation.
The administration and/or use of the unassigned treatment is/are alway s reportable as a 
medication error.
The admi nistration and/or use of an expired investigational product should be considered as a 
reportable medication error.
6KLUH &21),'(17,$/ 3DJH
6+33URWRFRO$PHQGPHQW6+3 0D\
 6HULRXV$GYHUVH(YHQW3URFHGXUHV
 5HIHUHQFH6DIHW\,QIRUPDWLRQ
7KHUHIHUHQFHIRUVDIHW\LQIRUPDWLRQIRUWKLVVWXG\LVWKH,% ZKLFKWKHVSRQVRUKDVSURYLGHG
XQGHUVHSDUDWHFRYHUWRDOOLQYHVWLJDWRUV
 5HSRUWLQJ3URFHGXUHV
$OOLQLWLDODQGIROORZXS6$(UHSRUWVPXVWEHUHSRUWHGE\WKHL QYHVWLJDWRUWRWKH6KLUH*OREDO
'UXJ6DIHW\'HSDUWPHQW DQGWKH&526KLUHPHGLFDOPRQLWRUZLWKLQ KRXUVRIWKHILUVW
DZDUHQHVVRIWKHHYHQW1RWH7KHKRXUUHSRUWLQJUHTXLUHPHQW IRU6$(VGRHVQRWDSSO\WR
UHSRUWVRIDEXVHPLVXVHRYHUGRVHRUPHGLFDWLRQHUURUVVHH6 HFWLRQXQOHVVWKH\UHVXOWLQ
DQ6$(
7KHLQYHVWLJDWRUPXVWFRPSOHWHVLJQDQGGDWHWKH6KLUH&OLQLF DO6WXG\6HULRXV$GYHUVH(YHQW
DQG1RQVHULRXV$(V5HTXLUHGE\WKH3URWRFRO)RUPYHULI\WKHDF FXUDF\RIWKHLQIRUPDWLRQ
UHFRUGHGRQWKHIRUPZLWKWKHFRUUHVSRQGLQJVRXUFHGRFXPHQWV1 RWH6RXUFHGRFXPHQWVDUHQRW
WREHVHQWXQOHVVUHTXHVWHGDQGID[RUHPDLOWKHIRUPWRWKH 6KLUH*OREDO'UXJ6DIHW\
'HSDUWPHQW$FRS\RIWKH6KLUH&OLQLFDO6WXG\6HULRXV$GYHUVH (YHQWDQG1RQVHULRXV$(V
5HTXLUHGE\WKH3URWRFRO)RUPDQGDQ\DSSOLFDEOHIROORZXSUHS RUWVPXVWDOVREHVHQWWRWKH
&526KLUHPHGLFDOPRQLWRUXVLQJWKHGHWDLOVVSHFLILHGLQWKHHP HUJHQF\FRQWDFWLQIRUPDWLRQ
VHFWLRQRIWKHSURWRFRO
(PDLODGGUHVVIRUUHSRUWLQJ6$(V
 6HULRXV$GYHUVH(YHQW'HILQLWLRQ
$Q6$(LVDQ\XQWRZDUGPHGLFDORFFXUUHQFHZKHWKHUFRQVLGHUHGWREHUH ODWHGWRLQYHVWLJDWLRQDO
SURGXFWRUQRWWKDWDWDQ\GRVH
â€¢5HVXOWVLQGHDWK
â€¢,VOLIHWKUHDWHQLQJ1RWH7KHWHUPÂ³OLIHWKUHDWHQLQJÂ´LQWKHG HILQLWLRQRIÂ³VHULRXVÂ´UHIHUVWRDQ
HYHQWLQZKLFKWKHVXEMHFWZDVDWULVNRIGHDWKDWWKHWLPHRI WKHHYHQWLWGRHVQRWUHIHUWRDQ
HYHQWZKLFKK\SRWKHWLFDOO\PLJKWKDYHFDXVHGGHDWKLILWZDVPR UHVHYHUH
â€¢5HTXLUHVLQSDWLHQWKRVSLWDOL]DWLRQRUSURORQJDWLRQRIH[LVWLQJ KRVSLWDOL]DWLRQ1RWH
+RVSLWDOL]DWLRQVWKDWDUHWKHUHVXOWRIHOHFWLYHRUSUHYLRXVO\ VFKHGXOHGVXUJHU\IRU
SUHH[LVWLQJFRQGLWLRQVDQGKDYHQRWZRUVHQHGDIWHULQLWLDWLRQ RIWUHDWPHQWVKRXOGQRWEH
FODVVLILHGDV6$(V)RUH[DPSOHDQDGPLVVLRQIRUDSUHYLRXVO\ VFKHGXOHGYHQWUDOKHUQLD
UHSDLUZRXOGQRWEHFODVVLILHGDVDQ6$(KRZHYHUFRPSOLFDWLRQ VUHVXOWLQJIURPD
KRVSLWDOL]DWLRQIRUDQHOHFWLYHRUSUHYLRXVO\VFKHGXOHGVXUJHU\ WKDWPHHWVVHULRXVFULWHULD
PXVWEHUHSRUWHGDV6$(V
â€¢5HVXOWVLQSHUVLVWHQWRUVLJQLILFDQWGLVDELOLW\LQFDSDFLW\
â€¢,VDFRQJHQLWDODEQRUPDOLW\ELUWKGHIHFW
â€¢,VDQLPSRUWDQWPHGLFDOHYHQW1RWH,PSRUWDQWPHGLFDOHYHQWVW KDWPD\QRWUHVXOWLQGHDWK
EHOLIHWKUHDWHQLQJRUUHTXLUHKRVSLWDOL]DWLRQPD\EHFRQVLGHU HGDQ6$(ZKHQEDVHGXSRQPPD
Shire CONFIDENTIAL Page 86
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
appropriate medical judgment, they  may  jeopardize the subject and may  require medical or 
surgic al intervention to prevent one of the outcomes listed in this definition. Examples of 
such medical events include allergic bronchospasm requiring intensive treatment in an 
emergency  room or at home; blood dy scrasias or convulsions that do not result in inp atient 
hospitalization; or the development of drug dependency  or drug abuse.
8.2.4 Serious Adverse Event Collection Time Frame
All SAEs (regardless of relationship to study ) are collected from the time the subject signs the 
informed consent until the defined fol low-up period stated in Section 7.1.3 and must be reported 
to the Shire Global Drug Safety  Department andthe CRO/Shire medical monitor within 24 hours 
of the first awareness of the event.
In addition, any  SAE(s) considered â€œrelatedâ€ to the investigational product and discovered by  the 
investigator at an y interval after the study has completed must be reported to the Shire Global 
Drug Safet y Department within 24 hours of the first awareness of the event.
8.2.5 Serious Adverse Event Onset and Resolution Dates
The onset date of the SAE is defined as the date the event meets serious criteria. The resolution 
date is the date the event no longer meets serious criteria, the date the s ymptoms resolve, or the 
event is considered chronic. I n the case of hospitalizations, t he hospital admission and discharge 
dates are considered the onset and resolution dates, respectivel y.
In addition, any  signs or sy mptoms experienced by  the subject after signing the ICF, or leading 
up to the onset date of the SAE, or following the resolut ion date of the SAE, must be recorded as 
an AE, if appropriate.
8.2.6 Fatal Outcome
Any SAE that results in the subjectâ€™s death (ie, the SAE was noted as the primary  cause of death) 
must have fatal checked as an outcome with the date of death recorded as the res olution date. For 
all other events ongoing at the time of death that did not contribute to the subjectâ€™s death, the 
outcome should be considered not resolved, without a resolution date recorded.
For an y SAE that results in the subjectâ€™s death or any ongoin g events at the time of death, unless 
another investigational product action was previously  taken (eg, drug interrupted, reduced, 
withdrawn), the action taken with the investigational product should be recorded as â€œdose not 
changedâ€ or â€œnot applicableâ€ (if the subject never received investigational product). The 
investigational product action of withdrawn should not be selected solel y as a result of the 
subjectâ€™s death.
8.2.7 Regulatory Agency, Institutional Review Board, and Site Reporting
Thesponsor is respons ible for notify ing the relevant regulatory  authorities/United States (US) 
central IRBs of related, unexpected SAEs.
In addition the sponsor is responsible for notify ing active sites of all related, unexpected SAEs 
occurring during all interventional stu dies across the SHP639 program.
Shire CONFIDENTIAL Page 87
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
The investigator is responsible for notify ing the local IRB or the relevant local regulatory  
authority  of all SAEs that occur at his/her site as required.
Shire CONFIDENTIAL Page 88
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
9. DATA MANAGEMENT AND STATISTICAL METHODS
9.1 Data Collection
The investigator sâ€™ authorized site personnel must enter the information required by  the protocol 
on the eCRF. A stud y monitor will visit each site in accordance with the monitoring plan and 
review the eCRF data against the source data for completeness and accuracy . Discre pancies 
between source data and data entered on the eCRF will be addressed b y qualified site personnel. 
When a data discrepancy warrants correction, the correction will be made by authorized site 
personnel. Data collection procedures will be discussed with the site at the site initiation visit 
and/or at the investigatorâ€™s meeting. Once a subject is randomly  assigned, it is expected that site 
personnel will complete the eCRF entry  within approximately  3 business day s of the subjectâ€™s 
visit.
9.2 Clinical Data Man agement
Data are to be entered into a clinical database as specified in the CROâ€™s data management plan. 
Quality  control and data validation procedures are applied to ensure the validity  and accuracy  of 
the clinical database.
Data are to be reviewed and che cked for omissions, errors, and values requiring further 
clarification using computerized and manual procedures. Data queries requiring clarification are 
to be communicated to the site for resolution. Only authorized personnel will make corrections to 
the clinical database, and all corrections are documented in an auditable manner.
9.3 Data Handling Considerations
Data that may  potentiall y unmask the treatment assignment (ie, investigational product blood 
concentrations, antidrug antibody , treatment allocation, and investigational product 
preparation/accountability  data) will be handled with special care during the data cleaning and 
review process. These data will be handled in such a way  that, before unmasking, any  data that 
may unmask study  team personnel will be presented as masked information or otherwise will not 
be made available. If applicable, unmasked data may  be made available to quality  assurance 
representatives for the purposes of conducting independent drug audits.
9.4 Statistical Analysis Process
The st udy will be anal yzed by  the sponsor or its agent .
The statistical anal ysis plan (SAP) will provide the statistical methods and definitions for the 
analysis of the PK, PD, and safet y data, as well as describe the approaches to be taken for 
summarizing other study  information such as subject disposition, demographics and baseline 
characteristics, investigational product exposure, and prior and concomitant medications. The 
SAP will also include a description of how missing, unused and spurious data will be add ressed.
To preserve the integrit y of the statistical anal ysis and study  conclusions, t he SAP will be 
finalized before database lock.
Shire CONFIDENTIAL Page 89
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
All statistical analy ses will be performed using SASïƒ’software (SAS Institute, I nc, Cary , NC 
27513). 
9.5 Planned Interim Analy sis, Adaptive Design, and Dose Escalation Committee
Shireâ€™s Dose Escalation Committee will be convened consisting of the coordinating principal 
ophthalmologist and Shire medical monitor. Ad hoc study  team members can be included such 
as biostatistics, phar macokinetics, drug safet y, and clinical operations if needed. The committee 
will review collective safety  data for Cohort A and Cohort B to decide whether Part 2 in the 
same dose level and Part 1 in the next dose level (concentration) can commence.
An unma sked interim analy sis (IA) will be performed after cohorts A1, A2, A3, B1, B2, and B3 
have completed through Day  29 of the B3 cohort. Data from sites will be entered into the 
database, queried, and discrepancies resolved. There is no intention to stop earl y based on data 
from the IA. The intent of this I A is to determine if the escalated doses have identified a 
pharmacod ynamicall y significant safe and tolerable dose(s) for further clinical evaluation.
Team members reviewing the interim anal ysis will be reviewing unmasked data from cohorts 
A1, A2, A3, B1, B2, and B3. The SAP will be finalized before data are frozen for this interim 
analysis.
All cohorts conducted after B3 (ie Part 1 of the study ) may  be unmasked following completion of 
Day 29 to permit revie w of safet y, tolerability  and the pharmacod ynamics effects of each cohort 
to better inform planning for additional cohorts and further clinical development options for 
SHP639.
A final unmasked anal ysis will be conducted when all subjects of the remaining c ohorts have 
completed through Day  29. The Day  88/FU visit is the planned study  completion for each
subject.
9.6 Sample Size Calculation and Power Considerations
A sufficient number of subjects will be screened to ensure the enrollment and completion of 
84subjects.
The number of subjects in this study  is not based on statistical power considerations because the 
statistical analy ses are primarily  descriptive in nature. However, if at least 7 subjects complete 
each cohort, then there will be at least 65% to 85% p robability  of observing at least 1 occurrence 
of an y AE with a true incidence rate for a given dose group of at least 15 -25%, respectively . 
It is estimated that dose escalation will occur for up to 3 dose levels (4 cohorts within each dose 
level). Each co hort will include 5 subjects randomized to active drug and 2 subjects randomized 
to placebo for an estimated total of at least 84 subjects.
For each cohort, the number of subjects will be increased as needed based on safet y and IOP 
response. An y cohort can be repeated to confirm findings with regard to safety  or IOP response. 
Shire CONFIDENTIAL Page 90
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
9.7 Study Population
The safety set will consist of all subjects who have been randomized and who have received at 
least 1 dose of investigational product.
The PK set will consist of all 
subjects in the safet y set for whom the primary PK data are 
considered sufficient and interpretable.
The PD set will consist of all subjects in the safet y set for whom the primary PD data are 
evaluable.
9.8 Pharmacokinetic and Pharmacodynamic Analyses
9.8.1 Pharmaco kinetic Analysis
All PK analy ses will be performed using the PK set.
Plasma concentrations of SHP639 will be measured using a full y validated bioanaly tical method. 
If data permit, PK parameters for SHP639 will be calculated based on plasma concentration -time 
data using a noncompartmental approach ( PhoenixÂ®WinNonlinÂ®version 6.4 or higher, Certara 
USA, I nc, Princeton, NJ, 08540) . 
9.8.1.1 Pharmacokinetic Endpoints
If data permit, PK parameters will be estimated as appropriate and may  include, but are not 
limited to , the following:
ï‚·Maximum observed concentration (C max)
ï‚·Time to reach C max(tmax)
ï‚·Area under the observed concentration vs time curve:
â€“ From time zero (predose) to the time of the last measurable concentration (AUC 0-t)
â€“Over the dosing interval (AUC 0-Ï„) for each multiple -dose regimen including QD, BID, 
TID, and QID
â€“From time zero (predose) extrapolated to infinity  (AUC 0-âˆž) for QD dosing
ï‚·Apparent terminal phase elimination half -life (tÂ½)
ï‚·Apparent clearance (CL /F)
ï‚·Apparent volume of distribution (Vz/F)
ï‚·Accumulat ion ratio based on AUC for each multiple -dose regimen, calculated as AUC 0-Ï„
(Day  27)/AUC 0-Ï„(Day  1) (R ac[AUC] )
ï‚·Accumulation ratio based on C maxfor each multiple -dose regimen, calculated as C max
(Day 27)/C max(Day  1) (R ac[Cmax] )
9.8.1.2 Statistical Analysis of Pha rmacokinetic Parameters
Summary  statistics (number of observations, mean, standard deviation [SD], coefficient of 
variation, median, maximum [max], minimum [min], and geometric mean) will be determined 
Shire CONFIDENTIAL Page 91
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
for all plasma PK parameters and will be presented by  dose, cohort, treatment period (single dose 
or multiple dose; Cohort A only ), and study  day. Plasma concentrations at each nominal 
sampling time will also be summarized using descriptive statistics. 
For accumulation ratios, the 95% confidence interval (CI ) for the arithmetic mean of the 
difference (for example, AUC 0
-Ï„[Day  28] - AUC 0-Ï„[Day  1]) on the logarithmic scale (natural 
base) will be calculated. The results will be back -transformed to give the ratio of geometric 
means together with the correspondin g 95% CI.
Before statistical comparisons, dose -dependent parameters (C max, AUC 0-t, AUC 0-Ï„,and AUC 0-âˆž) 
will be normalized to a common dose, assuming linearit y. Additionally, the linear dose 
proportionality  will be evaluated for C max, AUC 0-Ï„, AUC 0-t, and AU C0-âˆžusing the power function 
model (eg, C max=Î±Â·DoseÎ²or equivalentl y log[C max]=log[Î±]+Î²Â·log[Dose], where C maxis 
considered to increase linearl y proportional to dose if Î² is not significantl y different from 1.0) 
(Gough et al., 1995 ). 
9.8.2 Pharmacodynamic Analysis
All the PD analy ses will be performed using the PD set. Intraocular pressure (mmHg) will be 
measured using Gol dmann applanation tonometry .
9.8.2.1 Pharmacodynamic Endpoints
Pharmacod ynamic parameters will be estimated as appropriate and may include, but are not 
limited to, the following:
ï‚·Change from baseline in IOP
ï‚·Time to the maximum change from baseline in IOP
ï‚·Proportion of subjects maintaining IOP reduction after specified day s of treatment
Specific endpoints in order to understand the effect of SHP639 on I OP will be defined in the 
SAP.
9.8.2.2 Statistical Analysis of Pharmacodynamic Parameters
Descriptive summary  statistics fo r IOP (number of subjects, mean, SD, median, min, and max) 
will be calculated b y dose, cohort, treatment period (single dose or multiple dose; Cohort A 
only), study  day, and time point (for day s with multiple assessments per day ). Additionally , 95% 
CIs for each estimate and summary  statistics of change from baseline and percentage change 
from baseline, along with 95% CI s, will be calculated. Pharmacody namic parameters will be 
calculated and summarized by  dose, cohort, treatment period (single dose or multip le dose; 
Cohort A only ), and study  day as applicable. 
All IOP data will be listed by  dose, cohort, subject, treatment period (single dose or multiple 
dose; Cohort A only ), and study  day.
Shire CONFIDENTIAL Page 92
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
9.8.3 Pharmacokinetic and Pharmacodynamic Analysis
The relationship betwee n dose of SHP639 ophthalmic solution, plasma PK parameters, and 
changes in IOP may  be explored using graphical and/or regression methods if the data permit.
Further details of PK, PD, and PK -PD anal yses will be presented in the SAP.
9.9 Safety Analyses
9.9.1 Safety Endpoints
Safety  and tolerability  will be assessed by  monitoring AEs, vital sign measurements, clinical 
laboratory  assay s, ECGs, ADA, drop comfort assessment, and ophthalmologic examinations.
9.9.2 Statistical Analysis of Safety Data
The placebo subjects will be pooled together as a pooled placebo group.
All vital sign, clinical laboratory , ECG, ADA, drop comfort assessment, and ophthalmologic 
examination data (per schedule of events) will be listed by  dose, cohort, subject, treatment period 
(single dose or multiple dose; Cohort A only ), visit, day , and time point (for day s with multiple 
assessments per day ). If the ranges are available then abnormalities will be flagged. Summary  
statistics with number of subjects, mean, SD, median, minimum, and maximum will be pr ovided 
by dose, cohort, treatment period (single dose or multiple dose; Cohort A only ), visit, day , and 
time point (for day s with multiple assessments per day ).
Adverse events will be coded using the Medical Dictionary  for Regulatory  Activities. The 
number of events, incidence, and percentage of treatment -emergent AEs will be calculated 
overall and b y system organ class and preferred term by  dose and cohort. Treatment
-emergent 
AEs will be further summarized by severit y and relationship to investigational pr oduct. Adverse 
events related to investigational product, AEs leading to withdrawal, SAEs, and deaths will be 
similarly  summarized/listed. All information obtained on AEs will be display ed by  dose, cohort, 
subject, treatment period (single dose or multiple dose; Cohort A only ), visit, and day . A subject 
with multiple AEs within a body  system will be counted only  once.
9.10 Other Analyses
No other anal yses are planned in this study .
Shire CONFIDENTIAL Page 93
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
10. SPONSORâ€™S AND INVEST IGATORâ€™S RESPONSIBIL ITIES
This study  is conducted in accordan ce with current applicable regulations including ICH E6, EU 
Directive 2001/20/EC, and all updates, as well as local ethical and legal requirements.
Compliance with these regulations and guidelines also constitutes compliance with the ethical 
principles described in the Declaration of Helsinki
The name and address of each third -party vendor (eg, CRO) used in this study  will be maintained 
in the investigatorâ€™s and sponsorâ€™s files, as appropriate.
10.1 Sponsorâ€™s Responsibilities
10.1.1 Good Clinical Practice Compliance
The study  sponsor and any  third party  to whom aspects of the study  management or monitoring 
have been delegated will undertake their assigned roles for this study  in compliance with all 
applicable industry regulations and I CH GCP Guideline E6 (1996), EU Dire ctive 2001/20/EC , as 
well as all applicable national and local laws and regulations.
Visits to sites are conducted by  representatives of the study  sponsor and/or the company  
organizing/managing the research on behalf of the sponsor to inspect study  data, subjectsâ€™ 
medical records, and eCRFs in accordance with current GCP and the respective local and 
international/national government regulations and guidelines. Records and data may  additionally  
be reviewed b y auditors or by regulatory authorities.
The sponsor ensures that local regulatory  authority requirements are met before the start of the 
study . The sponsor (or a nominated designee) is responsible for the preparation, submission, and 
confirmation of receipt of an y regulatory  authority  approvals required before release of 
investigational product for shipment to the site.
10.1.2 Public Posting of Study Information
The sponsor is responsible for posting appropriate study  information on applicable websites. 
Information included in clinical study  registries may  includ e participating investigatorsâ€™ names 
and contact information.
10.1.3 Submission of Summary of Clinical Study Report to Competent Authorities 
of Member States Concerned and Ethics Committees
The sponsor will provide a summary  of the clinical study  report to the co mpetent authority  of the 
member state(s) concerned as required b y regulatory  requirement(s) and to comply  with the 
community  guideline on GCP. This requirement will be fulfilled within 6 months of the end of 
the study  completion date for pediatric studies and within 1 y ear for nonpediatric studies as per 
guidance.
Shire CONFIDENTIAL Page 94
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
10.1.4 Study Suspension, Termination, and Completion
The sponsor may  suspend or terminate the study , or part of the study , at any  time for any  reason. 
If the stud y is suspended or terminated, the sponsor will ensure that applicable sites, regulatory  
agencies, and IRBs are notified as appropriate. Additionally , the discontinuation of a registered 
clinical study  which has been posted to a designated public website will be updated accordingl y.
10.2 Investigatorâ€™s Responsibilities
10.2.1 Good Clinical Practice Compliance
The investigator must undertake to perform the study  in accordance with ICH GCP Guideline E6 
(1996), EU Directive 2001/20/EC, and applicable regulatory  requirements and guidelines.
It is the investigatorâ€™ s responsibility  to ensure that adequate time and appropriately  trained 
resources are available at the site before commitment to participate in this study . The investigator 
should also be able to estimate or demonstrate a potential for recruiting the requi red number of 
suitable subjects within the agreed recruitment period.
The investigator will maintain a list of appropriately  qualified persons to whom the investigator 
has delegated significant study -related tasks, and shall, upon request of the sponsor, p rovide 
documented evidence of any  licenses and certifications necessary  to demonstrate such 
qualification. Curricula vitae for investigators and subinvestigators are provided to the study  
sponsor (or designee) before starting the study .
If a potential rese arch subject has a primary  care phy sician, the investigator should, with the 
subjectâ€™s consent, inform them of the subjectâ€™s participation in the study .
A coordinating principal ophthalmologist is appointed to review the final clinical study  report for 
multicenter studies. Agreement with the final clinical study report is documented b y the signed 
and dated signature of the coordinating principal ophthalmologist, in compliance with Directive 
2001/83/EC as amended by  Directive 2003/63/EC and I CH Guideline E3 (1995).
10.2.2 Protocol Adherence and Investigator Agreement
The investigator and an y co-investigators must adhere to the protocol as detailed in this 
document. The investigator is responsible for enrolling only  those subjects who have met 
protocol eligibility  criteria. Investigators arerequired to sign an investigator agreement to 
confirm acceptance and willingness to comply  with the study  protocol.
If the investigator suspends or terminates the study  at their site, the investigator will promptly  
inform the spon sor and the I RB and provide them with a detailed written explanation. The 
investigator will also return all investigational product, containers, and other study materials to 
the sponsor. Upon study  completion, the investigator will provide the sponsor, I RB, and 
regulatory  agency  with final reports and summaries as required by  international/national 
regulations.
Shire CONFIDENTIAL Page 95
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
Communication with local I RBs to ensure accurate and timely  information is provided at all 
phases during the stud y, may be done b y the sponsor, appl icable CRO, investigator, or, for 
multicenter studies, the coordinating principal ophthalmologist, according to national provisions, 
and will be documented in the investigator agreement.
10.2.3 Documentation and Retention of Records
10.2.3.1 Case Report Forms
Electronic c ase report forms are supplied by the CRO and should be handled in accordance with 
instructions from the sponsor.
The investigator is responsible for maintaining adequate and accurate medical records from 
which accurate information is recorded into the eCRF s, which have been designed to record all 
observations and other data pertinent to the clinical investigation. Electronic case report forms 
must be completed by  the investigator or designee as stated in the site delegation log.
All data will have separate source documentation; no data will be recorded directly  into the 
eCRF.
All data sent to the sponsor must be endorsed b y the investigator.
The clinical research associate/study  monitor will verify  the contents against the source data per 
the monitoring plan . If the data are unclear or contradictory , queries are sent for corrections or 
verification of data.
10.2.3.2 Recording, Access, and Retention of Source Data and Study Documents
Original source data to be reviewed during this study  will include, but are not limite d to: 
subjectâ€™s medical file, subject diaries, and original clinical laboratory reports.
All key  data must be recorded in the subjectâ€™s medical records.
The investigator must permit authorized representatives of the sponsor; the respective national, 
local, or foreign regulatory  authorities; the I RB; and auditors to inspect facilities and to have 
direct access to original source records relevant to this study , regardless of media.
The clinical research associate/study  monitor (and auditors, I RB, or regulator y inspectors) may 
check the eCRF entries against the source documents. The consent form includes a statement by  
which the subject agrees to the monitor/auditor from the sponsor or its representatives, national 
or local regulatory  authorities, or I RB, havin g access to source data (eg, subjectâ€™s medical file, 
appointment books, original laboratory  reports, and X -rays). Non- study  site personnel will not 
disclose an y personal information or personal medical information.
These records must be made available within reasonable times for inspection and duplication, if 
required, b y a properly  authorized representative of any  regulatory  agency  (eg, the US Food and 
Drug Administration [FDA], European Medicines Agency  (EMA), United Kingdom Medicines 
and Healthcare produ cts Regulatory  Agency ) or an auditor.
Shire CONFIDENTIAL Page 96
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
Essential documents must be maintained according to ICH GCP requirements and may  not be 
destroy ed without written permission from the sponsor.
10.2.3.3 Audit/Inspection
To ensure compliance with relevant regulations, data gener ated b y this study must be available 
for inspection upon request by  representatives of, for example, the US FDA (as well as other US 
national and local regulatory  authorities), the EMA, the Medicines and Healthcare products 
Regulatory  Agency , other regulat ory authorities, the sponsor or its representatives, and the IRB 
for each site.
10.2.3.4 Financial Disclosure
The investigator is required to disclose an y financial arrangement during the study and for 1 year 
after, whereb y the outcome of the study  could be influenced b y the value of the compensation for 
conducting the study , or other pay ments the investigator received from the sponsor. The 
following information is collected: an y significant payments from the sponsor or subsidiaries 
such as a grant to fund ongoing r esearch, compensation in the form of equipment, retainer for 
ongoing consultation or honoraria; an y proprietary interest in investigational product; any 
significant equity  interest in the sponsor or subsidiaries as defined in 21 Code of Federal 
Regulations 54 2(b) (1998).
10.3 Ethical Considerations
10.3.1 Informed Consent
It is the responsibility  of the investigator to obtain written informed consent from all study  
subjects before an y stud y-related procedures including screening assessments. All consent 
documentation must be in accordance with applicable regulations and GCP. Each subject or the 
subjectâ€™s legall y authorized representative, as applicable, is requested to sign and date the subject 
ICF or a certified translation if applicable, after the subject has receive d and read (or been read) 
the written subject information and received an explanation of what the study  involves, including 
but not limited to: the objectives, potential benefits and risk, inconveniences, and the subjectâ€™s 
rights and responsibilities. A co py of the informed consent documentation (ie, a complete set of 
subject information sheets and fully  executed signature pages) must be given to the subject or the 
subjectâ€™s legall y authorized representative, as applicable. This document may require transla tion 
into the local language. Signed consent forms must remain in each subjectâ€™s study  file and must 
be available for verification at an y time.
The principal ophthalmologist provides the sponsor with a cop y of the consent form that was 
reviewed b y the IRB and received their favorable opinion/approval. A copy  of the IRBâ€™s written 
favorable opinion/approval of these documents must be provided to the sponsor before the start 
of the study  unless it is agreed to and documented (abiding by  regulatory  guidelines a nd national 
provisions) before stud y start that another part y (ie, sponsor or coordinating principal 
ophthalmologist) is responsible for this action. Additionally , if the IRB requires modification of 
the sample subject information and consent document prov ided by  the sponsor, the 
documentation supporting this requirement must be provided to the sponsor.
Shire CONFIDENTIAL Page 97
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
10.3.2 Institutional Review Board or Ethics Committee
For sites outside the EU, it is the responsibility  of the investigator to submit this protocol, the 
informed consent document (approved b y the sponsor or their designee), relevant supporting 
information and all ty pes of subject recruitment information to the I RB for review, and all must 
be approved before site initiation .
For multicenter studies, the applicant ca n be the coordinating principal ophthalmologist or 
sponsor, according to national provisions.
Responsibility  for coordinating with IRBs is defined in the clinical trial agreement.
Before implementing changes in the stud y, the sponsor and the IRB must appro ve an y revisions 
of all informed consent documents and amendments to the protocol unless there is a subject 
safet y issue.
Investigational product supplies will not be released until the sponsor or CRO has received 
written I RB approval of and copies of revi sed documents.
For sites outside the EU, the investigator is responsible for keeping the IRB apprised of the 
progress of the stud y and of an y changes made to the protocol, but in an y case at least once a 
year; for multicenter studies, this can be done by  the coordinating principal ophthalmologist, 
according to national provisions. The investigator must also keep the local IRB informed of any  
serious and significant AEs.
10.4 Privacy and Confidentiality
All US- based sites and laboratories or entities providing su pport for this study , must, where 
applicable, compl y with Health Insurance Portability  and Accountability  Act (HIPAA) of 1996. 
A site that is not a covered entity  as defined b y HIPAA must provide documentation of this fact 
to the CRO or sponsor.
The confidentialit y of records that may be able to identify subjects will be protected in 
accordance with applicable laws, regulations, and guidelines.
After subjects have consented to take part in the study , the sponsor and/or its representativesâ€™ 
reviews their med ical records and data collected during the study . These records and data may , in 
addition, be reviewed b y others including the following: independent auditors who validate the 
data on behalf of the sponsor; third parties with whom the sponsor may  develop, register, or 
market SHP639; national or local regulatory  authorities; and the I RB(s) which gave approval for 
the study  to proceed. The sponsor and/or its representatives accessing the records and data will 
take all reasonable precautions in accordance with applicable laws, regulations, and guidelines to 
maintain the confidentiality  of subjectsâ€™ identities.
Subjects are assigned a unique identify ing number; however, their initials and date of birth may  
also be collected and used to assist the sponsor to veri fy the accuracy  of the data (eg, to confirm 
that laboratory  results have been assigned to the correct subject).
Shire CONFIDENTIAL Page 98
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
The results of studies â€“containing subjectsâ€™ unique identify ing number, relevant medical 
records, and possibly  initials and dates of birth â€“will be recorded. They  may  be transferred 
to,and used in, other countries which may not afford the same level of protection that 
applies within the countries where this study  is conducted. The purpose of any  such 
transfer would include: to support regulator y submissions, to conduct new data anal yses to 
publish or present the study  results, or to answer questions asked by  regulatory  or health 
authorities.
10.5 Study Results/Publication Policy
The term â€œPublicationâ€ shall mean an y paper, article, manuscript, report , poster, internet posting, 
presentation slides, abstract, outline, video, instructional material, presentation (in the form of a 
written summary ), or other public disclosure of the study  results, in printed, electronic, oral, or 
other form. The parties understand and agree that participation in the study  may  involve a 
commitment to publish the data from all sites participating in the study  in a cooperative 
publication with other investigators prior to publication or oral presentations of the study  results 
on an individual basis. The site agrees not to publish or present the siteâ€™s study  results until such 
time as either the aggregate multi
-site study  results are published in a cooperative publication or 
for a period of one (1) year after termination or comp letion of the study  at all participating sites, 
whichever shall first occur. After that time, the site may  publish the siteâ€™s study  results in 
scientific journals or present the study  results at symposia or other professional meetings in 
accordance with th e following provisions:
If the stud y is part of a multicenter study, the first publication of the study results shall be made 
by the sponsor in conjunction with the sponsorâ€™s presentation of a joint, multicenter publication 
of the compiled and analy zed stu dy results. If such a multicenter publication is not submitted to a 
journal for publication by  the sponsor within an 18-month period after conclusion, abandonment, 
or termination of the study  at all sites, or after the sponsor confirms there shall be no mu lticenter 
study  publication of the study  results, an investigator may individuall y publish the study results 
from the specific site in accordance with this section. The investigator must, however, 
acknowledge in the publication the limitations of the singl e site data being presented.
At least sixty  (60) day s prior to submitting an abstract, manuscript, or other document for 
publication, a cop y of the proposed publication will be provided to the sponsor by the site for 
review. Upon the sponsorâ€™s request, the site agrees to remove an y and all confidential 
information (expressly  excluding study  results) identified in the publication and to delay  such 
submission or presentation for an additional sixty  (60) day  period in order to allow the sponsor 
time to file an y patent application(s). All publications of the study  results shall appropriatel y 
reference the multi- site study  publication, if an y, or the fact that the study results are a subset of 
data resulting from a larger multi- site study .
Shire is committed to t ransparent dissemination of all scientific, technical and medical 
manuscripts generated from Shire -supported research. Therefore, after January  1, 2018, Shire 
will require the submission of all Shire-supported research manuscripts to journals that offer 
public availability  via Open Access (including publisher platforms/repositories and self -
Shire CONFIDENTIAL Page 99
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
archiving). Open Access refers to the free at point of entry , online availability  of published 
research output with, where available, rights of re- use according to an En d User License.
Unless otherwise required by  the journal in which the publication appears, or the forum in which 
it is made, authorship will comply  with the International Committee of Medical Journal Editors 
(ICMJE) Recommendation for the Conduct, Reporting, Editing and Publication of Scholarl y 
Work in Medical journals. Participation as an investigator does not confer any rights to 
authorship of publications.
Shire CONFIDENTIAL Page 100
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
11. REFERENCES
AGIS Investigators 2000. The Advanced Glaucoma I ntervention Study  (AGIS): 7. The 
relationship between control of intraocular pressure and visual field deterioration.The 
AGIS Investigators. Am J Ophthalmol, 130, 429-40.
Becker, B. 1990. Topical 8 -bromo
-cyclic GMP lowers intraocular pressure in rabbits. Invest 
Ophthalmol Vi s Sci, 31, 1647-9.
Collaborative Normal -Tension Glaucoma Study  Group 1998. Comparison of glaucomatous 
progression between untreated patients with normal
-tension glaucoma and patients with 
therapeutically  reduced intraocular pressures. Collaborative Normal-Tension Glaucoma 
Study  Group. Am J Ophthalmol, 126, 487 -97.
Efron, N., Morgan, P. B.and Katsara, S. S. 2001. Validation of grading scales for contact lens 
complications. Ophthalmic Physiol Opt, 21, 17-29.
Goel, M., Picciani, R. G., L ee, R. K.and Bhattachar ya, S. K. 2010. Aqueous humor dy namics: a 
review. Open Ophthalmol J, 4, 52-9.
Gough, K., Hutchison, M., Keene, O., By rom, B., Ellis, S., L acey, L.and McKellar, J. 1995. 
Assessment of dose proportionality : report from the statisticians in the pharmaceutical
industry /pharmacokinetics UK joint working part y. Drug Information Journal, 29, 1039-
48.
Heijl, A., Leske, M. C., Bengtsson, B., Hy
man, L., Bengtsson, B.and Hussein, M. 2002. 
Reduction of intraocular pressure and glaucoma progression: results from the Ear ly 
Manifest Glaucoma Trial. Arch Ophthalmol, 120, 1268-79.
Kapetanakis, V. V., Chan, M. P., Foster, P. J., Cook, D. G., Owen, C. G.and Rudnicka, A. R. 
2016. Global variations and time trends in the prevalence of primary  open angle 
glaucoma (POAG): a s ystematic review and meta -analysis. Br J Ophthalmol, 100, 86-93.
Kass, M. A., Heuer, D. K., Higginbotham, E. J., Johnson, C. A., Keltner, J. L., Miller, J. P., 
Parrish, R. K., 2nd, Wilson, M. R.and Gordon, M. O. 2002. The Ocular Hypertension 
Treatment Study : a randomized trial determines that topical ocular h ypotensive 
medication delay s or prevents the onset of primary  open -angle glaucoma. Arch 
Ophthalmol, 120, 701- 13; discussion 829 -30.
Lemp, M. A. 1995. Report of the National Ey e Institute/I ndustry  workshop on Clinical Trials in 
Dry Eyes. CLAO Journal : official publication of the Contact Lens Association of 
Ophthalmologists, Inc, The, 21, 221-32.
Leske, M. C., Heijl, A., Hussein, M., Bengtsson, B., Hy man, L.and Komaroff, E. 2003. Factors 
for glaucoma progressi on and the effect of treatment: the earl y manifest glaucoma trial. 
Arch Ophthalmol, 121, 48-56.
Lichter, P. R., Musch, D. C., Gillespie, B. W., Guire, K. E., Janz, N. K., Wren, P. A.and Mills, R. 
P. 2001. I nterim clinical outcomes in the Collaborative Init ial Glaucoma Treatment Study  
comparing initial treatment randomized to medications or surgery . Ophthalmology, 108, 
1943-53.
Nathanson, J. A. 1988. Direct application of a guany late cy clase activator lowers intraocular 
pressure. Eur J Pharmacol, 147, 155-
6.
Nathanson, J. A. 1992. Nitrovasodilators as a new class of ocular h ypotensive agents. J 
Pharmacol Exp Ther, 260, 956 -65.
Quigley , H. A.and Broman, A. T. 2006. The number of people with glaucoma worldwide in 2010 
and 2020. Br J Ophthalmol, 90, 262-7.
Shire CONFIDENTIAL Page 101
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
Shimmura, S., Ono, M., Shinozaki, K., Toda, I ., Takamura, E., Mashima, Y.and Tsubota, K. 
1995. Sodium hy aluronate ey edrops in the treatment of dry  eyes. British Journal of 
Ophthalmology, 79, 1007-11.
Stein, P. J.and Clack, J. W. 1994. Topical application of a c yclic GMP analog lowers IOP in 
normal and ocular h ypertensive rabbits. Invest Ophthalmol Vis Sci, 35, 2765-8.
Vajaranant, T. S., Wu, S., Torres, M.and Varma, R. 2012. The Changing Face of Primary  Open -
Angle Glaucoma in the United States: Demographic and Ge ographic Changes From 2011 
to 2050. 
American Journal of Ophthalmology, 154, 303- 314.e3.
Weinreb, R. N., Aung, T.and Medeiros, F. A. 2014. The pathophy siology  and treatment of 
glaucoma: a review. Jama, 311, 1901-11.
Weinreb, R. N.and Khaw, P. T. 2004. Prima ry open -angle glaucoma. Lancet, 363, 1711-20.
Shire CONFIDENTIAL Page 102
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
12. APPENDICES
Shire CONFIDENTIAL Page 104
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
Clarification that all procedures, not only ocular procedures, performed 
within the 5 years before the first dose, should be recorded 
any ocular procedures performed within the 5 years before the date of 
the first dose of investigational product. Prior treatment information must 
be recorded on the appropriate eCRF page.Section 5.1
Clarification that subjects should receive the single or first dose on the 
same time each day.
Subjects should receive the single or first dose (depending on cohort 
assignment) each day between 7:00am  and 9:00am . This is particularly 
important for cohorts C and D as these subjects will receive 3 and 4 doses 
dailySection 6.2.3.1
Documentation that decision was made not to enroll cohort D1.
Footnote: Cohort D1 is not to be enrolled as it was decided that the resulting 
data would not contribute to the understanding of the safety of SHP639.Table 10
Addition of language to support not enrolling a proposed dose cohort if 
dose escalation meeting findings indicate that information from that dose 
cohort w ould not increase understanding of the safety of SHP639.
If, in the judgment of the coordinating principal ophthalmologist, the 
Shire medi cal monitor, and the Shire ophthalmic study physician, it is 
unclear whether there is a potential safety signal concern or whether 
dose escalation should occur, a dose level may be reduced, modified, or 
repeated depending on the outcome of the safety data review betw een 
doses or treatments. Further, based on the findings from  the dose 
escalation review m eetings a cohort (or cohorts) m ay be determined 
to not be necessary to determine the safety of SHP639. Finally, upon 
completion of all dose cohorts, additional doses may be studied based on 
emergent safety, PD, and PK data follow ing the necessary protocol 
amendment and Institutional Revie w Board (IRB) review s.Section 6.2.3.2
Clarification that the time points of ophthalmic assessments performed 
on Day - 2 and Day -1 are to be carried forw ard to assessments on Day 1.
Time points of ophthalmic assessments performed on Day -2 and 
Day -1 should be carried forward to assessments on Day 1. This 
ensures that the baseline IOP tim e points established before dosing 
begins are time -matched to the IOP assessments performed during 
dosing days for the duration of the study. Section 7.1.2.2
Clarification that ophthalmic assessments are considered safety 
assessments, and therefore, if their timing deviates from the schedul ed 
time (and window ), this will be considered a protocol deviation.Section 7.2.2
Clarification that pregnancy testing by Î² -hCG is only required for 
females of childbearing potential, as defined in Section 4.4.1.
Interpretation of Î² -hCG results performed for post -menopausal subjects 
also added. Biochemistry table in Section 7.2.2.6
Clarification that urine drug screen will include drugs of abuse included 
in marketed screening products.
Additional drugs of abuse, eg, m ethamphetamines and tricyclic anti -
depressants, which are included in currently m arketed products for 
drugs of abuse screening, will also be tested in these samples.Section 7.2.2.8
Shire CONFIDENTIAL Page 106
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
childbearing potential must use an acceptable form of contraception
throughout the study p eriod and for 30 days 60 days following the last dose 
of investigational product. If hormonal contraceptives are used, they should 
be administered according to the package insert. Females of childbearing 
potential who are not currently sexually active must agree to use acceptable 
contraception, as defined below, if they become sexually active during the 
period of the study and 30 days 60 days follow ing the last dose of 
investigational product.
Section 4.4.2 w ill be updated to state â€œMale subjects will be r equired to use 
a condom in conjunction with spermicidal gel, foam, cream, film, or 
suppository from the time of first dosing until 30 day s60 days after the last 
dose of investigational product. Childbearing female partners of male study 
participants will be required to follow  the acceptable methods of 
contraception for this study (described in Section 4.4.1) from the time of 
first dosing until 30 days 60 days after the last dose of investigational 
product.
Male subjects must not donate sperm for at least 30 days 3 months after the 
last dose of investigational product. 
Exclusion criteria #15 updated to remove restriction on the use of 
anticholinergic medication. 
â€œSubject has used belladonna alkaloids (sco polam ine, 
hyoscyamine, atropine) w ithin 7 days before randomization, cannabinoids 
or, opioids, or anticholinergic drugs within 28 days before randomization, 
or B-type natriuretic peptides within the past year before randomization; or 
subject has anticipated need for any of the aforementioned drugs/drug 
categories during the study.Synopsis 
Section 4.2
Table 8
Ophthalmologic assessments on screening and midwashout ophthalmic 
assessments (MWOA) need to be done one time during the day only. 
Ophthalmic asses sments include: 
BCVA, Manifest Refraction (Screening), Slit Lamp examination of anterior 
segment, Conjunctival Redness, Corneal Haze, Corneal Epithelial integrity using 
fluorescein stain, Anterior Chamber cell and flare, Lens Opacification, IOP, 
Posterio r Segment Examination, dilated (Screening and Day 29), Specular 
Microscopy (Day 29), Noncontact (Screening and Day 29), Corneal Pachymetry 
(Screening and Day 29)Table 1, Table 2, Table 3, Table 4, 
Table 5
IOP assessments on Screening and MWOA (D -14) need to be done one 
time during the day only. 
At screening: IOP may be measured at any time during the day. 
At MWOA (D -14) IOP w ill be measured in the morning at 10:00am (+3 
hours). 
Additional assessments other than the â€œmorning assessmentsâ€ at screening 
and MWOA (D -14) do not need to be conducted. Table 1, Table 2, Table 3, Table 4, 
Table 5
Clarification of last study drug dose: 
Subjects will be administered the last dose of study drug on the morning of 
Day 28. Add a footnote to tables 2, 3, 4, and 5 .Table 2, Table 3, Table 4, Table 5
Shire CONFIDENTIAL Page 107
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
Clarification of Corneal Pachymetry Timing: 
The timing of IOP and Corneal Pachymetry will be more closely aligned to 
allow  for procedure scheduling at sites: 
Corneal Pachymetry will be performed at the following ti me points for all 
applicable visit days: Predose/Morning, 1 hour post dose, 2 hours post 
dose, 4 hours post dose, and 12 hours post dose. Table 2, Table 3, Table 4, Table 5
Section 7.2.2.3
Clarification of Baseline: 
The Baseline â€œBLâ€ Column will be remo ved from Tables 2, 3, 4, and 5. All 
reference to â€œBLâ€ will be removed from the column titles â€œDays 
Performedâ€ and all reference to visits will be done by day number. 
Removed all reference to â€œBaselineâ€ in Section 7.2.2.3Table 2, Table 3, Table 4, Table 5
Section 7.2.2.3
Clarification of Antidrug antibody (Ab) sampling in Table 1: remove â€œXâ€ 
from Day 26 as no sample will be collected at Day 26. 
Clarification of Antidrug Ab sampling in Tables 2, 3, 4, 5. The column 
titled â€œDays Performedâ€ incorrectly id entifies Antidrug Ab blood sampling 
to be collected at the screening visit. No ADA samples will be taken at 
screening. 
Clarification of Antidrug Ab sampling at Day 26: 
No ADA samples will be taken at Day 26. 
In Table 2 only: Antidrug Ab blood sampling time point was added to 
Table 2 at the predose/morning time point. Site personnel should collect the 
Antidrug Ab blood sample at the predose/morning time point.Table 1, Table 2, Table 3, Table 4, 
Table 5
The volume of blood to be drawn per subject has changed due to the 
removal of an ADA sample at the Screening visit for all subjects. Table 11 and Table 12
Section 7.2.5
Clarification of Full and Abbreviated IOP exam time points: 
The schedule for abbreviated IOP exams is to be follow ed on Days 7, 14,
and 21. 
In tables 3, 4, and 5 update IOP, full schedule: Removed D7, D14, D21 
from â€œDays performedâ€ column. Table 3, Table 4, Table 5 on Days 7, 
14, and 21. 
Clarification of artificial tears use: 
When subjects are at a study visit artificial tears ar e not to be used. 
â€œThe use of non -preserved artificial tears is prohibited during the following 
intervals, which include study visits: 
â€¢ Cohort A, SDTP: Day -2 -1 to Day 2, after final assessment
â€¢ Cohort A, MDTP: Day -2 -1 to Day 29, after final assessm ent
â€¢ Cohorts B, C, and D: Day -2 -1 to Day 29, after final assessment.â€Section 5.2.2
Gonioscopy Time points: 
Gonioscopy will be done at screening at any time during the day. Table 2, Table 3, Table 4, Table 5
Section 7.2.2.3
Shire CONFIDENTIAL Page 108
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
Gonioscopy will not be done at D -2 or D -1. 
Gonioscopy will be performed at the morning time point on Day 29. 
Gonioscopy will not be performed at the 6 hour time point on Day 29. 
Conjunctival redness assessments will be done at the following time points: 
Predose, 1 hour, 3 hou rs, 6 hours, and 12 hoursTable 2, Table 3, Table 4, Table 5
Footnote added to column headings of Screening, MWOA, and Day 29 to 
clarify that only one round of ophthalmic assessments will be done in the 
morning. Table 1
Clarify that only the following will be done at check -in: 
Physical exam
Drugs of abuse screening 
Alcohol breathalyzer 
Vital signs 
Hem atology, Chemistry, Urinalysis
One ECGTable 1
A footnote was added to refer the reader to tables 2, 3, 4, and 5 for specific 
details on assessment t iming for study days. Table 1
Clarification on re -screening: 
Any subject who is qualified but not dosed (ie, an alternate subject) may be 
re-screened at a later date for the study. A subject who does not meet all 
eligibility criteria during screening ca nnot re -screen. Section 7.1.1.2
Clarify the study day for screening and clarify the study day window  
(days): 
Screening study day will become -28 and the study day window  will be 
+14. This does not change the duration of screening (up to 42 days total).Table 1
Remove all reference to â€œSDTPâ€ in tables 3, 4, 5. There is no SDTP in 
Cohorts B, C, and D. Table 3, Table 4, Table 5
Clarification of IOP on Day 29: 
Day 29 only a single IOP. Day 29 removed from the full IOP schedule.Table 3, Table 4, Table 5
Clarification of the Day 60 visit and total subject duration of participation: 
ADA sampling will be collected approximately 60 days post last dose (Day 
28). This is accurate in the synopsis, Section 3.1.4.2, and Section 3.1.5. 
The synopsis and Section 3.2 will now state: 
The subjectsâ€™ maximum duration of participation in the study is expected to 
be 146 122days or approximately 5 4 months (Cohort A1, A2, and A3). 
The subjectsâ€™ maximum duration of participation in the study for Cohorts 
B, C, and D is expected to be 130 days or approximately 4.5 months. 
â€¢ Maximum planned duration of screening and Washout 1: 42 days
â€¢ Planned duration of treatment period: 2 days for SDTP (Cohort A only) 
and 29 days for MDTP (all cohorts)
â€¢ Planned duration of Washout 2 (C ohort A only): 3 14 days
Planned duration of follow -up: until Day 8860Â±4 daysSynopsis
Section 3.2
Section 7.1
Section 7.1.1
Section 7.1.3
Table 1
6KLUH &21),'(17,$/ 3DJH
6+33URWRFRO$PHQGPHQW6+3 0D\
7KH7DEOHFROXPQKHDGHUWLWOHG'D\)8ZLOOEHUHQDPHG 'D\)8
DQGIRRWQRWHG
6HFWLRQZDVUHZRUGHGWRHQVXUHLWLVFOHDUWKDWWKHVDPS OHLVWREH
GUDZQDSSUR[LPDWHO\GD\VSRVWODVWGRVH'D\
&ODULI\9LWDOVZLOOQRWEHGRQHRQ'D\
&KDQJHÂ³DOOYLVLWVÂ´LQ'D\V3HUIRUPHGWRÂ³$OOYLVLWVH[FHSW'D\ )8Â´7DEOH7DEOH7DEOH7DEOH
&ODULI\%&9$WLPHSRLQWV
&KDQJHÂ³DOOYLVLWVÂ´LQ'D\V3HUIRUPHGWRÂ³$OOYLVLWVH[FHSW'D\ DQG'D\
)8Â´7DEOH7DEOH7DEOH7DEOH
&ODULILFDWLRQRIWKHIROORZXSSKRQHFDOOWLPLQJ
7KHV\QRSVLV6HFWLRQDQG6HFWLRQVWDWHWKDWWKH IROORZXS
SKRQHFDOOZLOOEHGD\VSRVWGLVFKDUJH
7DEOHIRRWQRWHÂ³JÂ´LQFRUUHFWO\VWDWHVWKDWWKHIROORZXSSKRQ HFDOOZLOOEH
GD\VSRVWODVWGRVHRIVWXG\GUXJ)RRWQRWHÂ³JÂ´ZDVFRUUHFWHG 7DEOH
5HPRYHG
,IXQDYDLODEOHSOHDVHFRQWDFW
7HOHSKRQH  KRXUFRYHUDJH
5HSODFHGZLWK
,IXQDYDLODEOHSOHDVHFRQWDFW
7HOHSKRQH KRXUFRYHUDJH$GGLWLRQDO&RQWDFW,QIRUPDWLRQ
PPD
PPDPPD
PPDPPD
PPD
Shire CONFIDENTIAL Page 111
SHP639 -101 Protocol Am endment 3
SHP639 11May 2018
Anterior Chamber Cell and Flare
Anterior chamber cell and flare will be assessed and graded using the Standardization of Uveitis 
Nomenclature grading scale at the time points outlined in Table 1(all cohorts) and specified in 
Table 2, Table 3, Table 4, and Table 5for Cohorts A, B, C, and D, respectively .
Lens Opacification
Lens opacification will be assessed with the slit lamp during dilated examination and graded in 
the nuclear, cortical, and subcapsular lay ers using the Lens Opacities Classification Sy stem III 
grading scale at the time points outlined in Table 1(all cohorts) and specified in Table 2, 
Table 3, Table 4, and Table 5, for Cohorts A, B, C, and D, respectively . The presence and 
placement of an intraocular lens and the presence of a post erior capsulotomy  will be recorded.